<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cell Dev Biol</journal-id><journal-id journal-id-type="iso-abbrev">Front Cell Dev Biol</journal-id><journal-id journal-id-type="publisher-id">Front. Cell Dev. Biol.</journal-id><journal-title-group><journal-title>Frontiers in Cell and Developmental Biology</journal-title></journal-title-group><issn pub-type="epub">2296-634X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7365855</article-id><article-id pub-id-type="doi">10.3389/fcell.2020.00616</article-id><article-categories><subj-group subj-group-type="heading"><subject>Cell and Developmental Biology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>nCOVID-19 Pandemic: From Molecular Pathogenesis to Potential Investigational Therapeutics</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kabir</surname><given-names>Md. Tanvir</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Uddin</surname><given-names>Md. Sahab</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/337138/overview"/></contrib><contrib contrib-type="author"><name><surname>Hossain</surname><given-names>Md. Farhad</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/969226/overview"/></contrib><contrib contrib-type="author"><name><surname>Abdulhakim</surname><given-names>Jawaher A.</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Alam</surname><given-names>Md. Asraful</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ashraf</surname><given-names>Ghulam Md</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref><xref ref-type="aff" rid="aff8"><sup>8</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/389048/overview"/></contrib><contrib contrib-type="author"><name><surname>Bungau</surname><given-names>Simona G.</given-names></name><xref ref-type="aff" rid="aff9"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bin-Jumah</surname><given-names>May N.</given-names></name><xref ref-type="aff" rid="aff10"><sup>10</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/888676/overview"/></contrib><contrib contrib-type="author"><name><surname>Abdel-Daim</surname><given-names>Mohamed M.</given-names></name><xref ref-type="aff" rid="aff11"><sup>11</sup></xref><xref ref-type="aff" rid="aff12"><sup>12</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/394429/overview"/></contrib><contrib contrib-type="author"><name><surname>Aleya</surname><given-names>Lotfi</given-names></name><xref ref-type="aff" rid="aff13"><sup>13</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/604668/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Pharmacy, Brac University</institution>, <addr-line>Dhaka</addr-line>, <country>Bangladesh</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Pharmacy, Southeast University</institution>, <addr-line>Dhaka</addr-line>, <country>Bangladesh</country></aff><aff id="aff3"><sup>3</sup><institution>Pharmakon Neuroscience Research Network</institution>, <addr-line>Dhaka</addr-line>, <country>Bangladesh</country></aff><aff id="aff4"><sup>4</sup><institution>Department of Physical Therapy, Graduate School of Inje University</institution>, <addr-line>Gimhae</addr-line>, <country>South Korea</country></aff><aff id="aff5"><sup>5</sup><institution>Department of Medical Laboratory, Faculty of Applied Medical Sciences, Taibah University</institution>, <addr-line>Yanbu</addr-line>, <country>Saudi Arabia</country></aff><aff id="aff6"><sup>6</sup><institution>School of Chemical Engineering, Zhengzhou University</institution>, <addr-line>Zhengzhou</addr-line>, <country>China</country></aff><aff id="aff7"><sup>7</sup><institution>King Fahd Medical Research Center, King Abdulaziz University</institution>, <addr-line>Jeddah</addr-line>, <country>Saudi Arabia</country></aff><aff id="aff8"><sup>8</sup><institution>Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University</institution>, <addr-line>Jeddah</addr-line>, <country>Saudi Arabia</country></aff><aff id="aff9"><sup>9</sup><institution>Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea</institution>, <addr-line>Oradea</addr-line>, <country>Romania</country></aff><aff id="aff10"><sup>10</sup><institution>Department of Biology, College of Science, Princess Nourah Bint Abdulrahman University</institution>, <addr-line>Riyadh</addr-line>, <country>Saudi Arabia</country></aff><aff id="aff11"><sup>11</sup><institution>Department of Zoology, College of Science, King Saud University</institution>, <addr-line>Riyadh</addr-line>, <country>Saudi Arabia</country></aff><aff id="aff12"><sup>12</sup><institution>Pharmacology Department, Faculty of Veterinary Medicine, Suez Canal University</institution>, <addr-line>Ismailia</addr-line>, <country>Egypt</country></aff><aff id="aff13"><sup>13</sup><institution>Chrono-Environnement Laboratory, UMR CNRS 6249, Bourgogne Franche-Comt&#x000e9; University</institution>, <addr-line>Besan&#x000e7;on</addr-line>, <country>France</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Tatsuo Shioda, Osaka University, Japan</p></fn><fn fn-type="edited-by"><p>Reviewed by: Newman Osafo, Kwame Nkrumah University of Science and Technology, Ghana; Aman Babanrao Upaganlawar, Shri Neminath Jain Brahmacharyashram, India</p></fn><corresp id="c001">*Correspondence: Md. Sahab Uddin <email>msu-neuropharma@hotmail.com</email>; <email>msu_neuropharma@hotmail.com</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Molecular Medicine, a section of the journal Frontiers in Cell and Developmental Biology</p></fn><fn fn-type="other" id="fn002"><p>&#x02020;ORCID: Md. Sahab Uddin <ext-link ext-link-type="uri" xlink:href="http://orcid.org/0000-0002-0805-7840">orcid.org/0000-0002-0805-7840</ext-link></p></fn></author-notes><pub-date pub-type="epub"><day>10</day><month>7</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>7</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>8</volume><elocation-id>616</elocation-id><history><date date-type="received"><day>03</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>22</day><month>6</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Kabir, Uddin, Hossain, Abdulhakim, Alam, Ashraf, Bungau, Bin-Jumah, Abdel-Daim and Aleya.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Kabir, Uddin, Hossain, Abdulhakim, Alam, Ashraf, Bungau, Bin-Jumah, Abdel-Daim and Aleya</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>In December 2019, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related epidemic was first observed in Wuhan, China. In 2020, owing to the highly infectious and deadly nature of the virus, this widespread novel coronavirus disease 2019 (nCOVID-19) became a worldwide pandemic. Studies have revealed that various environmental factors including temperature, humidity, and air pollution may also affect the transmission pattern of COVID-19. Unfortunately, still, there is no specific drug that has been validated in large-scale studies to treat patients with confirmed nCOVID-19. However, remdesivir, an inhibitor of RNA-dependent RNA polymerase (RdRp), has appeared as an auspicious antiviral drug. Currently, a large-scale study on remdesivir (i.e., 200 mg on first day, then 100 mg once/day) is ongoing to evaluate its clinical efficacy to treat nCOVID-19. Good antiviral activity against SARS-CoV-2 was not observed with the use of lopinavir/ritonavir (LPV/r). Nonetheless, the combination of umifenovir and LPV/r was found to have better antiviral activity. Furthermore, a combination of hydroxychloroquine (i.e., 200 mg 3 times/day) and azithromycin (i.e., 500 mg on first day, then 250 mg/day from day 2&#x02013;5) also exhibited good activity. Currently, there are also ongoing studies to evaluate the efficacy of teicoplanin and monoclonal and polyclonal antibodies against SARS-CoV-2. Thus, in this article, we have analyzed the genetic diversity and molecular pathogenesis of nCOVID-19. We also present possible therapeutic options for nCOVID-19 patients.</p></abstract><kwd-group><kwd>SARS-CoV-2</kwd><kwd>nCOVID-19</kwd><kwd>RdRp inhibitors</kwd><kwd>remdesivir</kwd><kwd>favipiravir</kwd><kwd>immunomodulators</kwd><kwd>corticosteroids</kwd><kwd>eculizumab</kwd></kwd-group><counts><fig-count count="4"/><table-count count="2"/><equation-count count="0"/><ref-count count="221"/><page-count count="23"/><word-count count="19265"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Coronaviruses (CoVs) belong to the large family of positive-sense, enveloped, highly diverse, and single-stranded RNA viruses (Fehr and Perlman, <xref rid="B65" ref-type="bibr">2015</xref>). Indeed, CoVs have been found to infect both humans and animals, therefore causing various respiratory, gastrointestinal, neuronal, and hepatic diseases (Weiss and Leibowitz, <xref rid="B192" ref-type="bibr">2011</xref>; Chan et al., <xref rid="B33" ref-type="bibr">2013</xref>; Zumla et al., <xref rid="B221" ref-type="bibr">2016</xref>). Former epidemics of CoVs include severe acute respiratory syndrome (SARS)-CoV and Middle East respiratory syndrome (MERS)-CoV, these outbreaks caused severe health problems in humans (Raoult et al., <xref rid="B153" ref-type="bibr">2020</xref>). A group of individuals was admitted to hospitals in late December of 2019 with a primary diagnosis of pneumonia due to an unknown cause (Bogoch et al., <xref rid="B19" ref-type="bibr">2020</xref>; Lu et al., <xref rid="B120" ref-type="bibr">2020</xref>). It was assumed by the earlier reports that the onset of a potential CoV epidemic provided the estimation of a reproduction number for the 2019 novel coronavirus (nCOVID-19, named by World Health Organization (WHO) on Feb 11, 2020) which was thought to be considerably &#x0003e;1 (ranges from 2.24&#x02013;3.58) (Zhao et al., <xref rid="B217" ref-type="bibr">2020</xref>).</p><p>This severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be transmitted largely via droplets and due to the close contact. It has been found that elderly people and individuals with chronic diseases or comorbidities are particularly high-risk populations (Li et al., <xref rid="B112" ref-type="bibr">2020a</xref>). There are various symptoms of nCOVID-19 including cough (68%), fever (88%), diarrhea (3.7%), and vomiting (5%) (Mungroo et al., <xref rid="B135" ref-type="bibr">2020</xref>). The mode of transmission of SARSCoV-2 is supposed to take place from human to human through respiratory secretions released by the infected people when sneezing and coughing (Mungroo et al., <xref rid="B135" ref-type="bibr">2020</xref>). nCOVID-19 patients can be asymptomatic, which is making the control of the transmission more difficult (Gao et al., <xref rid="B70" ref-type="bibr">2020</xref>; Li et al., <xref rid="B112" ref-type="bibr">2020a</xref>). Since February of 2020, strict infection control approaches were executed by the Centers for Disease Control (CDC) in order to limit the spread of SARS-CoV-2. In a recent study, To et al. (<xref rid="B178" ref-type="bibr">2020</xref>) mentioned that nCOVID-19 patients had the highest viral load (measured in saliva samples) near presentation. They also summarized that as viral load is quite high during the time of hospital admissions, use of potent antiviral agents at an early stage might prove beneficial in managing the severity of nCOVID-19 infection (To et al., <xref rid="B178" ref-type="bibr">2020</xref>).</p><p>Previously, SARS was found to be partially linked with environmental factors (Lin et al., <xref rid="B116" ref-type="bibr">2006</xref>). In a study, it was revealed that air pollution was linked with mortality in SARS patients in China (Cui et al., <xref rid="B52" ref-type="bibr">2003</xref>). In this regard, it was mentioned that lung functions can be compromised owing to long- or short-term exposure to certain environmental pollutants (Cui et al., <xref rid="B52" ref-type="bibr">2003</xref>). Air temperature is another factor that is also needed to be considered. It has been revealed by Lin et al. (<xref rid="B116" ref-type="bibr">2006</xref>) that the occurrence of SARS was much higher (18 times) at lower air temperatures as compared to higher temperatures. Researchers also showed that respiratory disorders are more likely to take place in colder environments since virulence of agents are likely to deteriorate at higher air temperatures because they might not endure the alterations in the environment (D'Amato et al., <xref rid="B54" ref-type="bibr">2018</xref>). In addition to this, they also summarized that SARS-CoV's transmissibility is comparable with the transmissibility of influenza virus. Moreover, the occurrence of influenza markedly elevates with high relative humidity and low temperatures (Park et al., <xref rid="B140" ref-type="bibr">2020</xref>), which is further suggesting that viral transmission can be significantly affected by environmental factors.</p><p>There are no therapeutic agents that have been approved to treat nCOVID-19. Various medicines including immunomodulatory or antiviral drugs such as remdesivir, favipiravir, ribavirin, chloroquine, hydroxychloroquine, azithromycin, nitazoxanide, teicoplanin etc. have been advised as potential investigational drugs, many of which are now being studied in animals and humans (Wang et al., <xref rid="B186" ref-type="bibr">2020b</xref>; WHO, <xref rid="B195" ref-type="bibr">2020c</xref>). On March 28, 2020, the Food and Drug Administration (FDA) gave an emergency use authorization (EUA) for emergency use of oral administrations of chloroquine phosphate and hydroxychloroquine sulfate to treat SARS-CoV-2 infection (FDA, <xref rid="B62" ref-type="bibr">2020</xref>). Along with oxygen and mechanical ventilation, a guideline has also been published by Belgium which involved recommendations from four other European countries, including Switzerland, Netherlands, France, and Italy that recommended the use of remdesivir, lopinavir/ritonavir, tocilizumab, and chloroquine or hydroxychloroquine (Sciensano, <xref rid="B162" ref-type="bibr">2020</xref>). In addition, Japan and China approved the use of favipiravir (an antiviral agent) to treat influenza, which is now under investigation to treat nCOVID-19 (Fujifilm, <xref rid="B67" ref-type="bibr">2020</xref>).</p><p>In this article, we have critically appraised the genetic diversity, molecular pathogenesis, symptoms, diagnosis, and prevention of nCOVID-19. Furthermore, we also specially reviewed the mechanisms, efficacy, and use of various drugs that might be beneficial in combating nCOVID-19 infection.</p></sec><sec id="s2"><title>Genetic Diversity and Evolution of nCOVID-19</title><p>In nature, nucleotide substitution is considered as a vital step for viral evolution (Lauring and Andino, <xref rid="B106" ref-type="bibr">2010</xref>). The rapid spreading of SARS-CoV-2 raised a suspicion that mutations are driving its evolution. In a recent study, from GISAID, Phan (<xref rid="B145" ref-type="bibr">2020a</xref>) collected 86 complete or near-complete SARS-CoV-2 genomes to estimate its genetic variation. In addition to this, these strains of SARS-CoV-2 were identified in patients with confirmed nCOVID-19 from USA (11), China (50), Japan (5), Australia (5), England (2), Singapore (3), France (4), Germany (1), Belgium (1), South Korea (1), Vietnam (1), and Taiwan (2). ClustalX2 was used to align the pair-wise nucleotide sequence (Saitou and Nei, <xref rid="B160" ref-type="bibr">1987</xref>). As a reference genome, the sequence of the strain &#x0201c;China/WHU01/2020/EPI_ISL_406716&#x0201d; was used. Interestingly, similar to other beta coronaviruses, the genome of SARS-CoV-2 contains a long ORF1ab polyprotein at the 5&#x02032; end, followed by 4 main structural proteins, such as nucleocapsid protein, matrix protein, small envelope protein, and spike surface glycoprotein (Phan, <xref rid="B146" ref-type="bibr">2020b</xref>). In addition to this, it was also observed that there were 3 deletions in the genomes of SARS-CoV-2 from Australia (Victoria), USA (Wisconsin), and Japan (Aichi). In contrast, 1 deletion (10 nucleotides) was found in the 3&#x02032; end of the genome, while 2 deletions (2 nucleotides and 24 nucleotides) were found in the ORF1ab polyprotein.</p><p>Furthermore, it was also observed from the nucleotide sequence alignment that there were 93 missense mutations in the entire genomes of novel coronavirus (<xref rid="T1" ref-type="table">Table 1</xref>). Except for the envelope protein, 42 mutations were detected in all of the main structural and non-structural proteins. Whereas, 4 missense mutations were observed in the nucleocapsid protein, 1 in the matrix protein, 29 in the ORF1ab polyprotein, and 8 in the spike surface glycoprotein. Interestingly 3 mutations (i.e., Phe<sup>367</sup>, Tyr<sup>364</sup>, and Asp<sup>354</sup>) were found in the spike surface glycoprotein receptor-binding domain. Indeed, spike surface glycoprotein contributes significantly in binding to receptors on the host cell and eventually regulates host tropism (Fung and Liu, <xref rid="B68" ref-type="bibr">2019</xref>). Furthermore, this spike glycoprotein is the main target of neutralizing antibodies (Yu et al., <xref rid="B211" ref-type="bibr">2020</xref>). Conformational changes of spike glycoprotein can be induced by the mutations, which can lead to altered antigenicity. Up until now, no study has identified the amino acids that are involved in conformational alterations of spike glycoprotein. Therefore, further studies are required to identify these important amino acids.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Several missense mutations have been identified in the entire genome of nCOVID-19 strains (Phan, <xref rid="B145" ref-type="bibr">2020a</xref>).</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Location</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Number of mutations</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Codon</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Mutation</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Region(s) of strain(s)</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Matrix protein</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">209</td><td valign="top" align="left" rowspan="1" colspan="1">Asp &#x02192; His</td><td valign="top" align="left" rowspan="1" colspan="1">Singapore</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3&#x02032;UTR</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Intergenic region</td><td valign="top" align="center" rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Intergenic region</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Nucleocapsid protein</td><td valign="top" align="center" rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">148</td><td valign="top" align="left" rowspan="1" colspan="1">Thr &#x02192; Ile</td><td valign="top" align="left" rowspan="1" colspan="1">China (Shenzhen)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">194</td><td valign="top" align="left" rowspan="1" colspan="1">Ile &#x02192; Leu</td><td valign="top" align="left" rowspan="1" colspan="1">China (Shenzhen) China (Foshan) USA USA</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">202</td><td valign="top" align="left" rowspan="1" colspan="1">Ser &#x02192; Asn</td><td valign="top" align="left" rowspan="1" colspan="1">Australia</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">344</td><td valign="top" align="left" rowspan="1" colspan="1">Pro &#x02192; Ser</td><td valign="top" align="left" rowspan="1" colspan="1">Hong Kong (Guangzhou)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">5&#x02032; UTR</td><td valign="top" align="center" rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Spike polyprotein</td><td valign="top" align="center" rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">32</td><td valign="top" align="left" rowspan="1" colspan="1">Phe &#x02192; Ile</td><td valign="top" align="left" rowspan="1" colspan="1">China (Wuhan)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">49</td><td valign="top" align="left" rowspan="1" colspan="1">His &#x02192; Tyr</td><td valign="top" align="left" rowspan="1" colspan="1">China (Guangdong)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">247</td><td valign="top" align="left" rowspan="1" colspan="1">Ser &#x02192; Arg</td><td valign="top" align="left" rowspan="1" colspan="1">Australia</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">354</td><td valign="top" align="left" rowspan="1" colspan="1">Asn &#x02192; Asp</td><td valign="top" align="left" rowspan="1" colspan="1">China (Shenzhen)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">364</td><td valign="top" align="left" rowspan="1" colspan="1">Asp &#x02192; Tyr</td><td valign="top" align="left" rowspan="1" colspan="1">China (Shenzhen)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">367</td><td valign="top" align="left" rowspan="1" colspan="1">Val &#x02192; Phe</td><td valign="top" align="left" rowspan="1" colspan="1">France</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">614</td><td valign="top" align="left" rowspan="1" colspan="1">Asp &#x02192; Gly</td><td valign="top" align="left" rowspan="1" colspan="1">Germany</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1143</td><td valign="top" align="left" rowspan="1" colspan="1">Pro &#x02192; Leu</td><td valign="top" align="left" rowspan="1" colspan="1">Australia</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ORF1ab polyprotein</td><td valign="top" align="center" rowspan="1" colspan="1">48</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">29</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">117</td><td valign="top" align="left" rowspan="1" colspan="1">Ala &#x02192; Thr</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">309</td><td valign="top" align="left" rowspan="1" colspan="1">Pro &#x02192; Ser</td><td valign="top" align="left" rowspan="1" colspan="1">France</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">428</td><td valign="top" align="left" rowspan="1" colspan="1">Ser &#x02192; Asn</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">609</td><td valign="top" align="left" rowspan="1" colspan="1">Thr &#x02192; Ile</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1176</td><td valign="top" align="left" rowspan="1" colspan="1">Ala &#x02192; Val</td><td valign="top" align="left" rowspan="1" colspan="1">Japan</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1599</td><td valign="top" align="left" rowspan="1" colspan="1">Leu &#x02192; Phe</td><td valign="top" align="left" rowspan="1" colspan="1">Korea</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1607</td><td valign="top" align="left" rowspan="1" colspan="1">Ile &#x02192; Val</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">2194</td><td valign="top" align="left" rowspan="1" colspan="1">Met &#x02192; Thr</td><td valign="top" align="left" rowspan="1" colspan="1">China (Shenzhen)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">2235</td><td valign="top" align="left" rowspan="1" colspan="1">Leu &#x02192; Ile</td><td valign="top" align="left" rowspan="1" colspan="1">China (Wuhan)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">2244</td><td valign="top" align="left" rowspan="1" colspan="1">Ile &#x02192; Thr</td><td valign="top" align="left" rowspan="1" colspan="1">China (Wuhan)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">2251</td><td valign="top" align="left" rowspan="1" colspan="1">Gly &#x02192; Ser</td><td valign="top" align="left" rowspan="1" colspan="1">China (Wuhan)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">2345</td><td valign="top" align="left" rowspan="1" colspan="1">Ala &#x02192; Val</td><td valign="top" align="left" rowspan="1" colspan="1">China (Shandong)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">2534</td><td valign="top" align="left" rowspan="1" colspan="1">Gly &#x02192; Val</td><td valign="top" align="left" rowspan="1" colspan="1">China (Wuhan)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">2579</td><td valign="top" align="left" rowspan="1" colspan="1">Asp &#x02192; Ala</td><td valign="top" align="left" rowspan="1" colspan="1">China (Wuhan)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">2708</td><td valign="top" align="left" rowspan="1" colspan="1">Asn &#x02192; Ser</td><td valign="top" align="left" rowspan="1" colspan="1">China (Wuhan)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">2908</td><td valign="top" align="left" rowspan="1" colspan="1">Phe &#x02192; Ile</td><td valign="top" align="left" rowspan="1" colspan="1">China (Wuhan)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">3058</td><td valign="top" align="left" rowspan="1" colspan="1">Thr &#x02192; Ile</td><td valign="top" align="left" rowspan="1" colspan="1">France</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">3099</td><td valign="top" align="left" rowspan="1" colspan="1">Ser &#x02192; Leu</td><td valign="top" align="left" rowspan="1" colspan="1">China (Shenzhen)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">3606</td><td valign="top" align="left" rowspan="1" colspan="1">Leu &#x02192; Phe</td><td valign="top" align="left" rowspan="1" colspan="1">China (Yunnan) China (Shandong) China (Chongqing) Singapore France USA</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">3764</td><td valign="top" align="left" rowspan="1" colspan="1">Glu &#x02192; Asp</td><td valign="top" align="left" rowspan="1" colspan="1">Japan</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">3833</td><td valign="top" align="left" rowspan="1" colspan="1">Asn &#x02192; Lys</td><td valign="top" align="left" rowspan="1" colspan="1">China (Wuhan)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">5308</td><td valign="top" align="left" rowspan="1" colspan="1">Trp &#x02192; Cys</td><td valign="top" align="left" rowspan="1" colspan="1">Taiwan</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">5579</td><td valign="top" align="left" rowspan="1" colspan="1">Thr &#x02192; Ile</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">6075</td><td valign="top" align="left" rowspan="1" colspan="1">Ile &#x02192; Thr</td><td valign="top" align="left" rowspan="1" colspan="1">England</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">6083</td><td valign="top" align="left" rowspan="1" colspan="1">Pro &#x02192; Leu</td><td valign="top" align="left" rowspan="1" colspan="1">Japan</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">6309</td><td valign="top" align="left" rowspan="1" colspan="1">Phe &#x02192; Tyr</td><td valign="top" align="left" rowspan="1" colspan="1">China (Sichuan)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">6565</td><td valign="top" align="left" rowspan="1" colspan="1">Glu &#x02192; Asp</td><td valign="top" align="left" rowspan="1" colspan="1">China (Shenzhen)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">6958</td><td valign="top" align="left" rowspan="1" colspan="1">Lys &#x02192; Arg</td><td valign="top" align="left" rowspan="1" colspan="1">China (Wuhan)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">7018</td><td valign="top" align="left" rowspan="1" colspan="1">Asp &#x02192; Asn</td><td valign="top" align="left" rowspan="1" colspan="1">China (Wuhan)</td></tr></tbody></table></table-wrap></sec><sec id="s3"><title>Transmission Pattern of nCOVID-19 and Environmental Factors</title><p>Various wild and domestic animals such as bats, cats, cattle, and camels might play a role as hosts for coronaviruses (Adhikari et al., <xref rid="B3" ref-type="bibr">2020</xref>). In general, animal coronaviruses do not spread among human beings (CDC, <xref rid="B29" ref-type="bibr">2020a</xref>). Nevertheless, exceptions have been noticed in case of MERS and SARS, where these diseases were found to be transmitted owing to the contact with respiratory droplets from sneezing or coughing of nCOVID-19 patients. Initial nCOVID-19 patients were detected in China, where there was an association with the seafood market of Wuhan, which is indicating that these initial infections took place because of the animal-to-person transmission. Later on, nCOVID-19 was also detected in healthcare professionals and also in other individuals where there was no history of contact with that affected area of Wuhan, which is further suggesting the human-to-human transmission (Gralinski and Menachery, <xref rid="B76" ref-type="bibr">2020</xref>; Huang et al., <xref rid="B86" ref-type="bibr">2020</xref>; Li et al., <xref rid="B113" ref-type="bibr">2020b</xref>; Liu et al., <xref rid="B118" ref-type="bibr">2020</xref>; WHO, <xref rid="B196" ref-type="bibr">2020d</xref>).</p><p>As per the recent guidelines from health authorities of China (Adhikari et al., <xref rid="B3" ref-type="bibr">2020</xref>; WHO, <xref rid="B197" ref-type="bibr">2020e</xref>), there are 3 major routes of nCOVID-19 transmission including droplets transmission, aerosol transmission, and contact transmission. Transmissions via droplets were found to take place when respiratory droplets of infected individuals are inhaled or ingested by people who are in close contact. Whereas, contact transmission might take place when a person touches a virus-contaminated-object or surface and then that person touches his/her nose, mouth, or eyes. On the other hand, aerosol transmission might take place when respiratory droplets mix into the air, thus forms aerosols and might result in infection when a high dose of aerosols are inhaled into the lungs in a comparatively closed environment (Adhikari et al., <xref rid="B3" ref-type="bibr">2020</xref>; WHO, <xref rid="B197" ref-type="bibr">2020e</xref>). In a study, it was revealed that the digestive system is also a possible route for SARS-CoV-2 transmission. Symptoms like diarrhea and abdominal discomfort have been observed in individuals with confirmed nCOVID-19, this observation led to studies which revealed that ACE2 (to which SARS-CoV-2 binds) is highly expressed in enterocytes of colon and ileum (Zhang et al., <xref rid="B215" ref-type="bibr">2020b</xref>).</p><sec><title>Temperature</title><p>The effect of temperature on the health of humans can be varied depending on the countries or even areas (Hajat and Kosatky, <xref rid="B81" ref-type="bibr">2010</xref>). In line with this aforesaid finding, it was also reported that temperature can affect the transmission of respiratory syndromes-causing viruses including SARS-CoV-2 (Ma et al., <xref rid="B122" ref-type="bibr">2020</xref>) and influenza virus (Park et al., <xref rid="B140" ref-type="bibr">2020</xref>). Studies have also revealed that novel coronavirus and influenza virus can survive only in some specific environmental conditions and their transmissions also depend on temperatures (Chan et al., <xref rid="B34" ref-type="bibr">2011</xref>; Jaakkola et al., <xref rid="B91" ref-type="bibr">2014</xref>), which is also applicable for SARS-CoV-2 transmission (Wang et al., <xref rid="B187" ref-type="bibr">2020c</xref>). It was observed in case of influenza virus that it can transmit more readily at lower temperatures (Lowen and Steel, <xref rid="B119" ref-type="bibr">2014</xref>), since host immunity is likely to remain weakened in cold weather, this can further increase the vulnerability toward infection (Kudo et al., <xref rid="B104" ref-type="bibr">2019</xref>). As the transmission process of coronaviruses is comparable with the influenza virus transmission (Lin et al., <xref rid="B116" ref-type="bibr">2006</xref>), thus it can be expected that these processes are also applicable for the SARS-CoV-2 transmission (Wang et al., <xref rid="B187" ref-type="bibr">2020c</xref>).</p></sec><sec><title>Other Environmental Factors</title><p>Several other environmental factors can affect the link between mortality and temperature including air pollution (Cai et al., <xref rid="B24" ref-type="bibr">2007</xref>), humidity (Jaakkola et al., <xref rid="B91" ref-type="bibr">2014</xref>; Kudo et al., <xref rid="B104" ref-type="bibr">2019</xref>), latitude (Bao et al., <xref rid="B14" ref-type="bibr">2016</xref>). In this regard, socio-demographic factors including income, age, and gender (Bao et al., <xref rid="B14" ref-type="bibr">2016</xref>) have also been reported to play roles. In a study, Chan et al. (<xref rid="B34" ref-type="bibr">2011</xref>) revealed that individuals who live at lower latitudes showed a strong adaptive capacity toward heat, and a relatively weak adaptive capacity was observed toward cold. These researchers also observed that the viability of SARS-CoV was much lower at higher relative humidity and higher temperatures (for example, relative humidity: over 95%, and temperature: 38&#x000b0;C). In a different study, it was revealed that humidity and temperature are linked with an increased risk of nCOVID-19 (Wang et al., <xref rid="B187" ref-type="bibr">2020c</xref>). Interestingly, coronaviruses can persist on inanimate surfaces including plastic, glass, or metal for up to 9 days (Kampf et al., <xref rid="B96" ref-type="bibr">2020</xref>).</p></sec></sec><sec id="s4"><title>Molecular Pathogenesis Underlying nCOVID-19</title><p>nCOVID-19 patients exhibit various clinical symptoms including cough, fever, fatigue, radiographic evidence of pneumonia, dyspnea, decreased or normal leukocyte counts, and myalgia (Huang et al., <xref rid="B86" ref-type="bibr">2020</xref>). These aforesaid symptoms are also similar to MERS-CoV and SARS-CoV infections (Peiris et al., <xref rid="B142" ref-type="bibr">2004</xref>). Even though nCOVID-19 pathogenesis is not well-understood, however the similar mechanisms used previously by MERS-CoV and SARS-CoV can provide a lot of information regarding SARS-CoV-2 pathogenesis (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>The life cycle of SARS-CoV-2 in host cells. SARS-CoV-2 contains 4 structural proteins including spike (S), envelope (E), matrix/membrane (M), and nucleocapsid (N), in association with various accessory proteins. SARS-CoV-2 enters into the host cell by binding with the S protein of the virus to the ACE2 receptor on the host cell. It has been found that S protein is cleaved into S1 and S2 by a cell-derived protease, where S1 binds with ACE2 receptor, and S2 is activated by the host serine protease TMPRSS2 and results in a fusion with the cell membrane. Following the entry into the host cell, SARS-CoV-2 takeovers the host cell machinery to transcribe, replicate, and translate its RNA genome and structural proteins before being reassembled, encapsulated, and exocytosed from the host cell. Following exocytosis, SARS-CoV-2 is presented to host antigen presenting cells (APCs), which eventually leads to the generation of various cytokines including, TNF-&#x003b1;, CXCL-10, IL-1, and IL-6 (InvivoGen, <xref rid="B88" ref-type="bibr">2020</xref>).</p></caption><graphic xlink:href="fcell-08-00616-g0001"/></fig><sec><title>Entry and Replication</title><p>Spike protein (S protein) of coronavirus determines the viral entry into the host cells (de Wit et al., <xref rid="B57" ref-type="bibr">2016</xref>). Interestingly, the envelope spike glycoprotein binds to its cellular receptor, angiotensin converting enzyme 2 (ACE2) for SARS-CoV (Li et al., <xref rid="B114" ref-type="bibr">2003b</xref>) and SARS-CoV-2 (Wu et al., <xref rid="B201" ref-type="bibr">2020b</xref>) (<xref ref-type="fig" rid="F1">Figure 1</xref>), dipeptidyl peptidase 4 for MERS-CoV (Raj et al., <xref rid="B152" ref-type="bibr">2013</xref>), and CD209L for SARS-CoV [26]. Although it was initially identified that SARS-CoV enters into cells by direct fusion of plasma membrane and virus (Simmons et al., <xref rid="B168" ref-type="bibr">2004</xref>). However, Belouzard et al. (<xref rid="B18" ref-type="bibr">2009</xref>) revealed that a vital proteolytic cleavage process takes place at SARS-CoV S protein at position (S2&#x02032;) that facilitated the membrane fusion and infectivity of the virus. For membrane fusion, MERS-CoV also has evolved an aberrant 2 steps furin activation (Mille and Whittaker, <xref rid="B129" ref-type="bibr">2014</xref>). Other than membrane fusion, entry of SARS-CoV was also found to be mediated by the clathrin-independent and -dependent endocytosis (Wang et al., <xref rid="B185" ref-type="bibr">2008</xref>; Kuba et al., <xref rid="B103" ref-type="bibr">2010</xref>). Following the entry of virus into the cells, RNA genome of SARS-CoV is released into the cytoplasm and is translated into 2 polyproteins and structural proteins, subsequently the viral genome starts to replicate (Perlman and Netland, <xref rid="B143" ref-type="bibr">2009</xref>). The newly generated envelope glycoproteins are then inserted into the membrane of the endoplasmic reticulum or Golgi apparatus, and the nucleocapsid is generated by the combination of nucleocapsid protein and genomic RNA. Subsequently, viral particles begin to germinate into the endoplasmic reticulum-Golgi intermediate compartment. Finally, virus particles containing vesicles then form fusion with the plasma membrane in order to release the virus (de Wit et al., <xref rid="B57" ref-type="bibr">2016</xref>).</p></sec><sec><title>Antigen Presentation in SARS-CoV-2 Infection</title><p>When the SARS-CoV-2 enters into the cells, its antigen will be presented to the antigen presentation cells (APCs) (<xref ref-type="fig" rid="F1">Figure 1</xref>), this process is crucial for the anti-viral immunity of the human body (Kumar et al., <xref rid="B105" ref-type="bibr">2020</xref>). Peptides of antigens are presented via major histocompatibility complex (MHC; or human leukocyte antigen (HLA) in humans) and then identified by virus-specific cytotoxic T lymphocytes. Therefore, the understanding of antigen presentation (AP) of the virus will provide a better understanding of the pathogenesis of nCOVID-19. However, not much information is available regarding this, thus we can obtain information from previous studies on MERS-CoV and SARS-CoV. AP of SARS-CoV-2 mostly relies on MHC I molecules (Liu et al., <xref rid="B117" ref-type="bibr">2010</xref>), nonetheless MHC II also plays roles in its presentation. Former studies revealed that many HLA polymorphisms associate with the susceptibility of SARS-CoV, for instance HLA-Cw*0801 (Chen et al., <xref rid="B41" ref-type="bibr">2006b</xref>), HLA-B*0703, HLA-DR B1*1202, and HLA-B*4601 (Keicho et al., <xref rid="B99" ref-type="bibr">2009</xref>), while HLA-A*0201, HLA-DR0301, and HLA-Cw1502 alleles are associated with the protection from SARS infection (Wang et al., <xref rid="B188" ref-type="bibr">2011</xref>). In case of MERS-CoV, it was observed that MHC II molecules (for example HLA-DQB1*02:0 and HLA-DRB1*11:01) were linked with the susceptibility to MERS-CoV infection (Hajeer et al., <xref rid="B82" ref-type="bibr">2016</xref>). Other than mannose-binding lectin gene polymorphisms linked with AP are associated with the risk of SARS-CoV infection (Tu et al., <xref rid="B180" ref-type="bibr">2015</xref>). Indeed, the aforementioned findings will give us an important idea regarding the mechanism, prevention, and treatment of nCOVID-19.</p></sec><sec><title>Humoral and Cellular Immune Responses</title><p>AP subsequently induces the human body's humoral and cellular immune responses, which are then facilitated via virus-specific B and T cells. Like other common acute viral infections, antibodies including IgG and IgM are produced against SARS-CoV virus. It is estimated that at the end of week 12, SARS-specific IgM antibodies disappear. Whereas, SARS-specific IgG antibody can stay for a longer period, which is suggesting that IgG mainly has a protective function (Li et al., <xref rid="B110" ref-type="bibr">2003a</xref>). Furthermore, it was also found that SARS-specific IgG antibodies mainly are N-specific and S-specific antibodies (de Wit et al., <xref rid="B57" ref-type="bibr">2016</xref>). Most of the studies have focused on cellular immune responses, as compared to the humoral immune responses in case of coronavirus. Recent findings have revealed that the levels of CD8<sup>+</sup> and CD4<sup>+</sup> T cells in the peripheral blood of nCOVID-19 individuals were significantly decreased, as confirmed by increased percentages of CD38 (CD8 39.4%) and HLA-DR (CD4 3.47%) double-positive fractions (Xu et al., <xref rid="B203" ref-type="bibr">2020</xref>). Likewise, acute phase response in individuals with nCOVID-19 is linked with a marked decrease of CD8<sup>+</sup> T and CD4<sup>+</sup> T cells. Interestingly, it was found that although there is no presence of antigen, CD8<sup>+</sup>, and CD4<sup>+</sup> memory T cells can last for 4 years in individuals who have recovered from SARS-CoV and can perform IFN-&#x003b3; generation, delayed-type hypersensitivity response and T cell proliferation (Fan et al., <xref rid="B59" ref-type="bibr">2009</xref>). After 6 years of infection with SARS-CoV, specific T-cell memory responses to the SARS-CoV S peptide library can still be identified in 14 of 23 recovered SARS individuals (Tang et al., <xref rid="B175" ref-type="bibr">2011</xref>). In mouse models, specific CD8<sup>+</sup> T cells also exhibited similar activity in the clearance of MERS-CoV (Zhao et al., <xref rid="B216" ref-type="bibr">2014</xref>). Indeed, these results might be useful in the rational designing of an effective vaccine against SARS-CoV-2.</p></sec><sec><title>Cytokine Storm in nCOVID-19</title><p>Acute respiratory distress syndrome (ARDS) is considered as the major cause of nCOVID-19-related death. In the early stages of the epidemic, 6 out of the 41 admitted patients with confirmed nCOVID-19 died owing to ARDS (Huang et al., <xref rid="B86" ref-type="bibr">2020</xref>). This ARDS is found to be the main immunopathological characteristic of SARS-CoV, MERS-CoV, and SARS-CoV-2 infections (Xu et al., <xref rid="B203" ref-type="bibr">2020</xref>). Cytokine storm is the major characteristic of ARDS. This storm is a fatal uncontrolled systemic inflammatory response that takes place because of the high secretions of chemokines (i.e., C-X-C motif chemokine 10 [CXCL10], CXCL9, CXCL8, C-C motif chemokine ligand 5 [CCL5], CCL3, CCL2, etc.) and pro-inflammatory cytokines (i.e., transforming growth factor-&#x003b2; [TGF&#x003b2;], tumor necrosis factor alpha [TNF&#x003b1;], interleukin 33 [IL-33], IL-18, IL-12, interferon gamma [IFN&#x003b3;], IL-6, IL-1&#x003b2;, IFN-&#x003b1;, etc.) via immune effector cells in case of SARS-CoV infection (Cameron et al., <xref rid="B27" ref-type="bibr">2008</xref>; Williams and Chambers, <xref rid="B198" ref-type="bibr">2014</xref>; Channappanavar and Perlman, <xref rid="B37" ref-type="bibr">2017</xref>; Huang et al., <xref rid="B86" ref-type="bibr">2020</xref>) as shown in <xref ref-type="fig" rid="F1">Figure 1</xref>. Like SARS-CoV, MERS patients showed increased levels of CXCL-10, CXCL8, CCL5, IFN-&#x003b1;, and interleukin 6 (IL-6) in serum as compared to individuals with the mild to moderate disease (Min et al., <xref rid="B130" ref-type="bibr">2016</xref>). In the human body, a powerful cytokine storm will induce an aggressive attack by the immune system, which will lead to multiple organ failure and ARDS, and will ultimately result in death in severe novel coronavirus infection, as like MERS-CoV and SARS-CoV infection (Xu et al., <xref rid="B203" ref-type="bibr">2020</xref>).</p></sec><sec><title>Immune Evasion by SARS-CoV-2</title><p>Various strategies are used by viruses including SARS-CoV and MERS-CoV to evade immune responses for their better survival in host cells. The pattern recognition receptors (PRRs) can identify the evolutionarily conserved microbial structures called pathogen-associated molecular patterns. Nonetheless, MERS-CoV and SARS-CoV can stimulate the generation of double-membrane vesicles lacking PRRs and subsequently can replicate in these vesicles, thus evading the host detection of their double-strand RNA (dsRNA) (Snijder et al., <xref rid="B172" ref-type="bibr">2006</xref>). IFN-I (IFN-&#x003b2; and IFN-&#x003b1;) plays a protective function on MERS-CoV and SARS-CoV infection, however the IFN-I mechanism is suppressed in infected mouse models (Channappanavar et al., <xref rid="B35" ref-type="bibr">2016</xref>, <xref rid="B36" ref-type="bibr">2019</xref>). Interestingly, by directly interacting with the dsRNA, MERS-CoV's accessory protein 4a might block the stimulation of IFN at the level of melanoma differentiation-associated protein 5 activation (Niemeyer et al., <xref rid="B136" ref-type="bibr">2013</xref>). IFN &#x003b2; promoter activation and transportation of IFN regulatory factor 3 to the nucleus can be inhibited by the ORF5, ORF4b, ORF4a, and membrane proteins of MERS-CoV (Yang et al., <xref rid="B207" ref-type="bibr">2013</xref>). SARS-CoV-2 can also affect the AP. In this regard, for instance, gene expression associated with AP is downregulated following MERS-CoV infection (Menachery et al., <xref rid="B127" ref-type="bibr">2018</xref>). Therefore, it is vital to terminate the immune evasion of coronavirus to develop specific and effective therapies.</p></sec></sec><sec id="s5"><title>Clinical Manifestations of nCOVID-19 Patients</title><p>Following an incubation period of around 5.2 days, the symptoms of SARS-CoV-2 infection appear (Li et al., <xref rid="B113" ref-type="bibr">2020b</xref>). It takes around 6 to 41 days from the first appearance of the symptoms to death, along with a median of 14 days (Wang et al., <xref rid="B189" ref-type="bibr">2020d</xref>). However, the aforesaid durations depend on various factors including the patient's age and status of the immune system. This duration was found to be shorter for individuals older than 70-years old as compared to the individuals who are under the age of 70 (Wang et al., <xref rid="B189" ref-type="bibr">2020d</xref>). At the onset of the disease, the most commonly observed symptoms are cough, fatigue, and fever (<xref ref-type="fig" rid="F2">Figure 2</xref>). In addition to this, various other symptoms including headache, lymphopenia, dyspnea, sputum production, diarrhea, and hemoptysis (Graham Carlos et al., <xref rid="B75" ref-type="bibr">2020</xref>; Huang et al., <xref rid="B86" ref-type="bibr">2020</xref>; Ren et al., <xref rid="B156" ref-type="bibr">2020</xref>; Wang et al., <xref rid="B189" ref-type="bibr">2020d</xref>). Pneumonia has also been identified by computed tomography scan in nCOVID-19 patients, Unfortunately, various aberrant clinical features including ground-glass opacity (GGO), acute cardiac injury, and ARDS led to death (Huang et al., <xref rid="B86" ref-type="bibr">2020</xref>). Occasionally, in subpleural areas of both lungs, the multiple peripheral GGOs were detected (Lei et al., <xref rid="B108" ref-type="bibr">2020</xref>) and these triggered both localized and systemic immune responses, which collectively raised the level of inflammation. Unfortunately, treatment with interferon inhalation did not result in any clinical benefit, rather it aggravated the condition via facilitating pulmonary opacities (Lei et al., <xref rid="B108" ref-type="bibr">2020</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Symptoms exhibited by nCOVID-19 patients.</p></caption><graphic xlink:href="fcell-08-00616-g0002"/></fig><p>Indeed, some of the symptoms of nCOVID-19 are similar to the earlier betacoronavirus including dyspnea, dry cough, fever, and bilateral GGOs (Huang et al., <xref rid="B86" ref-type="bibr">2020</xref>). Nonetheless, there are some unique clinical manifestations of nCOVID-19 such as sore throat, sneezing, rhinorrhea (Lee et al., <xref rid="B107" ref-type="bibr">2003</xref>; Assiri et al., <xref rid="B10" ref-type="bibr">2013</xref>). As revealed by chest radiographs following admission, in some cases it was observed that an infiltrate in lung's upper lobe is linked with growing dyspnea with hypoxemia (Phan et al., <xref rid="B144" ref-type="bibr">2020</xref>). Although nCOVID-19 exhibited digestive disorders like diarrhea, only a small proportion of SARS-CoV or MERS-CoV showed similar gastrointestinal symptoms. Thus, testing urine and fecal samples are important to eliminate a possible alternative mode of transmission (Lee et al., <xref rid="B107" ref-type="bibr">2003</xref>; Assiri et al., <xref rid="B10" ref-type="bibr">2013</xref>). Henceforth, developing methods to detect different routes of transmission for example urine and fecal samples are immediately required to develop ways to suppress and/or minimize the transmission and also to discover therapies to treat nCOVID-19.</p><p>Recently, it has been observed that nCOVID-19 might predispose to both arterial and venous thromboembolic disease because of immobilization, hypoxia, inflammation, and diffuse intravascular coagulation (Chen et al., <xref rid="B40" ref-type="bibr">2020b</xref>; Guan et al., <xref rid="B79" ref-type="bibr">2020</xref>; Klok et al., <xref rid="B101" ref-type="bibr">2020</xref>; Wang et al., <xref rid="B184" ref-type="bibr">2020a</xref>; Zhou et al., <xref rid="B218" ref-type="bibr">2020</xref>). Furthermore, it was also revealed that respiratory failure in the disease is not only driven by the ARDS, rather microvascular thrombotic activities might also contribute in this regard (Grillet et al., <xref rid="B78" ref-type="bibr">2020</xref>). Therefore, Klok et al. (<xref rid="B101" ref-type="bibr">2020</xref>) have strongly suggested to administer pharmacological agents in a prophylactic manner to all the intensive care unit (ICU) nCOVID-19 patients.</p></sec><sec id="s6"><title>Diagnosis of nCOVID-19 Patients</title><p>For any given emergency department (ED) visiting patients with the symptoms of fever and respiratory diseases, healthcare workers must need to get a travel history in detail from that patient. If a patient shows flu-like symptoms and has a travel history to a country or area with confirmed nCOVID-19 cases or if the patient came into close contact with a confirmed nCOVID-19 patient in the last 14 days then the patient ought to be considered as a patient under investigation (PUI) (NPR, <xref rid="B138" ref-type="bibr">2020</xref>). It needs to be noted that here close contact means any individual who was within six feet of an individual with confirmed nCOVID-19 for an extended period. Furthermore, any individual who came into direct contact with the secretions of any nCOVID-19 patient will also be considered as a close contact.</p><p>Individuals who have traveled from high-risk countries or areas with confirmed nCOVID-19 cases and members of a family who are suffering from nCOVID-19 and not staying at home care or not maintaining isolation precautions are regarded as high-risk exposures. While medium risk exposures involve individuals who have traveled from low-risk countries or areas and family members are stringently maintaining appropriate home care and adhering with proper isolation precautions (WHO, <xref rid="B197" ref-type="bibr">2020e</xref>). In contrast, low-risk exposures involve those individuals who were in the same indoor environment (for example in a waiting hall) for a longer period with nCOVID-19 patients but did not come into close contact.</p><p>Molecular assays of respiratory specimens are performed for diagnosis purposes usually at the regional referral laboratories designated by WHO (Kaiser Health News, <xref rid="B95" ref-type="bibr">2020</xref>). For regional testing, the CDC started distributing nCOVID-19 test kits on February 7 (WHO, <xref rid="B193" ref-type="bibr">2020a</xref>). nCOVID-19 test is getting more widely available day by day. For hospitals or institutions where nCOVID-19 test is not available, the only option is the testing by CDC. nCOVID-19 should be tested on an urgent basis for the PUI cases. An individual should be removed from PUI status only if that individual is fully evaluated clinically and has consulted with proper healthcare professionals.</p></sec><sec id="s7"><title>Key Messages and Measures for nCOVID-19 Prevention</title><p>The mode of SARS-CoV-2 transmission is still complex. Guidelines for nCOVID-19 prevention is mainly based on the previously developed guidelines for SARS and MERS and also on the intervening guidelines provided by CDC and WHO (CDC, <xref rid="B29" ref-type="bibr">2020a</xref>,<xref rid="B30" ref-type="bibr">b</xref>; WHO, <xref rid="B193" ref-type="bibr">2020a</xref>). Before or upon arrival in ED, a PUI ought to be identified by the hospitals to protect the healthcare professionals and other patients. Prevention measures should involve maintaining hand and respiratory hygiene and also screening questions including travel history. Following a PUI identification, both local health department and hospital infection control ought to be immediately notified to avert further spread among healthcare professionals and other patients. A surgical mask must need to be given to any PUI and need to be isolated in a private room or if possible in a negative pressure room (WHO, <xref rid="B193" ref-type="bibr">2020a</xref>).</p><p>As like SARS and MERS, nCOVID-19 is also found to spread through the airborne route. Therefore, surgical face masks might be beneficial to prevent sneeze and cough-related larger fluid droplets, however they are less likely to prevent small airborne contaminants (Yee et al., <xref rid="B209" ref-type="bibr">2020</xref>). In this regard, respirators containing air filters and adequate seal should be more beneficial (Tran et al., <xref rid="B179" ref-type="bibr">2012</xref>; Smith et al., <xref rid="B171" ref-type="bibr">2016</xref>). In healthcare settings, right use of respirators and personal protective equipment and proper hand hygiene are likely to prevent transmission (Cowling et al., <xref rid="B51" ref-type="bibr">2009</xref>; Radonovich et al., <xref rid="B151" ref-type="bibr">2019</xref>; Yee et al., <xref rid="B209" ref-type="bibr">2020</xref>). If a patient requires hospital admission and there is no private or separate room for that patient, then that patient needs to be taken to an adequate facility containing institution. Isolated rooms and care provide would need to be customized in a way that reduces the exposure of healthcare providers to the patient. Indeed, along with an eye shield, all the healthcare providers must take measures to prevent contact with droplets and to maintain airborne precautions. Since the risk of transmission is much higher during the aerosol-generating procedures (such as intubation), in these cases the importance of PPE is enormous (Raboud et al., <xref rid="B150" ref-type="bibr">2010</xref>; CDC, <xref rid="B29" ref-type="bibr">2020a</xref>). Still, it remains not known, regarding how long nCOVID-19 can stay airborne following a patient leaves the room. Respiratory protection is essential to enter into the vacated room.</p><sec><title>Effectiveness of Personal-Level Prevention</title><p>Since still there is no specific drug to treat nCOVID-19, therefore the best approach will be taking preventative measures at a personal level including avoiding public transport, unnecessary travel, contact with nCOVID-19 suspected individuals, and so on.</p><sec><title>Importance of Hand Washing</title><p>Indeed, the significance of maintaining frequent and proper hand hygiene is paramount. Like other coronaviruses, SARS-CoV-2 has a lipid envelope, thus proper hand-washing with soap can break apart that lipid envelope and therefore can make it difficult or even impossible for the virus to infect humans. So far, this proper hand-washing is considered as the most effective preventative measure. In addition, duration of hand-washing with soap is also equally important. CDC has recommended that effective hand-washing should last at least for 20 s. In a study, Borchgrevink et al. (<xref rid="B20" ref-type="bibr">2013</xref>) showed that out of 3,749 individuals in a college town environment, only 5% of those individuals properly followed the hand-washing rules (i.e., washing, rubbing, and rinsing). This finding indicates that there is a poor understanding of the significance of proper hand-washing among the general people. Therefore, awareness among people should be increased about the importance of frequent and proper hand-washing.</p></sec><sec><title>Proper Use of Face Mask</title><p>In order to form a physical barrier, the WHO has recommended the use of a face mask by those individuals who are showing respiratory symptoms (WHO, <xref rid="B194" ref-type="bibr">2020b</xref>). However, healthy people are not required to use face masks. A typical surgical mask only provides one-way protection and can avert the spreading of droplets during coughing and sneezing to the surrounding areas. Healthcare professionals who are treating or in contact with a suspected or confirmed nCOVID-19 patient must need to wear a specialized respirator (for example N95 or its equivalent) to effectively prevent the droplets entry and thus can reduce the chance of acquiring the infection (Bae et al., <xref rid="B13" ref-type="bibr">2020</xref>; WHO, <xref rid="B194" ref-type="bibr">2020b</xref>). Strict precautionary measures must need to be taken by the individuals during handling affected individual's body secretions including sputum, urine, or stools (Yeo et al., <xref rid="B210" ref-type="bibr">2020</xref>).</p></sec></sec></sec><sec id="s8"><title>Therapeutic Options for nCOVID-19 Patients</title><sec><title>Inhibitors of RNA-Dependent RNA Polymerase</title><sec><title>Remdesivir</title><p>Out of all the investigational drugs, remdesivir (<xref ref-type="fig" rid="F3">Figure 3</xref>) has appeared as the most effective and promising antiviral drug (Li and De Clercq, <xref rid="B111" ref-type="bibr">2020</xref>). This antiviral drug targets RNA-dependent RNA polymerase (RdRp) of the virus while escaping proofreading via viral exoribonuclease, (Agostini et al., <xref rid="B5" ref-type="bibr">2018</xref>) which can ultimately lead to early termination of viral RNA transcription as given in <xref ref-type="fig" rid="F4">Figure 4</xref>. Interestingly, remdesivir is a phosphoramidate prodrug and has a wide range of activities against numerous virus families, such as pneumoviridae, paramyxoviridae, filoviridae, and orthocoronavirinae (for example pathogenic MERS-CoV and SARS-CoV) (Sheahan et al., <xref rid="B164" ref-type="bibr">2017</xref>; Martinez, <xref rid="B124" ref-type="bibr">2020</xref>).</p><fig id="F3" position="float"><label>Figure 3</label><caption><p>Chemical structures of potential investigational nCOVID-19 therapeutic agents.</p></caption><graphic xlink:href="fcell-08-00616-g0003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><p>Replication cycle of SARS-CoV-2 and potential anti-SARS-CoV-2 drug targets. Following bindings of SARS-CoV-2 particles with the cell receptors including dipeptidyl peptidase 4 (DPP4), aminopeptidase N (APN), and angiotensin-converting enzyme 2 (ACE2), RNA of the virus then enters into the host cell and viral RNA transcription takes place via RNA-dependent RNA polymerase (RdRp). After that viral protein synthesis takes place that is encapsulated and then released from the host cell. Dotted arrows have been used to indicate the drug targets of investigational therapies for nCOVID-19.</p></caption><graphic xlink:href="fcell-08-00616-g0004"/></fig><p>In a COVID-19 mouse model, when remdesivir was administered prophylactically and as early therapeutic intervention, it significantly decreased the pulmonary viral load, which ultimately reduced the progression of the disease and significantly improved respiration (Sheahan et al., <xref rid="B164" ref-type="bibr">2017</xref>). In tissue culture models, Brown et al. (Brown et al., <xref rid="B23" ref-type="bibr">2019</xref>) revealed that remdesivir showed half-maximal effective concentration (EC<sub>50</sub>) of 0.074 mM and 0.069 mM for MERS-CoV and SARS-CoV, successively (Brown et al., <xref rid="B23" ref-type="bibr">2019</xref>). Furthermore, remdesivir (within the submicromolar EC50s) also effectively inhibited zoonotic CoV and human CoVs (HCoV-229E and HCoV-OC43) (Brown et al., <xref rid="B23" ref-type="bibr">2019</xref>; Ko et al., <xref rid="B102" ref-type="bibr">2020</xref>). Similar results were also observed when remdesivir was administered therapeutically (12 h post-inoculation) and prophylactically (24 h before prior inoculation) in MERS animal (rhesus macaque) model (de Wit et al., <xref rid="B56" ref-type="bibr">2020</xref>). Even 2 amino acid substitutions (V553L and F476L) in the non-structural protein 12 polymerase were found to show lower-level of resistance toward remdesivir (Agostini et al., <xref rid="B5" ref-type="bibr">2018</xref>).</p><p>In humans, pharmacokinetic data of remdesivir is not available. However, it has been revealed in rhesus monkeys that intravenous remdesivir administration at the dose of 10 mg/kg increased the intracellular concentration (over 10 mM) of active triphosphate form in peripheral blood mononuclear cells for a minimum of 24 h, (Warren et al., <xref rid="B191" ref-type="bibr">2016</xref>) which is indicating its clinical significance in nCOVID-19 treatment. Furthermore, human safety data of remdesivir are available online (Mulangu et al., <xref rid="B134" ref-type="bibr">2019</xref>). In USA, the first patient with confirmed nCOVID-19 was effectively treated with remdesivir for the advancement of pneumonia on 7th day of hospital admission in January, 2020 (Holshue et al., <xref rid="B85" ref-type="bibr">2020</xref>). Moreover, to assess its efficacy and safety to treat individuals with confirmed nCOVID-19, phase III clinical trials (ClinicalTrials.gov, <xref rid="B47" ref-type="bibr">2020e</xref>) have been started in March 2020. In that study, individuals received 200 mg of remdesivir on first day, subsequently received 100 mg/day. Although remdesivir showed promising <italic>in vitro</italic> and clinical activity against coronavirus (Sheahan et al., <xref rid="B164" ref-type="bibr">2017</xref>; Holshue et al., <xref rid="B85" ref-type="bibr">2020</xref>), recently it has been reported that there are some uncertainties because of its multiple adverse effects including hepatotoxicity, rectal hemorrhage (Jean et al., <xref rid="B93" ref-type="bibr">2020b</xref>).</p></sec><sec><title>Favipiravir</title><p>In Japan, favipiravir (<xref ref-type="fig" rid="F3">Figure 3</xref>) was primarily developed and approved as an anti-influenza drug (Shiraki and Daikoku, <xref rid="B166" ref-type="bibr">2020</xref>; Wang et al., <xref rid="B186" ref-type="bibr">2020b</xref>). This antiviral drug has a wide range of activities against various RNA viruses including rhinovirus, respiratory syncytial virus (RSV), and influenza. Former studies revealed that favipiravir was successfully used to treat infections associated with rabies, Lassa virus, and Ebola virus (Shiraki and Daikoku, <xref rid="B166" ref-type="bibr">2020</xref>). Furthermore, favipiravir was also found to be effective to treat severe fever with thrombocytopenia syndrome (Shiraki and Daikoku, <xref rid="B166" ref-type="bibr">2020</xref>). Nevertheless, favipiravir was found to be ineffective against DNA viruses.</p><p>Favipiravir is a potent antiviral drug that selectively suppresses the RdRp of RNA viruses (<xref ref-type="fig" rid="F4">Figure 4</xref>) Favipiravir is likely to produce resistant viruses, as compared to oseltamivir (Shiraki and Daikoku, <xref rid="B166" ref-type="bibr">2020</xref>). Indeed, this feature of favipiravir can be beneficial in the treatment of nCOVID-19. To treat influenza, favipiravir's recommended oral dose is 1,600 mg two times on first day, subsequently 600 mg twice/day from day 2 to 5, and 600 mg once/day on the sixth day. In recent times, initial findings of clinical trials have revealed that favipiravir exhibited significant activity in treating Chinese nCOVID-19 patients (<xref rid="T2" ref-type="table">Table 2</xref>) (Xinhua News Agency). In China, favipiravir has been approved to treat nCOVID-19 in March 2020. Furthermore, in China, randomized controlled trials involving nCOVID-19 patients are also assessing the efficacy of favipiravir plus baloxavir marboxil (an antiviral drug) (Qiu et al., <xref rid="B149" ref-type="bibr">2020</xref>) and favipiravir plus IFN-&#x003b1; (Arab-Zozani et al., <xref rid="B8" ref-type="bibr">2020</xref>).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Potential investigational therapies for nCOVID-19.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Drug class</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Drug</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Mechanism of action</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Outcome</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>References</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Antiviral agents</td><td valign="top" align="left" rowspan="1" colspan="1">Remdesivir</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibits viral RNA-dependent RNA polymerase (RdRp)</td><td valign="top" align="left" rowspan="1" colspan="1">Showed promising <italic>in vitro</italic> and clinical activity against coronavirus</td><td valign="top" align="left" rowspan="1" colspan="1">Brown et al., <xref rid="B23" ref-type="bibr">2019</xref>; ClinicalTrials.gov, <xref rid="B47" ref-type="bibr">2020e</xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Favipiravir</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Exhibited excellent activity in treating nCOVID-19 patients</td><td valign="top" align="left" rowspan="1" colspan="1">Xinhua News Agency, <xref rid="B202" ref-type="bibr">2020</xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Ribavirin</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">It showed effective antiviral activity against SARS-CoV, but can be detrimental for the patients with respiratory distress</td><td valign="top" align="left" rowspan="1" colspan="1">Chan et al., <xref rid="B32" ref-type="bibr">2015</xref>; Martinez, <xref rid="B124" ref-type="bibr">2020</xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Umifenovir</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibits entry of virus into the host cell</td><td valign="top" align="left" rowspan="1" colspan="1">It can inhibit viral entry into the host cell</td><td valign="top" align="left" rowspan="1" colspan="1">Boriskin et al., <xref rid="B21" ref-type="bibr">2008</xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Lopinavir/ritonavir (LPV/r)</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Combination of umifenovir and LPV/r showed better activity as compared to the sole use of LPV/r in nCOVID-19 treatment</td><td valign="top" align="left" rowspan="1" colspan="1">Deng et al., <xref rid="B58" ref-type="bibr">2020</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Antimalarials</td><td valign="top" align="left" rowspan="1" colspan="1">Chloroquine</td><td valign="top" align="left" rowspan="1" colspan="1">Prevents the viral fusion with the cell membrane of the host cell</td><td valign="top" align="left" rowspan="1" colspan="1">Findings from <italic>in vitro</italic> studies are promising</td><td valign="top" align="left" rowspan="1" colspan="1">Vincent et al., <xref rid="B182" ref-type="bibr">2005</xref>; Cortegiani et al., <xref rid="B50" ref-type="bibr">2020</xref>; Wang et al., <xref rid="B186" ref-type="bibr">2020b</xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Hydroxychloroquine</td><td valign="top" align="left" rowspan="1" colspan="1">Controls cytokine storm</td><td valign="top" align="left" rowspan="1" colspan="1">Showed excellent <italic>in vitro</italic> activity as well as more potent and less likely to interact with other drugs as compared to chloroquine</td><td valign="top" align="left" rowspan="1" colspan="1">Yao et al., <xref rid="B208" ref-type="bibr">2020</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Macrolide antibiotics</td><td valign="top" align="left" rowspan="1" colspan="1">Azithromycin</td><td valign="top" align="left" rowspan="1" colspan="1">Enhances the anti-SARS-CoV-2 effect of hydroxychloroquine</td><td valign="top" align="left" rowspan="1" colspan="1">Combined use led to a reinforcement of hydroxychloroquine's efficacy in treating nCOVID-19 patients</td><td valign="top" align="left" rowspan="1" colspan="1">Gautret et al., <xref rid="B71" ref-type="bibr">2020</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Glycopeptide antibiotics</td><td valign="top" align="left" rowspan="1" colspan="1">Teicoplanin and its derivatives</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibits cathepsin L and cathepsin B in host cells</td><td valign="top" align="left" rowspan="1" colspan="1">They can selectively suppress the effects of cathepsins B and L in the host cell</td><td valign="top" align="left" rowspan="1" colspan="1">Wang et al., <xref rid="B190" ref-type="bibr">2016</xref>; Zhou et al., <xref rid="B219" ref-type="bibr">2016</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Antiparasitic agent</td><td valign="top" align="left" rowspan="1" colspan="1">Ivermectin</td><td valign="top" align="left" rowspan="1" colspan="1">Dissociates IMP&#x003b1;/&#x003b2;1 heterodimer</td><td valign="top" align="left" rowspan="1" colspan="1">Recent <italic>in vivo</italic> study has been demonstrated that it can remarkably decrease the level of viral RNA</td><td valign="top" align="left" rowspan="1" colspan="1">Caly et al., <xref rid="B25" ref-type="bibr">2020</xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Nitazoxanide</td><td valign="top" align="left" rowspan="1" colspan="1">Interferes with the host-regulated pathways linked with viral replication</td><td valign="top" align="left" rowspan="1" colspan="1">Exerted a potent <italic>in vitro</italic> antiviral activity against SARS CoV-2</td><td valign="top" align="left" rowspan="1" colspan="1">Wang et al., <xref rid="B186" ref-type="bibr">2020b</xref></td></tr></tbody></table></table-wrap></sec><sec><title>Ribavirin</title><p>Ribavirin (<xref ref-type="fig" rid="F3">Figure 3</xref>) is a RdRp inhibitor (<xref ref-type="fig" rid="F4">Figure 4</xref>) used to treat various viral infections, for example, infections caused by RSV and hepatitis C virus (HCV) (Ogawa and Morisada, <xref rid="B139" ref-type="bibr">2002</xref>). It was revealed by <italic>in vitro</italic> studies that when ribavirin was administered at a concentration of 50 mg/mL, it showed effective antiviral activity against SARS-CoV (Chan et al., <xref rid="B32" ref-type="bibr">2015</xref>). Unfortunately, this antiviral drug was found to decrease the level of hemoglobin, therefore it can be detrimental for individuals with respiratory distress (Martinez, <xref rid="B124" ref-type="bibr">2020</xref>).</p></sec></sec><sec><title>Viral Entry Inhibitors</title><sec><title>Umifenovir</title><p>Umifenovir (<xref ref-type="fig" rid="F3">Figure 3</xref>) is a potent antiviral agent that has a wide-range of activities against various viruses including HCV, influenza A and B viruses (Boriskin et al., <xref rid="B21" ref-type="bibr">2008</xref>). Umifenovir's mechanism slightly varies with different viruses. It has been revealed that umifenovir suppresses the fusion of the virus with the host cell membrane (<xref ref-type="fig" rid="F4">Figure 4</xref>), thus the subsequent viral entry into the host cell is inhibited (Boriskin et al., <xref rid="B21" ref-type="bibr">2008</xref>).</p></sec><sec><title>Lopinavir/Ritonavir</title><p>In a clinical trial, it has recently been observed that lopinavir/ritonavir (LPV/r, <xref ref-type="fig" rid="F3">Figure 3</xref>) protease inhibitors that are mainly used in human immunodeficiency virus (HIV) treatment did not significantly improve the nCOVID-19 symptoms (Cao et al., <xref rid="B28" ref-type="bibr">2020</xref>). Furthermore, in a different study, effect of umifenovir plus LPV/r was compared with the sole treatment with LPV/r to treat nCOVID-19 (Deng et al., <xref rid="B58" ref-type="bibr">2020</xref>). The findings of that study revealed that better effects were observed with the treatment of umifenovir plus LPV/r in comparison with the sole LPV/r treatment (Deng et al., <xref rid="B58" ref-type="bibr">2020</xref>). However, more studies are required to evaluate the incidence of resistance and efficacy. As coronavirus becomes activated on the membrane of the host cell, thus combination of LPV/r and umifenovir are likely to inhibit/prevent the viral entry into the host cell (<xref ref-type="fig" rid="F4">Figure 4</xref>). Besides, there is also a need regarding a better understanding of the more precise mechanisms to improve future clinical applications.</p></sec></sec><sec><title>Inhibitors of Viral Fusion and Cytokine Storm</title><sec><title>Chloroquine</title><p>Chloroquine (<xref ref-type="fig" rid="F3">Figure 3</xref>) is mainly used as an antimalarial drug. Furthermore, chloroquine is also used to treat various autoimmune disorders including rheumatoid arthritis and lupus erythematosus. In an animal model, it has recently been observed that chloroquine can also play a role as a potent antiviral drug against various viruses including influenza H5N1 (Yan et al., <xref rid="B204" ref-type="bibr">2013</xref>). Interestingly, chloroquine can prevent the viral fusion with the cell membrane of host cell by increasing endosomal pH (<xref ref-type="fig" rid="F4">Figure 4</xref>). Glycosylation of SARS-CoV's cellular receptors can also be interfered by chloroquine (Vincent et al., <xref rid="B182" ref-type="bibr">2005</xref>; Wang et al., <xref rid="B186" ref-type="bibr">2020b</xref>). Even though findings from <italic>in vitro</italic> studies regarding chloroquine is auspicious (EC<sub>90</sub> = 6.90 mM, used nCOVID-19-infected Vero E6 cells), however use of chloroquine to treat nCOVID-19 infection is a completely off-label use. Furthermore, this drug is not strongly indicated due to some of its safety reasons including QT prolongation with ventricular dysrhythmia and adverse reactions on the renal, hepatic, and hematologic systems (Cortegiani et al., <xref rid="B50" ref-type="bibr">2020</xref>).</p></sec><sec><title>Hydroxychloroquine</title><p>Hydroxychloroquine (a chloroquine derivative, <xref ref-type="fig" rid="F3">Figure 3</xref>) is also mainly used as antimalarial and anti-inflammatory drugs (Sinha and Balayla, <xref rid="B169" ref-type="bibr">2020</xref>). It has been proposed that hydroxychloroquine controls cytokine storm (<xref ref-type="fig" rid="F4">Figure 4</xref>), which takes place in critically ill late phase nCOVID-19 patients (Yao et al., <xref rid="B208" ref-type="bibr">2020</xref>). As compared to chloroquine, hydroxychloroquine is more potent and their EC<sub>50</sub> values are 5.47 and 0.72, successively. In addition to this, hydroxychloroquine is less likely to interact with other drugs as compared to chloroquine. Moreover, in comparison with chloroquine phosphate, pharmacokinetic data confirmed that hydroxychloroquine is much more effective (5 days before) at inhibiting SARS-CoV-2 <italic>in vitro</italic> (Yao et al., <xref rid="B208" ref-type="bibr">2020</xref>). It has been declared on March 26, 2020 by Taiwan CDC that hydroxychloroquine has a significant role in the treatment of nCOVID-19 patients. However, treatment with hydroxychloroquine is contraindicated for the patients who are pregnant or breastfeeding, allergic to hydroxychloroquine, glucose-6-phosphatase deficient, and for individuals with prolonged QT interval in electrocardiograms and retinopathy (Gautret et al., <xref rid="B71" ref-type="bibr">2020</xref>).</p></sec></sec><sec><title>Enhancer of Anti-SARS-CoV-2 Effect of Hydroxychloroquine</title><sec><title>Azithromycin</title><p>Previously, azithromycin (<xref ref-type="fig" rid="F3">Figure 3</xref>) showed excellent <italic>in vitro</italic> activity against Ebola virus (Madrid et al., <xref rid="B123" ref-type="bibr">2016</xref>). It was found that azithromycin was administered to individuals with viral infection, it prevented severe infections of respiratory tract in pre-school children (Bacharier et al., <xref rid="B12" ref-type="bibr">2015</xref>). In a recent study, when azithromycin was administered (i.e., 500 mg on first day, then 250 mg per day from day 2-5), it remarkably reinforced the hydroxychloroquine's efficacy (when 200 mg was administered 3 times/day for 10 days) to treat 20 severely ill nCOVID-19 patients (<xref ref-type="fig" rid="F4">Figure 4</xref>). The mean serum concentration of hydroxychloroquine was 0.46 &#x000b1; 0.20 mg/mL. It is assumed that this excellent virus eliminating activity was achieved owing to the use of the aforesaid combination therapy (Gautret et al., <xref rid="B71" ref-type="bibr">2020</xref>). Therefore, use of azithromycin along with hydroxychloroquine can be an effective future alternative to remdesivir in nCOVID-19 treatment. However, in this regard, a possible complication related to prolonged QT interval should be taken into consideration.</p></sec></sec><sec><title>Inhibitors of Cathepsins B and L</title><sec><title>Teicoplanin and Its Derivatives</title><p>Teicoplanin is a glycopeptide antibiotic and it has been revealed by Zhou et al. (Zhou et al., <xref rid="B219" ref-type="bibr">2016</xref>) that teicoplanin exerted inhibitory activity (IC<sub>50</sub> as low as 330 nm) against replication- and transcription-competent virus-like particles. Studies confirmed that teicoplanin can suppress the entry of MERS and SARS envelope pseudotyped viruses (Wang et al., <xref rid="B190" ref-type="bibr">2016</xref>; Zhou et al., <xref rid="B219" ref-type="bibr">2016</xref>). In terms of its mechanism, teicoplanin can selectively suppress the effects of cathepsins B and L in host cell. These proteases are involved with cleaving the viral glycoprotein permitting exposure of the receptor-binding domain of its core genome and then release into the cytoplasm of host cells (Zhou et al., <xref rid="B219" ref-type="bibr">2016</xref>; Baron et al., <xref rid="B15" ref-type="bibr">2020</xref>). Therefore, teicoplanin blocked the entry of Ebola virus in the late endosomal pathway. Also, the derivatives of teicoplanin including telavancin, dalbavancin, and oritavancin, were also found to block the entry of SARS, MERS, and Ebola viruses (Zhou et al., <xref rid="B219" ref-type="bibr">2016</xref>). Collectively, these findings suggest that teicoplanin and its derivatives might play a vital role in inhibiting the viruses that are dependent on cathepsin L (<xref rid="T2" ref-type="table">Table 2</xref>).</p></sec></sec><sec><title>Immunomodulators</title><sec><title>Ivermectin</title><p>Ivermectin (<xref ref-type="fig" rid="F3">Figure 3</xref>) is an antiparasitic agent and it has broad-spectrum of activity (Caly et al., <xref rid="B25" ref-type="bibr">2020</xref>), Recent <italic>in vitro</italic> studies have revealed that this drug also has an antiviral effect against dengue and HIV viruses (Wagstaff et al., <xref rid="B183" ref-type="bibr">2012</xref>). It has been found that the preformed IMP&#x003b1;/&#x003b2;1 heterodimer is accountable for the transport of viral protein into the nucleus and ivermectin can dissociate this heterodimer. Since this transport of viral protein into the nucleus is important for the replication cycle and suppression of the host's antiviral response, thus targeting this viral protein transport might prove as a significant target in the development of therapeutic agents against RNA viruses (Caly et al., <xref rid="B26" ref-type="bibr">2012</xref>; Yang et al., <xref rid="B205" ref-type="bibr">2020a</xref>). Following 48 h of nCOVID-19 infection, a recent <italic>in vivo</italic> study has been demonstrated that ivermectin can decrease the level of viral RNA (<xref ref-type="fig" rid="F4">Figure 4</xref>) up to 5,000-times (Caly et al., <xref rid="B25" ref-type="bibr">2020</xref>). Since ivermectin has an established safety profile as an antiparasitic agent, thus now it is needed to establish a safe and effective dose of this drug in clinical trials to treat nCOVID-19 infection.</p></sec><sec><title>Nitazoxanide</title><p>Nitazoxanide (<xref ref-type="fig" rid="F3">Figure 3</xref>) is an effective antiparasitic and antiviral drug (Rossignol, <xref rid="B158" ref-type="bibr">2016</xref>). This drug has a broad-spectrum <italic>in vitro</italic> antiviral activity against a range of viruses including RSV, rotavirus, parainfluenza, influenza, and coronavirus (Rossignol, <xref rid="B158" ref-type="bibr">2016</xref>). In Vero-E6 cells, nitazoxanide exerted a potent <italic>in vitro</italic> antiviral activity against SARS CoV-2 (EC<sub>50</sub> = 2.12 &#x003bc;M, at 48 h) (Wang et al., <xref rid="B186" ref-type="bibr">2020b</xref>). Furthermore, this strong antiviral effect is in line with the observed EC<sub>50</sub> values for nitazoxanide (EC<sub>50</sub> = 0.92 &#x003bc;M) and tizoxanide (an active metabolite of nitazoxanide) (EC<sub>50</sub> = 0.83 &#x003bc;M) against MERS-CoV in LLC-MK2 cells (Rossignol, <xref rid="B158" ref-type="bibr">2016</xref>). In terms of its mechanism of action, it is believed that nitazoxanide has potent antiviral effect because of its ability to interfere with the host-regulated pathways associated with viral replication instead of the virus-specific pathways (Rossignol, <xref rid="B158" ref-type="bibr">2016</xref>). Therefore, studies were carried out to evaluate the ability of this drug to treat influenza and other related acute respiratory infections. In the phase IIb/III of a clinical trial, positive effects of nitazoxanide were observed in the management of influenza symptoms, where 600 mg of nitazoxanide was orally administered twice a day (Haffizulla et al., <xref rid="B80" ref-type="bibr">2014</xref>). Unfortunately, in phase II clinical trial it was observed that nitazoxanide neither alleviated the symptoms nor decrease the length of stay in hospitals of individuals infected with respiratory viruses (Gami&#x000f1;o-Arroyo et al., <xref rid="B69" ref-type="bibr">2019</xref>). However, <italic>in vitro</italic> data regarding the activity of nitazoxanide against coronavirus is promising. Therefore, further studies are required to estimate its potential in nCOVID-19 treatment.</p></sec><sec><title>Janus Kinase Inhibitors</title><p>Baricitinib most commonly used in rheumatoid arthritis treatment. This drug is a reversible and selective inhibitor of Janus kinase 1 (JAK1) and JAK2. It has been found that these latter mentioned enzymes transduce intracellular signals for growth factors and cytokines associated with immune response, inflammation, and haematopoiesis. Moreover, this JAK inhibitor blocks the activities of AP2-associated with protein kinase 1, which ultimately prevents viral binding with the alveolar epithelium (Mayence and Vanden Eynde, <xref rid="B125" ref-type="bibr">2019</xref>). It has also been indicated that baricitinib might be used as an additional therapy for the COVID-19 treatment (Richardson et al., <xref rid="B157" ref-type="bibr">2020</xref>). In order to determine the safety and efficacy of sarilumab, hydroxychloroquine, lopinavir/ritonavir, and baricitinib to treat 1,000 hospitalized COVID-19 patients, a non-randomized phase II clinical study has recently been started (Scavone et al., <xref rid="B161" ref-type="bibr">2020</xref>). Other selective JAK inhibitors including ruxolitinib, fedratinib, and sunitinib might also be effective against COVID-19 in decreasing endocytosis of virus, inflammation, and levels of cytokines including IL-6 and IFN-&#x003b3; (Bekerman et al., <xref rid="B17" ref-type="bibr">2017</xref>; ClinicalTrials.gov, <xref rid="B48" ref-type="bibr">2020f</xref>; Favalli et al., <xref rid="B61" ref-type="bibr">2020</xref>; Scavone et al., <xref rid="B161" ref-type="bibr">2020</xref>; Stebbing et al., <xref rid="B173" ref-type="bibr">2020</xref>).</p></sec></sec><sec><title>Convalescent Plasma</title><p>Previously, convalescent plasma therapy was used as a terminal therapy to increase the survival rate of individuals with a range of viral infections including SARS, severe infection caused by Ebola virus, pandemic 2009 influenza A H1N1, H5N1 avian influenza (Chen et al., <xref rid="B38" ref-type="bibr">2020a</xref>; Shen et al., <xref rid="B165" ref-type="bibr">2020</xref>). Convalescent plasma therapy can be effective because viremia can be suppressed due to the presence of plasma immunoglobulin antibodies in recovering patients. In a study, Shen et al. (<xref rid="B165" ref-type="bibr">2020</xref>) evaluated the effect of convalescent plasma therapy in 5 severely ill nCOVID-19 patients with ARDS. In that study, convalescent plasma was transfused in those patients with a novel coronavirus-specific antibody (neutralization titer &#x0003e;40 and binding titer &#x0003e; 1:1000). The used convalescent plasma of that study was obtained from five nCOVID-19-recovered individuals. The obtained convalescent plasma was then administered to the 5 patients (in between 10 and 22 days following admission) along with methylprednisolone and antiviral drugs. After convalescent plasma transfusion, clinical conditions of the patients were found to be improved, including decreased viral loads (patients became nCOVID-19 negative within 12 days), elevated level of SARS-CoV-2-specific enzyme-linked immunosorbent assay (ELISA), neutralizing antibody titers, normalized body temperature (within 3 days in four/five patients), improved ARDS (four patients at 12 days following transfusion), successful weaning from mechanical ventilation (three participating individuals within 2 weeks of therapy), increased partial pressure of oxygen/fraction of inspired oxygen, and reduced score in sequential organ failure assessment. Out of the 5 participants, 2 of them were in stable condition (at 37 days following transfusions), while 3 of them were discharged from the hospital (following 51, 53, and 55 days of staying in the hospital) (Shen et al., <xref rid="B165" ref-type="bibr">2020</xref>). Finally, the researchers summarized that although there were a small number of participants in this study, they suggested the therapy with convalescent plasma can be effective in the nCOVID-19 treatment (Shen et al., <xref rid="B165" ref-type="bibr">2020</xref>).</p></sec><sec><title>Monoclonal or Polyclonal Antibodies and Other Potential Therapies</title><p>As a prophylactic measure and therapy, monoclonal and polyclonal antibodies (targeting hemagglutinin binding) have been recommended to treat various viral infections including influenza (Beigel et al., <xref rid="B16" ref-type="bibr">2019</xref>). The effectiveness of these antibodies against MERS-CoV largely encouraged the recent efforts to develop monoclonal and polyclonal antibodies against coronaviruses (Sheahan et al., <xref rid="B164" ref-type="bibr">2017</xref>). For instance, in a phase I trial, SAB-301 (a human polyclonal antibody) which was produced in transchromosomic cattle was found to be safe and better tolerated in healthy participants (Beigel et al., <xref rid="B16" ref-type="bibr">2019</xref>). In a study, Cockrell et al. (<xref rid="B49" ref-type="bibr">2016</xref>) revealed in mouse models that human monoclonal antibodies (mAbs)-based immunotherapy only mediated protection in the early stage of MERS (Martinez, <xref rid="B124" ref-type="bibr">2020</xref>).</p><p>Many <italic>in vitro</italic> analyses showed that S protein of SARS-CoV is crucial to mediate the viral entry into the host cells. In addition to this, the cleavage and subsequent activation of the S protein of SARS-CoV via a host cell's protease is vital for the entry of the virus (Glowacka et al., <xref rid="B73" ref-type="bibr">2011</xref>). In cell cultures, it has been noticed that transmembrane serine protease 2 (TMPRSS2) is a vital protease of host cells that causes activation of S protein of SARS-CoV, therefore it was studied as an important target for antiviral drugs (Sheahan et al., <xref rid="B164" ref-type="bibr">2017</xref>). Previously, camostat mesylate (an inhibitor of serine protease) showed inhibitory activity against TMPRSS2 (Kawase et al., <xref rid="B98" ref-type="bibr">2012</xref>). Furthermore, K11777 (a cysteine protease inhibitor) exhibited significant inhibitory activity (at submicromolar range) against replication of MERS-CoV and SARS-CoV (Zhou et al., <xref rid="B220" ref-type="bibr">2015</xref>). Sarilumab is a human monoclonal antibody and 3 clinical trials are ongoing to assess the safety and efficacy of this antibody (alone or along with other standard therapies) in nearly 1,500 COVID-19 patients (ClinicalTrials.gov, <xref rid="B43" ref-type="bibr">2020a</xref>,<xref rid="B46" ref-type="bibr">d</xref>,<xref rid="B48" ref-type="bibr">f</xref>; Scavone et al., <xref rid="B161" ref-type="bibr">2020</xref>).</p><p>Eculizumab (a monoclonal antibody) is approved to treat neuromyelitis spectrum disorders, refractory generalized myasthenia gravis, and atypical hemolytic uraemic syndrome. This monoclonal antibody inhibits the terminal portion of the inflammatory response-associated complement cascade. Although the function of the complement cascade in nCOVID-19 pathogenesis is not clear, numerous studies revealed that its suppression may effectively function as a therapeutic technique (Ip et al., <xref rid="B90" ref-type="bibr">2005</xref>; Yuan et al., <xref rid="B212" ref-type="bibr">2005</xref>; Gralinski et al., <xref rid="B77" ref-type="bibr">2018</xref>). Due to these findings, eculizumab will be tested in the SOLID-C19 clinical trial to treat individuals with severe ARDS and nCOVID-19 (ClinicalTrials.gov, <xref rid="B44" ref-type="bibr">2020b</xref>). Currently, emapalumab (a monoclonal antibody) is being studied in an open-label, randomized, phase II/III study to evaluate the safety and efficacy of this antibody in decreasing respiratory distress and hyper-inflammation in nCOVID-19 patients (ClinicalTrials.gov, <xref rid="B45" ref-type="bibr">2020c</xref>).</p><p>In China, stem cells are currently being studied as a treatment for nCOVID-19. Tocilizumab (a mAb) is an immunosuppressive agent and is used to treat rheumatoid arthritis (Kaneko, <xref rid="B97" ref-type="bibr">2013</xref>). This agent was designed to suppress the IL-6 binding with its receptors to alleviate cytokine storm syndrome. Tocilizumab is now being studied as a potential nCOVID-19 treatment (Jean et al., <xref rid="B93" ref-type="bibr">2020b</xref>; Slater, <xref rid="B170" ref-type="bibr">2020</xref>).</p></sec><sec><title>Herbal Medicines</title><p>In nCOVID-19 high-risk populations, traditional Chinese medicines were also regarded as a preventative measure, based on the traditional uses and anecdotal evidence of prevention of H1N1 pdm09 and SARS. Nonetheless, there is a lacking of clinical data regarding the effectiveness of these herbal medicines as an nCOVID-19 treatment (Cunningham et al., <xref rid="B53" ref-type="bibr">2020</xref>; Luo et al., <xref rid="B121" ref-type="bibr">2020</xref>). In China, several traditional medicines were widely used during the nCOVID-19 epidemic and 6 of these herbal medicines include Lianqiao (<italic>Fructus forsythia</italic>), Jinyinhua (Lonicerae Japonicae Flos), Gancao (Glycyrrhizae Radix Et Rhizoma), Baizhu (Atractylodis Macrocephalae Rhizoma, rhizome of <italic>Atractylodes macrocephala</italic> Koidz), Fangfeng (Saposhnikoviae Radix, dried root from the perennial herb <italic>Saposhnikovia divaricate</italic>), and Huangqi (Astragali Radix, dried root of <italic>Astragalus membranaceus Bge</italic>. <italic>Var</italic>. <italic>mongholicus</italic>). Indeed, stringent clinical studies are required with a large number of participants to demonstrate the preventive role of these traditional Chinese medicines (Cunningham et al., <xref rid="B53" ref-type="bibr">2020</xref>; Luo et al., <xref rid="B121" ref-type="bibr">2020</xref>).</p></sec><sec><title>Adjunctive Medications</title><sec><title>Antimicrobial Agents</title><p>The occurrence of co-infection can widely vary among the patients with confirmed nCOVID-19. Various reports suggest that several co-pathogens including viruses (such as rhinovirus, influenza, and HIV) and bacteria (for example <italic>Candida</italic> species, <italic>Mycoplasma pneumonia</italic>) can co-exist in these patients. Among them, influenza A virus was most commonly found to co-exist (Jean et al., <xref rid="B93" ref-type="bibr">2020b</xref>). Furthermore, nCOVID-19 patients with pneumonia were found to be commonly treated by the coadministration of anti-influenza drugs and antibiotics (Jean et al., <xref rid="B93" ref-type="bibr">2020b</xref>). Therefore, careful selection of potential broad-spectrum antibiotic(s) is required for the long-stay (over 6 days) hospitalized patients (Chou et al., <xref rid="B42" ref-type="bibr">2019</xref>; Jean et al., <xref rid="B92" ref-type="bibr">2020a</xref>).</p></sec><sec><title>Corticosteroids</title><p>Mixed clinical findings were observed with the use of corticosteroids to treat SARS-CoV infections. Although various reports suggested that there was no significant contribution of corticosteroids in clinical outcomes (Stockman et al., <xref rid="B174" ref-type="bibr">2006</xref>). In contrast, it was suggested by a report that decreased mortality rate was observed due to the use of corticosteroids in critically ill patients (Chen et al., <xref rid="B39" ref-type="bibr">2006a</xref>; Wu et al., <xref rid="B200" ref-type="bibr">2020a</xref>). Unfortunately, several reports suggested worse outcomes including longer time for viral clearance, or elevated composite endpoint of ICU admission or even death, owing to the use of corticosteroids (Auyeung et al., <xref rid="B11" ref-type="bibr">2005</xref>). In a cohort (<italic>n</italic> = 309), a longer time in viral clearance was observed in the corticosteroids-receiving MERS-CoV patients (Arabi et al., <xref rid="B7" ref-type="bibr">2018</xref>). Nevertheless, in the same study, it was observed that there was an insignificant decrease in 90-day mortality in corticosteroids-receiving patients. Recent reports suggested that there was a decreased rate of mortality in nCOVID-19 patients with ARDS due to the use of corticosteroids (Wu et al., <xref rid="B200" ref-type="bibr">2020a</xref>).</p><p>These findings suggest that use of corticosteroids resulted in inconsistent outcomes. However, corticosteroids might be beneficial for patients with cytokine-linked lung injury and those who might rapidly develop progressive pneumonia (Shang et al., <xref rid="B163" ref-type="bibr">2020</xref>). Indeed, healthcare professionals need to carefully assess the risk and benefit ratio of corticosteroid use for each patient. This necessity to assess risk and benefit of corticosteroid use in individual patients and its careful dose consideration has been demonstrated in diagnosis and treatment guidelines from China's National Health Commission. As per that guideline, glucocorticoid (equivalent to methylprednisolone 1-2 mg/kg per day for three-five days or less) may be considered based on chest imaging and respiratory distress. Large-dose of glucocorticoids can suppress the immune system, this can result in delayed SARS-CoV-2 clearance (McCreary and Pogue, <xref rid="B126" ref-type="bibr">2020</xref>). Recently, Chinese Thoracic Society recommended a lower dose of methylprednisolone (&#x02264; 0.5&#x02013;1 mg/kg per day) for a maximum of 7 days in selected patients, prior to treatment these selected patients should be carefully assessed for potential risks and benefits (Shang et al., <xref rid="B163" ref-type="bibr">2020</xref>). More clinical studies are immediately required to elucidate the function of corticosteroids in nCOVID-19.</p></sec><sec><title>Angiotensin II Receptor Blockers, ACE Inhibitors, and Statins</title><p>In a study, Yang et al. (<xref rid="B206" ref-type="bibr">2020b</xref>) mentioned that diabetes and cerebrovascular diseases were the commonly observed comorbidities in the non-survivors of nCOVID-19 in ICUs. Furthermore, Guan et al. (<xref rid="B79" ref-type="bibr">2020</xref>) also observed similar results in their study and these nCOVID-19 patients received angiotensin II receptor blockers (ARBs) or ACE inhibitors. Indeed, SARS-CoV-2 and SARS-CoV can bind with the ACE2 receptors on the epithelial cells of lung, kidney, and intestine (Fang et al., <xref rid="B60" ref-type="bibr">2020</xref>). Therefore, when ARDS is not present, ARB or ACE inhibitors can be administered to nCOVID-19 patients. Increased activity of ACE2 was found to be linked with decreased severity of ARDS among individuals with RSV-caused lower respiratory tract infection (W&#x000f6;sten-van Asperen et al., <xref rid="B199" ref-type="bibr">2013</xref>). Interestingly, Fedson (<xref rid="B63" ref-type="bibr">2016</xref>) revealed in their study that statins mainly target host response to infection, instead of the virus itself. These researchers also indicated that combination therapy with statins and ARB may induce the reversal of homeostatic processes, which will allow the self-recovery of individuals (Fedson et al., <xref rid="B64" ref-type="bibr">2020</xref>).</p></sec><sec><title>Non-steroidal Anti-inflammatory Drugs</title><p>There is an argument regarding the usage of non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen since it can increase the ACE2 receptors (Day, <xref rid="B55" ref-type="bibr">2020</xref>). If the severely ill nCOVID-19 individuals suffer from fever, acetaminophen can be a good option to control body temperature as compared to other NSAIDs (Therapeutics Initiative, <xref rid="B177" ref-type="bibr">2020</xref>).</p></sec><sec><title>Anticoagulant Therapy</title><p>Tang et al. (<xref rid="B176" ref-type="bibr">2020</xref>) confirmed that anticoagulant therapy by heparin (an anticoagulant) specially with low molecular weight heparin improved the prognosis in severely ill patients with nCOVID-19. Furthermore, 28-day mortality of heparin receivers was found to be lower as compared to the non-users among individuals with sepsis-stimulated coagulopathy scores 4 or D-dimer &#x0003e; 6-times the upper limit of normal (Tang et al., <xref rid="B176" ref-type="bibr">2020</xref>).</p></sec><sec><title>Enhancing Immunity by Vitamins and Minerals in nCOVID-19</title><sec><title>Vitamin A</title><p>In human body, vitamin A plays various important functions including protecting mucosal and epithelium integrity, mediating growth and development, and proper maintenance of vision (Huang et al., <xref rid="B87" ref-type="bibr">2018</xref>). Vitamin A is also essential for enhancing immune response and maintaining regulatory action in both humoral and cellular immune responses (Huang et al., <xref rid="B87" ref-type="bibr">2018</xref>). In case of infants, supplementation with vitamin A was found to ameliorate antibody response following several vaccines including anti-rabies (Siddiqui et al., <xref rid="B167" ref-type="bibr">2001</xref>) and measles vaccination (Huang et al., <xref rid="B87" ref-type="bibr">2018</xref>). Moreover, an improved immune response to influenza virus vaccination has also been reported in children (2&#x02013;8 years) who had a deficiency of vitamin A and D at baseline, following supplementation with vitamin A and D (Patel et al., <xref rid="B141" ref-type="bibr">2019</xref>).</p></sec><sec><title>Vitamin D</title><p>Vitamin D has a significant contribution in modifying both adaptive and innate immune responses (Aranow, <xref rid="B9" ref-type="bibr">2011</xref>). It has been revealed by epidemiological studies that there is a link between deficiency of vitamin D and elevated susceptibility to acute viral respiratory infections (Monlezun et al., <xref rid="B132" ref-type="bibr">2015</xref>). It has also been suggested that vitamin D significantly modulates the innate immune responses against various viral respiratory infections including RSV, parainfluenza 1 and 2, and influenza A and B (Zdrenghea et al., <xref rid="B213" ref-type="bibr">2017</xref>). Indeed, studies have revealed that there is a strong relationship between vitamin D deficiency and elevated risk of both lower and upper respiratory tract infections (Jolliffe et al., <xref rid="B94" ref-type="bibr">2013</xref>). Nonetheless, conflicting and heterogeneity in dosage regimens and baseline vitamin D conditions in study populations were observed in randomized controlled trials (RCTs) (Jolliffe et al., <xref rid="B94" ref-type="bibr">2013</xref>). In a study, Aglipay et al. (<xref rid="B4" ref-type="bibr">2017</xref>) observed no significant difference between the action of high-dose (2000 IU per day) vs. standard-dose (400 IU per day) vitamin D supplementation on viral upper respiratory tract infections (Aglipay et al., <xref rid="B4" ref-type="bibr">2017</xref>). Nevertheless, only one-third of the study subjects received vitamin D at doses below 30 ng/ml. Vitamin D increased the plasma level of TGF&#x003b2; without ameliorating antibody generation in a RCT on the effect of vitamin D administration on influenza vaccine response in deficient elderly person (Goncalves-Mendes et al., <xref rid="B74" ref-type="bibr">2019</xref>). In addition to this, it was also indicated in the latter mentioned RCT that vitamin D administration perhaps directed the polarization of lymphocyte toward a tolerogenic immune response (Goncalves-Mendes et al., <xref rid="B74" ref-type="bibr">2019</xref>). In a different RCT, monthly administration of high-dose of vitamin D (100,000 IU/month) decreased the occurrence of acute respiratory infections in older long-term care residents as compared to a standard dose group (12,000 IU/month) (Ginde et al., <xref rid="B72" ref-type="bibr">2017</xref>). Therefore, it is quite clear that the effect of vitamin D on antiviral immunity against respiratory infections is dependent on an individual's vitamin D status. Moreover, it has been confirmed that vitamin D supplementation is also useful in case of other viral infections, for instance, vitamin D addition to conventional Peg-&#x003b1;-2b/ribavirin therapy for treatment-naive individuals with chronic HCV genotype 1 infection considerably ameliorated the viral response (Abu-Mouch et al., <xref rid="B1" ref-type="bibr">2011</xref>), and similar action was also seen in individuals with HCV genotype 2&#x02013;3 (Nimer and Mouch, <xref rid="B137" ref-type="bibr">2012</xref>).</p></sec><sec><title>Vitamin E</title><p>Vitamin E possesses strong antioxidant property and it can modify host immune responses [14]. The deficiency of this vitamin can lead to impairment of both cellular and humoral immune responses (Moriguchi and Muraga, <xref rid="B133" ref-type="bibr">2000</xref>). Some studies revealed that administration of vitamin E may exert harmful activities in case of infectious disease. Vitamin E increased the risk of pneumonia among 50&#x02013;69 years old adult smokers (Hemil&#x000e4; and Kaprio, <xref rid="B84" ref-type="bibr">2008</xref>). Similarly, vitamin E supplementation (200 IU/day) did not significantly reduce the respiratory tract infections in elderly nursing facility residents (Meydani et al., <xref rid="B128" ref-type="bibr">2004</xref>). Nevertheless, in a small pilot RCT, positive activities of vitamin E were seen in the treatment of chronic hepatitis B, where vitamin E administration markedly normalized the liver enzymes and HBV-DNA negativization (Andreone et al., <xref rid="B6" ref-type="bibr">2001</xref>). Similarly, in a RCT, vitamin E supplementation increased anti-HBe seroconversion and virological response in the pediatric population (Fiorino et al., <xref rid="B66" ref-type="bibr">2017</xref>).</p></sec><sec><title>Vitamin C</title><p>Vitamin C plays a significant role as an enzymatic cofactor in numerous physiological reactions including immune potentiation, collagen synthesis, and hormone generation (Kim et al., <xref rid="B100" ref-type="bibr">2013</xref>). In mouse models, it was revealed that vitamin C plays important role in the antiviral immune responses against the influenza A virus (H3N2) via the elevated generation of IFN-&#x003b1;/&#x003b2;, particularly at the early stages of infection (Kim et al., <xref rid="B100" ref-type="bibr">2013</xref>). Nonetheless, no significant benefit has been observed in using mega-dose of vitamin C as a prophylactic measure to lower the incidence of common cold caused by viral infections (Hemil&#x000e4; and Chalker, <xref rid="B83" ref-type="bibr">2013</xref>).</p></sec><sec><title>Zinc</title><p>Zinc (an essential trace element) contributes significantly in the growth, development, and maintenance of immune responses (Prasad, <xref rid="B147" ref-type="bibr">2013</xref>; Read et al., <xref rid="B155" ref-type="bibr">2019</xref>). The deficiency of zinc is linked with an enhanced susceptibility toward infectious diseases, for example, viral infections. An individual's zinc status is a vital factor that can affect the immune response against viral infections. Indeed, zinc-deficient individuals are at greater risk of developing infections including HCV or HIV (Read et al., <xref rid="B155" ref-type="bibr">2019</xref>). Acevedo-Murillo et al. (<xref rid="B2" ref-type="bibr">2019</xref>) reported that there was a noticeable clinical improvement in the 103 children (1 month&#x02212;5 years) with pneumonia in the zinc-receiving group as compared to placebo (Acevedo-Murillo et al., <xref rid="B2" ref-type="bibr">2019</xref>). The researchers also confirmed that there was a rise in the cytokine response in Th1 pattern (INF-&#x003b3; and IL-2) only in the zinc-receiving group, along with Th2 cytokines (IL-10 and IL-4) being increased or remained elevated in both groups. Following stem cell transplantation, oral administration of a high dose of zinc (150 mg/day) increased thymic activity and output of new CD4<sup>+</sup> naive T cells, which eventually helped in the prevention of Torque Teno virus reactivation (Iovino et al., <xref rid="B89" ref-type="bibr">2018</xref>). Nonetheless, Provinciali et al. (<xref rid="B148" ref-type="bibr">1998</xref>) summarized that prolonged administration of zinc (400 mg/day) or zinc plus arginine (4 d/day) in the elderly (age 64&#x02013;100 years) people restored zinc concentrations in plasma, which was ineffective in stimulating or improving the antibody response or number of CD3, CD4, or CD8 lymphocytes following influenza vaccination.</p></sec><sec><title>Selenium</title><p>Selenium (a trace element) also exerts a range of important functions including antioxidant effects, various pleiotropic activities, and anti-inflammatory effects (Rayman, <xref rid="B154" ref-type="bibr">2012</xref>). Selenium deficiency is found to be linked with cognitive impairment, poor immune response, and elevated risk of mortality, whereas an increased level of selenium or treatment with selenium has exhibited antiviral actions (Rayman, <xref rid="B154" ref-type="bibr">2012</xref>). Broome et al. (<xref rid="B22" ref-type="bibr">2004</xref>) assessed whether an increased selenium administration (50&#x02013;100 &#x003bc;g/day) ameliorated immune response in adults with a borderline concentration of selenium (Broome et al., <xref rid="B22" ref-type="bibr">2004</xref>). Treatment with selenium elevated the plasma selenium levels, and also increased the activities of cytosolic glutathione peroxidase and lymphocyte phospholipid. Furthermore, selenium also increased the cellular immune responses (elevated level of IFN-&#x003b3; and other cytokines), along with an increased level of T-helper cells and earlier peak T-cell proliferation. Nonetheless, it was observed that humoral immune responses were not affected (Broome et al., <xref rid="B22" ref-type="bibr">2004</xref>). Moreover, selenium treatment in participants also induced rapid poliovirus clearance.</p></sec><sec><title>Copper</title><p>Copper (another essential trace element) has a significant contribution in the differentiation and development of immune cells (Li et al., <xref rid="B109" ref-type="bibr">2019</xref>). It has also been confirmed that copper exerted <italic>in vitro</italic> antiviral effects. Intracellular copper was found to regulate the life cycle of influenza virus (Rupp et al., <xref rid="B159" ref-type="bibr">2017</xref>), while thujaplicin-copper chelates inhibited the replication of human influenza viruses (Miyamoto et al., <xref rid="B131" ref-type="bibr">1998</xref>). In a study, Turnlund et al. (<xref rid="B181" ref-type="bibr">2004</xref>) determined the effects of chronic administration of copper on immune response, oxidative stress, and indices of copper status. These researchers observed that when copper was administered at a dose of 7.8 mg/day, copper significantly increased the level of superoxide dismutase, benzylamine oxidase, and plasma ceruloplasmin activity as compared to 1.6 mg/day dose, which further suggesting an enhancement in antioxidant status. Nonetheless, increased copper administration (7.8 mg/day) markedly decreased the proportion of antibody titer, serum IL-2R, and circulating neutrophils against the Beijing strain of influenza (Turnlund et al., <xref rid="B181" ref-type="bibr">2004</xref>).</p></sec><sec><title>Magnesium</title><p>Magnesium (an essential mineral) has a significant contribution in regulating immune response via significantly affecting the T helper-B cell adherence, macrophage response to lymphokines, Immunoglobulin M (IgM) lymphocyte binding, adherence with immune cells, antibody-dependent cytolysis, and immunoglobulin synthesis (Liang et al., <xref rid="B115" ref-type="bibr">2012</xref>). It has also been reported in <italic>in vivo</italic> and <italic>in-vitro</italic> studies that magnesium may have a contribution in the immune function against viral infections (Chaigne-Delalande et al., <xref rid="B31" ref-type="bibr">2013</xref>).</p></sec></sec></sec></sec><sec id="s9"><title>Controversies Regarding nCOVID-19 Treatments</title><p>Still now there is no specific antiviral drug to treat nCOVID-19, but some of the investigational drugs were found to be useful. Various drugs are being analyzed <italic>in vitro</italic> studies or clinical trials. Although ribavirin is a potent antiviral drug, its clinical effects are not clear and its side effects ought to be carefully considered. On the other hand, chloroquine has been studied in 15 interventional studies. Furthermore, in the Chinese Clinical Trial Registry, the derivatives of chloroquine were prospectively registered; and more studies are required to evaluate their antiviral effects and to estimate the recommended dose in nCOVID-19 patients (Zhang et al., <xref rid="B214" ref-type="bibr">2020a</xref>). Along with antiviral drugs, glucocorticoids ought to be utilized carefully and in a timely manner in nCOVID-19 patients. In addition to this, extracorporeal support need to be considered under strict contraindications and indications, otherwise, there will be numerous additional complications and also a waste of resources (Zhang et al., <xref rid="B214" ref-type="bibr">2020a</xref>).</p></sec><sec id="s10"><title>Future Research Directions</title><p>In order to manage the current nCOVID-19 outbreak, extensive measures are needed to be taken to lower the person-to-person transmission of the virus. In addition to this, special efforts and attention are required to reduce or protect the susceptible populations such as elderly people, health care providers, and children. More studies are also essential to understand the mechanisms related to nCOVID-19 pathogenesis. This better understanding will help the development of specific and effective therapies against SARS-CoV-2. Since the respiratory tract is mainly affected by SARS-CoV-2, thus special consideration is required to deliver the drug into the respiratory tract. More studies in animals and clinical trials on drug repositioning can also be considered to identify potential drugs to treat nCOVID-19.</p></sec><sec sec-type="conclusions" id="s11"><title>Conclusion</title><p>Still there is no available specific drug or vaccine to treat nCOVID-19, thus effective preventative measures are recommended. Specific drugs are urgently required to inhibit the entry of the virus and subsequent replication to overcome this outbreak. Currently, as mentioned in this article, multiple investigational drugs and clinical trials are ongoing. The discovery of new drugs will ultimately enable us to better control this outbreak. Furthermore, <italic>in silico</italic> studies can also be considered to faster the drug development process. Finally, sharing findings or data will be effective to fight against nCOVID-19 globally.</p></sec><sec id="s12"><title>Author Contributions</title><p>MK and MU conceived the original idea and designed the outlines of the study and prepared the figures for the manuscript. MK wrote the initial draft of the manuscript. MU revised and improved the draft. MH, JA, MA, GA, SB, MB-J, MA-D, and LA participated in the literature review of the manuscript. All authors have read and approved the final manuscript.</p></sec><sec id="s13"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ack><p>This work was funded by the Deanship of Scientific Research at Princess Nourah bint Abdulrahman University, through the Fast-track Research Funding Program. This work was supported by King Saud University, Deanship of Scientific Research, College of Science Research Center.</p></ack><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abu-Mouch</surname><given-names>S.</given-names></name><name><surname>Fireman</surname><given-names>Z.</given-names></name><name><surname>Jarchovsky</surname><given-names>J.</given-names></name><name><surname>Zeina</surname><given-names>A. R.</given-names></name><name><surname>Assy</surname><given-names>N.</given-names></name></person-group> (<year>2011</year>). <article-title>Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-na&#x000ef;ve patients</article-title>. <source>World J. Gastroenterol.</source>
<volume>17</volume>, <fpage>5184</fpage>&#x02013;<lpage>5190</lpage>. <pub-id pub-id-type="doi">10.3748/wjg.v17.i47.5184</pub-id><?supplied-pmid 22215943?><pub-id pub-id-type="pmid">22215943</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acevedo-Murillo</surname><given-names>J. A.</given-names></name><name><surname>Garc&#x000ed;a Le&#x000f3;n</surname><given-names>M. L.</given-names></name><name><surname>Firo-Reyes</surname><given-names>V.</given-names></name><name><surname>Santiago-Cordova</surname><given-names>J. L.</given-names></name><name><surname>Gonzalez-Rodriguez</surname><given-names>A. P.</given-names></name><name><surname>Wong-Chew</surname><given-names>R. M.</given-names></name></person-group> (<year>2019</year>). <article-title>Zinc supplementation promotes a Th1 response and improves clinical symptoms in fewer hours in children with pneumonia younger than 5 years old</article-title>. <source>A randomized controlled clinical trial. Front. Pediatr.</source>
<volume>7</volume>:<fpage>431</fpage>. <pub-id pub-id-type="doi">10.3389/fped.2019.00431</pub-id><?supplied-pmid 31803694?><pub-id pub-id-type="pmid">31803694</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adhikari</surname><given-names>S. P.</given-names></name><name><surname>Meng</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>Y. J.</given-names></name><name><surname>Mao</surname><given-names>Y. P.</given-names></name><name><surname>Ye</surname><given-names>R. X.</given-names></name><name><surname>Wang</surname><given-names>Q. Z.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review</article-title>. <source>Infect. Dis. Poverty</source>
<volume>9</volume>:<fpage>29</fpage>. <pub-id pub-id-type="doi">10.1186/s40249-020-00646-x</pub-id><?supplied-pmid 32183901?><pub-id pub-id-type="pmid">32183901</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aglipay</surname><given-names>M.</given-names></name><name><surname>Birken</surname><given-names>C. S.</given-names></name><name><surname>Parkin</surname><given-names>P. C.</given-names></name><name><surname>Loeb</surname><given-names>M. B.</given-names></name><name><surname>Thorpe</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Effect of high-dose vs standard-dose wintertime Vitamin D supplementation on viral upper respiratory tract infections in young healthy children</article-title>. <source>J. Am. Med. Assoc.</source>
<volume>318</volume>, <fpage>245</fpage>&#x02013;<lpage>254</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2017.8708</pub-id><?supplied-pmid 28719693?><pub-id pub-id-type="pmid">28719693</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agostini</surname><given-names>M. L.</given-names></name><name><surname>Andres</surname><given-names>E. L.</given-names></name><name><surname>Sims</surname><given-names>A. C.</given-names></name><name><surname>Graham</surname><given-names>R. L.</given-names></name><name><surname>Sheahan</surname><given-names>T. P.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease</article-title>. <source>MBio</source>
<volume>9</volume>, <fpage>e00221</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1128/mBio.00221-18</pub-id><?supplied-pmid 29511076?><pub-id pub-id-type="pmid">29511076</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreone</surname><given-names>P.</given-names></name><name><surname>Fiorino</surname><given-names>S.</given-names></name><name><surname>Cursaro</surname><given-names>C.</given-names></name><name><surname>Gramenzi</surname><given-names>A.</given-names></name><name><surname>Margotti</surname><given-names>M.</given-names></name><name><surname>Di Giammarino</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2001</year>). <article-title>Vitamin E as treatment for chronic hepatitis B: results of a randomized controlled pilot trial</article-title>. <source>Antiviral Res.</source>
<volume>49</volume>, <fpage>75</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/S0166-3542(00)00141-8</pub-id><?supplied-pmid 11248360?><pub-id pub-id-type="pmid">11248360</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arabi</surname><given-names>Y. M.</given-names></name><name><surname>Mandourah</surname><given-names>Y.</given-names></name><name><surname>Al-Hameed</surname><given-names>F.</given-names></name><name><surname>Sindi</surname><given-names>A. A.</given-names></name><name><surname>Almekhlafi</surname><given-names>G. A.</given-names></name><name><surname>Hussein</surname><given-names>M. A.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Corticosteroid therapy for critically ill patients with middle east respiratory syndrome</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>197</volume>, <fpage>757</fpage>&#x02013;<lpage>767</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201706-1172OC</pub-id><?supplied-pmid 29161116?><pub-id pub-id-type="pmid">29161116</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arab-Zozani</surname><given-names>M.</given-names></name><name><surname>Hassanipour</surname><given-names>S.</given-names></name><name><surname>Ghoddoosi-Nejad</surname><given-names>D. J.</given-names></name></person-group> (<year>2020</year>). <article-title>Favipiravir for treating novel coronavirus (COVID-19) patients: protocol for a systematic review and meta-analysis of controlled trials</article-title>. <source>medRxiv.</source>
<pub-id pub-id-type="doi">10.1101/2020.04.27.20081471</pub-id>. [Epub ahead of print].</mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aranow</surname><given-names>C.</given-names></name></person-group> (<year>2011</year>). <article-title>Vitamin D and the immune system</article-title>. <source>J. Investig. Med.</source>
<volume>59</volume>, <fpage>881</fpage>&#x02013;<lpage>886</lpage>. <pub-id pub-id-type="doi">10.2310/JIM.0b013e31821b8755</pub-id><?supplied-pmid 21527855?><pub-id pub-id-type="pmid">21527855</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Assiri</surname><given-names>A.</given-names></name><name><surname>Al-Tawfiq</surname><given-names>J. A.</given-names></name><name><surname>Al-Rabeeah</surname><given-names>A. A.</given-names></name><name><surname>Al-Rabiah</surname><given-names>F. A.</given-names></name><name><surname>Al-Hajjar</surname><given-names>S.</given-names></name><name><surname>Al-Barrak</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study</article-title>. <source>Lancet Infect. Dis.</source>
<volume>13</volume>, <fpage>752</fpage>&#x02013;<lpage>761</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(13)70204-4</pub-id><?supplied-pmid 23891402?><pub-id pub-id-type="pmid">23891402</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auyeung</surname><given-names>T. W.</given-names></name><name><surname>Lee</surname><given-names>J. S. W.</given-names></name><name><surname>Lai</surname><given-names>W. K.</given-names></name><name><surname>Choi</surname><given-names>C. H.</given-names></name><name><surname>Lee</surname><given-names>H. K.</given-names></name><name><surname>Lee</surname><given-names>J. S.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study</article-title>. <source>J. Infect.</source>
<volume>51</volume>, <fpage>98</fpage>&#x02013;<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2004.09.008</pub-id><?supplied-pmid 16038758?><pub-id pub-id-type="pmid">16038758</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bacharier</surname><given-names>L. B.</given-names></name><name><surname>Guilbert</surname><given-names>T. W.</given-names></name><name><surname>Mauger</surname><given-names>D. T.</given-names></name><name><surname>Boehmer</surname><given-names>S.</given-names></name><name><surname>Beigelman</surname><given-names>A.</given-names></name><name><surname>Fitzpatrick</surname><given-names>A. M.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Early Administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses a randomized clinical trial</article-title>. <source>J. Am. Med. Assoc.</source>
<volume>314</volume>, <fpage>2034</fpage>&#x02013;<lpage>2044</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2015.13896</pub-id><?supplied-pmid 26575060?><pub-id pub-id-type="pmid">26575060</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>M.-C.</given-names></name><name><surname>Kim</surname><given-names>J. Y.</given-names></name><name><surname>Cha</surname><given-names>H.-H.</given-names></name><name><surname>Lim</surname><given-names>J. S.</given-names></name><name><surname>Jung</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Effectiveness of surgical and cotton masks in blocking SARS&#x02013;CoV-2: a controlled comparison in 4 patients</article-title>. <source>Ann. Intern. Med.</source>
<volume>6</volume>, <fpage>M20</fpage>&#x02013;<lpage>M1342</lpage>. <pub-id pub-id-type="doi">10.7326/m20-1342</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Yu</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name></person-group> (<year>2016</year>). <article-title>The influence of temperature on mortality and its lag effect: a study in four Chinese cities with different latitudes</article-title>. <source>BMC Public Health</source>
<volume>16</volume>:<fpage>375</fpage>. <pub-id pub-id-type="doi">10.1186/s12889-016-3031-z</pub-id><?supplied-pmid 27146378?><pub-id pub-id-type="pmid">27146378</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baron</surname><given-names>S. A.</given-names></name><name><surname>Devaux</surname><given-names>C.</given-names></name><name><surname>Colson</surname><given-names>P.</given-names></name><name><surname>Raoult</surname><given-names>D.</given-names></name><name><surname>Rolain</surname><given-names>J. M.</given-names></name></person-group> (<year>2020</year>). <article-title>Teicoplanin: an alternative drug for the treatment of COVID-19?</article-title>
<source>Int. J. Antimicrob. Agents</source>
<volume>55</volume>:<fpage>105944</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105944</pub-id><?supplied-pmid 32179150?><pub-id pub-id-type="pmid">32179150</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beigel</surname><given-names>J. H.</given-names></name><name><surname>Nam</surname><given-names>H. H.</given-names></name><name><surname>Adams</surname><given-names>P. L.</given-names></name><name><surname>Krafft</surname><given-names>A.</given-names></name><name><surname>Ince</surname><given-names>W. L.</given-names></name><name><surname>El-Kamary</surname><given-names>S. S.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Advances in respiratory virus therapeutics &#x02013; a meeting report from the 6th isirv antiviral group conference</article-title>. <source>Antiviral Res.</source>
<volume>167</volume>, <fpage>45</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2019.04.006</pub-id><?supplied-pmid 30974127?><pub-id pub-id-type="pmid">30974127</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bekerman</surname><given-names>E.</given-names></name><name><surname>Neveu</surname><given-names>G.</given-names></name><name><surname>Shulla</surname><given-names>A.</given-names></name><name><surname>Brannan</surname><given-names>J.</given-names></name><name><surname>Pu</surname><given-names>S. Y.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects</article-title>. <source>J. Clin. Invest.</source>
<volume>127</volume>, <fpage>1338</fpage>&#x02013;<lpage>1352</lpage>. <pub-id pub-id-type="doi">10.1172/JCI89857</pub-id><?supplied-pmid 28240606?><pub-id pub-id-type="pmid">28240606</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belouzard</surname><given-names>S.</given-names></name><name><surname>Chu</surname><given-names>V. C.</given-names></name><name><surname>Whittaker</surname><given-names>G. R.</given-names></name></person-group> (<year>2009</year>). <article-title>Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>106</volume>, <fpage>5871</fpage>&#x02013;<lpage>5876</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0809524106</pub-id><?supplied-pmid 19321428?><pub-id pub-id-type="pmid">19321428</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bogoch</surname><given-names>I. I.</given-names></name><name><surname>Watts</surname><given-names>A.</given-names></name><name><surname>Thomas-Bachli</surname><given-names>A.</given-names></name><name><surname>Huber</surname><given-names>C.</given-names></name><name><surname>Kraemer</surname><given-names>M. U. G.</given-names></name><name><surname>Khan</surname><given-names>K.</given-names></name></person-group> (<year>2020</year>). <article-title>Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel</article-title>. <source>J. Travel Med</source>. <volume>27</volume>:<fpage>taaa008</fpage>. <pub-id pub-id-type="doi">10.1093/jtm/taaa008</pub-id><?supplied-pmid 31943059?><pub-id pub-id-type="pmid">31943059</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borchgrevink</surname><given-names>C. P.</given-names></name><name><surname>Cha</surname><given-names>J. M.</given-names></name><name><surname>Kim</surname><given-names>S. H.</given-names></name></person-group> (<year>2013</year>). <article-title>Hand washing practices in a college town environment</article-title>. <source>J. Environ. Health</source>
<volume>75</volume>, <fpage>18</fpage>&#x02013;<lpage>24</lpage>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://europepmc.org/article/med/23621052">https://europepmc.org/article/med/23621052</ext-link><?supplied-pmid 23621052?><pub-id pub-id-type="pmid">23621052</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boriskin</surname><given-names>Y.</given-names></name><name><surname>Leneva</surname><given-names>I.</given-names></name><name><surname>Pecheur</surname><given-names>E.-I.</given-names></name><name><surname>Polyak</surname><given-names>S.</given-names></name></person-group> (<year>2008</year>). <article-title>Arbidol: a broad-spectrum antiviral compound that blocks viral fusion</article-title>. <source>Curr. Med. Chem.</source>
<volume>15</volume>, <fpage>997</fpage>&#x02013;<lpage>1005</lpage>. <pub-id pub-id-type="doi">10.2174/092986708784049658</pub-id><?supplied-pmid 18393857?><pub-id pub-id-type="pmid">18393857</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broome</surname><given-names>C. S.</given-names></name><name><surname>McArdle</surname><given-names>F.</given-names></name><name><surname>Kyle</surname><given-names>J. A. M.</given-names></name><name><surname>Andrews</surname><given-names>F.</given-names></name><name><surname>Lowe</surname><given-names>N. M.</given-names></name><name><surname>Hart</surname><given-names>C. A.</given-names></name><etal/></person-group>. (<year>2004</year>). <article-title>An increase in selenium intake improves immune function and poliovirus handling in adults with marginal selenium status</article-title>. <source>Am. J. Clin. Nutr.</source>
<volume>80</volume>, <fpage>154</fpage>&#x02013;<lpage>162</lpage>. <pub-id pub-id-type="doi">10.1093/ajcn/80.1.154</pub-id><?supplied-pmid 15213043?><pub-id pub-id-type="pmid">15213043</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>A. J.</given-names></name><name><surname>Won</surname><given-names>J. J.</given-names></name><name><surname>Graham</surname><given-names>R. L.</given-names></name><name><surname>Dinnon</surname><given-names>K. H.</given-names></name><name><surname>Sims</surname><given-names>A. C.</given-names></name><name><surname>Feng</surname><given-names>J. Y.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase</article-title>. <source>Antiviral Res.</source>
<volume>169</volume>:<fpage>104541</fpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2019.104541</pub-id><?supplied-pmid 31233808?><pub-id pub-id-type="pmid">31233808</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Q. C.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>Q. F.</given-names></name><name><surname>Guo</surname><given-names>Q.</given-names></name><name><surname>Xu</surname><given-names>D. Z.</given-names></name><name><surname>Sun</surname><given-names>Q. W.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>Influence of meteorological factors and air pollution on the outbreak of severe acute respiratory syndrome</article-title>. <source>Public Health</source>
<volume>121</volume>, <fpage>258</fpage>&#x02013;<lpage>265</lpage>. <pub-id pub-id-type="doi">10.1016/j.puhe.2006.09.023</pub-id><?supplied-pmid 17307207?><pub-id pub-id-type="pmid">17307207</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caly</surname><given-names>L.</given-names></name><name><surname>Druce</surname><given-names>J. D.</given-names></name><name><surname>Catton</surname><given-names>M. G.</given-names></name><name><surname>Jans</surname><given-names>D. A.</given-names></name><name><surname>Wagstaff</surname><given-names>K. M.</given-names></name></person-group> (<year>2020</year>). <article-title>The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 <italic>in vitro</italic></article-title>. <source>Antiviral Res.</source>
<volume>178</volume>:<fpage>104787</fpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104787</pub-id><?supplied-pmid 32251768?><pub-id pub-id-type="pmid">32251768</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caly</surname><given-names>L.</given-names></name><name><surname>Wagstaff</surname><given-names>K. M.</given-names></name><name><surname>Jans</surname><given-names>D. A.</given-names></name></person-group> (<year>2012</year>). <article-title>Nuclear trafficking of proteins from RNA viruses: potential target for antivirals?</article-title>
<source>Antiviral Res.</source>
<volume>95</volume>, <fpage>202</fpage>&#x02013;<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2012.06.008</pub-id><?supplied-pmid 22750233?><pub-id pub-id-type="pmid">22750233</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname><given-names>M. J.</given-names></name><name><surname>Bermejo-Martin</surname><given-names>J. F.</given-names></name><name><surname>Danesh</surname><given-names>A.</given-names></name><name><surname>Muller</surname><given-names>M. P.</given-names></name><name><surname>Kelvin</surname><given-names>D. J.</given-names></name></person-group> (<year>2008</year>). <article-title>Human immunopathogenesis of severe acute respiratory syndrome (SARS)</article-title>. <source>Virus Res.</source>
<volume>133</volume>, <fpage>13</fpage>&#x02013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2007.02.014</pub-id><?supplied-pmid 17374415?><pub-id pub-id-type="pmid">17374415</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wen</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>A Trial of lopinavir&#x02013;ritonavir in adults hospitalized with severe covid-19</article-title>. <source>N. Engl. J. Med.</source>
<volume>382</volume>, <fpage>1787</fpage>&#x02013;<lpage>1799</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa2001282</pub-id><?supplied-pmid 32187464?><pub-id pub-id-type="pmid">32187464</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>CDC</collab></person-group> (<year>2020a</year>). <source>Cases in the U.S</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fcases-updates%2Fsummary.html">https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fcases-updates%2Fsummary.html</ext-link> (accessed June 7, 2020a).</mixed-citation></ref><ref id="B30"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>CDC</collab></person-group> (<year>2020b</year>). <source>Infection Control Guidance for Healthcare Professionals about Coronavirus (COVID-19)</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control.html">https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control.html</ext-link> (accessed June 7, 2020b).</mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaigne-Delalande</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>F. Y.</given-names></name><name><surname>O'Connor</surname><given-names>G. M.</given-names></name><name><surname>Lukacs</surname><given-names>M. J.</given-names></name><name><surname>Jiang</surname><given-names>P.</given-names></name><name><surname>Zheng</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D</article-title>. <source>Science</source>
<volume>341</volume>, <fpage>186</fpage>&#x02013;<lpage>191</lpage>. <pub-id pub-id-type="doi">10.1126/science.1240094</pub-id><?supplied-pmid 23846901?><pub-id pub-id-type="pmid">23846901</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J. F.-W.</given-names></name><name><surname>Yao</surname><given-names>Y.</given-names></name><name><surname>Yeung</surname><given-names>M.-L.</given-names></name><name><surname>Deng</surname><given-names>W.</given-names></name><name><surname>Bao</surname><given-names>L.</given-names></name><name><surname>Jia</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Treatment with lopinavir/ritonavir or interferon-&#x003b2;1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset</article-title>. <source>J. Infect. Dis.</source>
<volume>212</volume>, <fpage>1904</fpage>&#x02013;<lpage>1913</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiv392</pub-id><?supplied-pmid 26198719?><pub-id pub-id-type="pmid">26198719</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J. F. W.</given-names></name><name><surname>Lau</surname><given-names>S. K. P.</given-names></name><name><surname>Woo</surname><given-names>P. C. Y.</given-names></name></person-group> (<year>2013</year>). <article-title>The emerging novel middle east respiratory syndrome coronavirus: the &#x0201c;knowns&#x0201d; and &#x0201c;unknowns.&#x0201d;</article-title>
<source>J. Formos. Med. Assoc.</source>
<volume>112</volume>, <fpage>372</fpage>&#x02013;<lpage>381</lpage>. <pub-id pub-id-type="doi">10.1016/j.jfma.2013.05.010</pub-id><?supplied-pmid 23883791?><pub-id pub-id-type="pmid">23883791</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>K. H.</given-names></name><name><surname>Peiris</surname><given-names>J. S. M.</given-names></name><name><surname>Lam</surname><given-names>S. Y.</given-names></name><name><surname>Poon</surname><given-names>L. L. M.</given-names></name><name><surname>Yuen</surname><given-names>K. Y.</given-names></name><name><surname>Seto</surname><given-names>W. H.</given-names></name></person-group> (<year>2011</year>). <article-title>The effects of temperature and relative humidity on the viability of the SARS coronavirus</article-title>. <source>Adv. Virol.</source>
<volume>2011</volume>:<fpage>734690</fpage>. <pub-id pub-id-type="doi">10.1155/2011/734690</pub-id><?supplied-pmid 22312351?><pub-id pub-id-type="pmid">22312351</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Channappanavar</surname><given-names>R.</given-names></name><name><surname>Fehr</surname><given-names>A. R.</given-names></name><name><surname>Vijay</surname><given-names>R.</given-names></name><name><surname>Mack</surname><given-names>M.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Meyerholz</surname><given-names>D. K.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Dysregulated type i interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice</article-title>. <source>Cell Host Microbe</source>
<volume>19</volume>, <fpage>181</fpage>&#x02013;<lpage>193</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2016.01.007</pub-id><?supplied-pmid 26867177?><pub-id pub-id-type="pmid">26867177</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Channappanavar</surname><given-names>R.</given-names></name><name><surname>Fehr</surname><given-names>A. R.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Wohlford-Lenane</surname><given-names>C.</given-names></name><name><surname>Abrahante</surname><given-names>J. E.</given-names></name><name><surname>Mack</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes</article-title>. <source>J. Clin. Invest.</source>
<volume>129</volume>, <fpage>3625</fpage>&#x02013;<lpage>3639</lpage>. <pub-id pub-id-type="doi">10.1172/JCI126363</pub-id><?supplied-pmid 31355779?><pub-id pub-id-type="pmid">31355779</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Channappanavar</surname><given-names>R.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology</article-title>. <source>Semin. Immunopathol.</source>
<volume>39</volume>, <fpage>529</fpage>&#x02013;<lpage>539</lpage>. <pub-id pub-id-type="doi">10.1007/s00281-017-0629-x</pub-id><?supplied-pmid 28466096?><pub-id pub-id-type="pmid">28466096</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Xiong</surname><given-names>J.</given-names></name><name><surname>Bao</surname><given-names>L.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name></person-group> (<year>2020a</year>). <article-title>Convalescent plasma as a potential therapy for COVID-19</article-title>. <source>Lancet Infect. Dis.</source>
<volume>20</volume>, <fpage>398</fpage>&#x02013;<lpage>400</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30141-9</pub-id><?supplied-pmid 32113510?><pub-id pub-id-type="pmid">32113510</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>R. C.</given-names></name><name><surname>Tang</surname><given-names>X. P.</given-names></name><name><surname>Tan</surname><given-names>S. Y.</given-names></name><name><surname>Liang</surname><given-names>B. L.</given-names></name><name><surname>Wan</surname><given-names>Z. Y.</given-names></name><name><surname>Fang</surname><given-names>J. Q.</given-names></name><etal/></person-group>. (<year>2006a</year>). <article-title>Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience</article-title>. <source>Chest</source>
<volume>129</volume>, <fpage>1441</fpage>&#x02013;<lpage>1452</lpage>. <pub-id pub-id-type="doi">10.1378/chest.129.6.1441</pub-id><?supplied-pmid 16778260?><pub-id pub-id-type="pmid">16778260</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>T.</given-names></name><name><surname>Wu</surname><given-names>D.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Yan</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>D.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>2020b</year>). <article-title>Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study</article-title>. <source>BMJ</source>
<volume>368</volume>:<fpage>m1091</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.m1091</pub-id><?supplied-pmid 32217556?><pub-id pub-id-type="pmid">32217556</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y. M. A.</given-names></name><name><surname>Liang</surname><given-names>S. Y.</given-names></name><name><surname>Shih</surname><given-names>Y. P.</given-names></name><name><surname>Chen</surname><given-names>C. Y.</given-names></name><name><surname>Lee</surname><given-names>Y. M.</given-names></name><name><surname>Chang</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2006b</year>). <article-title>Epidemiological and genetic correlates of severe acute respiratory syndrome coronavirus infection in the hospital with the highest nosocomial infection rate in Taiwan in 2003</article-title>. <source>J. Clin. Microbiol.</source>
<volume>44</volume>, <fpage>359</fpage>&#x02013;<lpage>365</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.44.2.359-365.2006</pub-id><?supplied-pmid 16455884?><pub-id pub-id-type="pmid">16455884</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>C. C.</given-names></name><name><surname>Shen</surname><given-names>C. F.</given-names></name><name><surname>Chen</surname><given-names>S. J.</given-names></name><name><surname>Chen</surname><given-names>H. M.</given-names></name><name><surname>Wang</surname><given-names>Y. C.</given-names></name><name><surname>Chang</surname><given-names>W. S.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Recommendations and guidelines for the treatment of pneumonia in Taiwan</article-title>. <source>J. Microbiol. Immunol. Infect.</source>
<volume>52</volume>, <fpage>172</fpage>&#x02013;<lpage>199</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmii.2018.11.004</pub-id><?supplied-pmid 30612923?><pub-id pub-id-type="pmid">30612923</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>ClinicalTrials.gov</collab></person-group> (<year>2020a</year>). <source>Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04324073?load=cart">https://clinicaltrials.gov/ct2/show/NCT04324073?load=cart</ext-link> (accessed June 4, 2020)</mixed-citation></ref><ref id="B44"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>ClinicalTrials.gov</collab></person-group> (<year>2020b</year>). <source>Eculizumab (Soliris) in Covid-19 Infected Patients</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04288713">https://clinicaltrials.gov/ct2/show/NCT04288713</ext-link> (accessed June 4, 2020).</mixed-citation></ref><ref id="B45"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>ClinicalTrials.gov</collab></person-group> (<year>2020c</year>). <source>Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04324021">https://clinicaltrials.gov/ct2/show/NCT04324021</ext-link> (accessed June 4, 2020).</mixed-citation></ref><ref id="B46"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>ClinicalTrials.gov</collab></person-group> (<year>2020d</year>). <source>Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04315298">https://clinicaltrials.gov/ct2/show/NCT04315298</ext-link> (accessed June 4, 2020).</mixed-citation></ref><ref id="B47"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>ClinicalTrials.gov</collab></person-group> (<year>2020e</year>). <source>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734TM) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04292730">https://clinicaltrials.gov/ct2/show/NCT04292730</ext-link> (accessed June 7, 2020).</mixed-citation></ref><ref id="B48"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>ClinicalTrials.gov</collab></person-group> (<year>2020f</year>). <source>Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04321993">https://clinicaltrials.gov/ct2/show/NCT04321993</ext-link> (accessed June 4, 2020).</mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cockrell</surname><given-names>A. S.</given-names></name><name><surname>Yount</surname><given-names>B. L.</given-names></name><name><surname>Scobey</surname><given-names>T.</given-names></name><name><surname>Jensen</surname><given-names>K.</given-names></name><name><surname>Douglas</surname><given-names>M.</given-names></name><name><surname>Beall</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>A mouse model for MERS coronavirus-induced acute respiratory distress syndrome</article-title>. <source>Nat. Microbiol.</source>
<volume>2</volume>, <fpage>1</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1038/nmicrobiol.2016.226</pub-id><?supplied-pmid 27892925?><pub-id pub-id-type="pmid">27892925</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortegiani</surname><given-names>A.</given-names></name><name><surname>Ingoglia</surname><given-names>G.</given-names></name><name><surname>Ippolito</surname><given-names>M.</given-names></name><name><surname>Giarratano</surname><given-names>A.</given-names></name><name><surname>Einav</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19</article-title>. <source>J. Crit. Care</source>. <volume>57</volume>, <fpage>279</fpage>&#x02013;<lpage>283</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcrc.2020.03.005</pub-id><pub-id pub-id-type="pmid">32173110</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowling</surname><given-names>B. J.</given-names></name><name><surname>Chan</surname><given-names>K. H.</given-names></name><name><surname>Fang</surname><given-names>V. J.</given-names></name><name><surname>Cheng</surname><given-names>C. K. Y.</given-names></name><name><surname>Fung</surname><given-names>R. O. P.</given-names></name><name><surname>Wai</surname><given-names>W.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Facemasks and hand hygiene to prevent influenza transmission in households: a cluster randomized trial</article-title>. <source>Ann. Intern. Med.</source>
<volume>151</volume>, <fpage>437</fpage>&#x02013;<lpage>446</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-151-7-200910060-00142</pub-id><?supplied-pmid 19652172?><pub-id pub-id-type="pmid">19652172</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Z.-F.</given-names></name><name><surname>Froines</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Yu</surname><given-names>S.-Z.</given-names></name><etal/></person-group>. (<year>2003</year>). <article-title>Air pollution and case fatality of SARS in the people's republic of China: an ecologic study</article-title>. <source>Environ. Heal.</source>
<volume>2</volume>:<fpage>15</fpage>. <pub-id pub-id-type="doi">10.1186/1476-069x-2-15</pub-id><?supplied-pmid 14629774?><pub-id pub-id-type="pmid">14629774</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>A. C.</given-names></name><name><surname>Goh</surname><given-names>H. P.</given-names></name><name><surname>Koh</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>). <article-title>Treatment of COVID-19: Old tricks for new challenges</article-title>. <source>Crit. Care</source>
<volume>24</volume>, <fpage>1</fpage>&#x02013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1186/s13054-020-2818-6</pub-id><?supplied-pmid 32178711?><pub-id pub-id-type="pmid">31898531</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Amato</surname><given-names>M.</given-names></name><name><surname>Molino</surname><given-names>A.</given-names></name><name><surname>Calabrese</surname><given-names>G.</given-names></name><name><surname>Cecchi</surname><given-names>L.</given-names></name><name><surname>Annesi-Maesano</surname><given-names>I.</given-names></name><name><surname>D'Amato</surname><given-names>G.</given-names></name></person-group> (<year>2018</year>). <article-title>The impact of cold on the respiratory tract and its consequences to respiratory health</article-title>. <source>Clin. Transl. Allergy</source>
<volume>8</volume>:<fpage>20</fpage>. <pub-id pub-id-type="doi">10.1186/s13601-018-0208-9</pub-id><?supplied-pmid 29997887?><pub-id pub-id-type="pmid">29997887</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Day</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists</article-title>. <source>BMJ</source>
<volume>368</volume>:<fpage>m1086</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.m1086</pub-id><?supplied-pmid 32205306?><pub-id pub-id-type="pmid">32184201</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wit</surname><given-names>E.</given-names></name><name><surname>Feldmann</surname><given-names>F.</given-names></name><name><surname>Cronin</surname><given-names>J.</given-names></name><name><surname>Jordan</surname><given-names>R.</given-names></name><name><surname>Okumura</surname><given-names>A.</given-names></name><name><surname>Thomas</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>117</volume>, <fpage>6771</fpage>&#x02013;<lpage>6776</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1922083117</pub-id><?supplied-pmid 32054787?><pub-id pub-id-type="pmid">32054787</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wit</surname><given-names>E.</given-names></name><name><surname>van Doremalen</surname><given-names>N.</given-names></name><name><surname>Falzarano</surname><given-names>D.</given-names></name><name><surname>Munster</surname><given-names>V. J.</given-names></name></person-group> (<year>2016</year>). <article-title>SARS and MERS: recent insights into emerging coronaviruses</article-title>. <source>Nat. Rev. Microbiol.</source>
<volume>14</volume>, <fpage>523</fpage>&#x02013;<lpage>534</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro.2016.81</pub-id><?supplied-pmid 27344959?><pub-id pub-id-type="pmid">27344959</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Zeng</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study</article-title>. <source>J. Infect.</source>
<volume>81</volume>, <fpage>e1</fpage>&#x02013;<lpage>e5</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2020.03.002</pub-id><?supplied-pmid 32171872?><pub-id pub-id-type="pmid">32171872</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>Y. Y.</given-names></name><name><surname>Huang</surname><given-names>Z. T.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Wu</surname><given-names>M. H.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Koup</surname><given-names>R. A.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection</article-title>. <source>Arch. Virol.</source>
<volume>154</volume>, <fpage>1093</fpage>&#x02013;<lpage>1099</lpage>. <pub-id pub-id-type="doi">10.1007/s00705-009-0409-6</pub-id><?supplied-pmid 19526193?><pub-id pub-id-type="pmid">19526193</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>L.</given-names></name><name><surname>Karakiulakis</surname><given-names>G.</given-names></name><name><surname>Roth</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?</article-title>
<source>Lancet Respir. Med.</source>
<volume>8</volume>:<fpage>e21</fpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(20)30116-8</pub-id><?supplied-pmid 32171062?><pub-id pub-id-type="pmid">32171062</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Favalli</surname><given-names>E. G.</given-names></name><name><surname>Ingegnoli</surname><given-names>F.</given-names></name><name><surname>De Lucia</surname><given-names>O.</given-names></name><name><surname>Cincinelli</surname><given-names>G.</given-names></name><name><surname>Cimaz</surname><given-names>R.</given-names></name><name><surname>Caporali</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19 infection and rheumatoid arthritis: faraway, so close!</article-title>
<source>Autoimmun. Rev</source>. <volume>19</volume>:<fpage>102523</fpage>. <pub-id pub-id-type="doi">10.1016/j.autrev.2020.102523</pub-id><?supplied-pmid 32205186?><pub-id pub-id-type="pmid">32205186</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>FDA</collab></person-group> (<year>2020</year>). <source>Request for Emergency Use Authorization For Use of Chloroquine Phosphate or Hydroxychloroquine Sulfate Supplied From the Strategic National Stockpile for Treatment of, 019 Coronavirus Disease</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/media/136534/download">https://www.fda.gov/media/136534/download</ext-link> (accessed June 7, 2020).</mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fedson</surname><given-names>D. S.</given-names></name></person-group> (<year>2016</year>). <article-title>Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola</article-title>. <source>Ann. Transl. Med.</source>
<volume>4</volume>:<fpage>421</fpage>. <pub-id pub-id-type="doi">10.21037/12396</pub-id><?supplied-pmid 27942512?><pub-id pub-id-type="pmid">27942512</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fedson</surname><given-names>D. S.</given-names></name><name><surname>Opal</surname><given-names>S. M.</given-names></name><name><surname>Rordam</surname><given-names>O. M.</given-names></name></person-group> (<year>2020</year>). <article-title>Hiding in plain sight: an approach to treating patients with severe covid-19 infection</article-title>. <source>MBio</source>
<volume>11</volume>, <fpage>e00398</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1128/mBio.00398-20</pub-id><?supplied-pmid 32198163?><pub-id pub-id-type="pmid">32198163</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fehr</surname><given-names>A. R.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name></person-group> (<year>2015</year>). <article-title>Coronaviruses: an overview of their replication and pathogenesis</article-title>, in <source>Coronaviruses: Methods and Protocols</source>, eds <person-group person-group-type="editor"><name><surname>Helena</surname><given-names>M.</given-names></name><name><surname>Erica</surname><given-names>B.</given-names></name><name><surname>Paul</surname><given-names>B.</given-names></name></person-group> (<publisher-loc>New York, NY</publisher-loc>: <publisher-name>Springer</publisher-name>), <fpage>1</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-2438-7_1</pub-id>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.springer.com/gp/book/9781493924370">https://www.springer.com/gp/book/9781493924370</ext-link><?supplied-pmid 25720466?></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiorino</surname><given-names>S.</given-names></name><name><surname>Bacchi-Reggiani</surname><given-names>M. L.</given-names></name><name><surname>Leandri</surname><given-names>P.</given-names></name><name><surname>Loggi</surname><given-names>E.</given-names></name><name><surname>Andreone</surname><given-names>P.</given-names></name></person-group> (<year>2017</year>). <article-title>Vitamin E for the treatment of children with hepatitis B e antigen-positive chronic hepatitis: a systematic review and meta-analysis</article-title>. <source>World J. Hepatol.</source>
<volume>9</volume>, <fpage>333</fpage>&#x02013;<lpage>342</lpage>. <pub-id pub-id-type="doi">10.4254/wjh.v9.i6.333</pub-id><?supplied-pmid 28293383?><pub-id pub-id-type="pmid">28293383</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Fujifilm</collab></person-group> (<year>2020</year>). <source>Global Fujifilm accelerates production of its influenza antiviral drug &#x0201c;Avigan&#x000ae; Tablet&#x0201d; for COVID-19</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.fujifilm.com/news/n200415.html">https://www.fujifilm.com/news/n200415.html</ext-link> (accessed June 7, 2020).</mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fung</surname><given-names>T. S.</given-names></name><name><surname>Liu</surname><given-names>D. X.</given-names></name></person-group> (<year>2019</year>). <article-title>Human coronavirus: host-pathogen interaction</article-title>. <source>Annu. Rev. Microbiol.</source>
<volume>73</volume>, <fpage>529</fpage>&#x02013;<lpage>557</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-micro-020518-115759</pub-id><?supplied-pmid 31226023?><pub-id pub-id-type="pmid">31226023</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gami&#x000f1;o-Arroyo</surname><given-names>A. E.</given-names></name><name><surname>Guerrero</surname><given-names>M. L.</given-names></name><name><surname>McCarthy</surname><given-names>S.</given-names></name><name><surname>Ram&#x000ed;rez-Venegas</surname><given-names>A.</given-names></name><name><surname>Llamosas-Gallardo</surname><given-names>B.</given-names></name><name><surname>Galindo-Fraga</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Efficacy and safety of nitazoxanide in addition to standard of care for the treatment of severe acute respiratory illness</article-title>. <source>Clin. Infect. Dis.</source>
<volume>69</volume>, <fpage>1903</fpage>&#x02013;<lpage>1911</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciz100</pub-id><?supplied-pmid 30753384?><pub-id pub-id-type="pmid">30753384</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Qiu</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>A systematic review of asymptomatic infections with COVID-19</article-title>. <source>J. Microbiol. Immunol. Infect.</source>
<pub-id pub-id-type="doi">10.1016/j.jmii.2020.05.001</pub-id>. [Epub ahead of print].<?supplied-pmid 32425996?><pub-id pub-id-type="pmid">32425996</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gautret</surname><given-names>P.</given-names></name><name><surname>Lagier</surname><given-names>J.-C.</given-names></name><name><surname>Parola</surname><given-names>P.</given-names></name><name><surname>Hoang</surname><given-names>V. T.</given-names></name><name><surname>Meddeb</surname><given-names>L.</given-names></name><name><surname>Mailhe</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial</article-title>. <source>Int. J. Antimicrob. Agents</source>
<pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105949</pub-id>. [Epub ahead of print].<?supplied-pmid 32205204?><pub-id pub-id-type="pmid">32205204</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginde</surname><given-names>A. A.</given-names></name><name><surname>Blatchford</surname><given-names>P.</given-names></name><name><surname>Breese</surname><given-names>K.</given-names></name><name><surname>Zarrabi</surname><given-names>L.</given-names></name><name><surname>Linnebur</surname><given-names>S. A.</given-names></name><name><surname>Wallace</surname><given-names>J. I.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>High-dose monthly vitamin D for prevention of acute respiratory infection in older long-term care residents: a randomized clinical trial</article-title>. <source>J. Am. Geriatr. Soc.</source>
<volume>65</volume>, <fpage>496</fpage>&#x02013;<lpage>503</lpage>. <pub-id pub-id-type="doi">10.1111/jgs.14679</pub-id><?supplied-pmid 27861708?><pub-id pub-id-type="pmid">27861708</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glowacka</surname><given-names>I.</given-names></name><name><surname>Bertram</surname><given-names>S.</given-names></name><name><surname>Muller</surname><given-names>M. A.</given-names></name><name><surname>Allen</surname><given-names>P.</given-names></name><name><surname>Soilleux</surname><given-names>E.</given-names></name><name><surname>Pfefferle</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response</article-title>. <source>J. Virol.</source>
<volume>85</volume>, <fpage>4122</fpage>&#x02013;<lpage>4134</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.02232-10</pub-id><?supplied-pmid 21325420?><pub-id pub-id-type="pmid">21325420</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goncalves-Mendes</surname><given-names>N.</given-names></name><name><surname>Talvas</surname><given-names>J.</given-names></name><name><surname>Dual&#x000e9;</surname><given-names>C.</given-names></name><name><surname>Guttmann</surname><given-names>A.</given-names></name><name><surname>Corbin</surname><given-names>V.</given-names></name><name><surname>Marceau</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Impact of vitamin D supplementation on influenza vaccine response and immune functions in deficient elderly persons: a randomized placebo-controlled trial</article-title>. <source>Front. Immunol.</source>
<volume>10</volume>:<fpage>65</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2019.00065</pub-id><?supplied-pmid 30800121?><pub-id pub-id-type="pmid">30800121</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham Carlos</surname><given-names>W.</given-names></name><name><surname>Dela Cruz</surname><given-names>C. S.</given-names></name><name><surname>Cao</surname><given-names>B.</given-names></name><name><surname>Pasnick</surname><given-names>S.</given-names></name><name><surname>Jamil</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Novel wuhan (2019-NCoV) coronavirus</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>201</volume>, <fpage>P7</fpage>&#x02013;<lpage>P8</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.2014P7</pub-id><?supplied-pmid 32004066?><pub-id pub-id-type="pmid">32004066</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gralinski</surname><given-names>L. E.</given-names></name><name><surname>Menachery</surname><given-names>V. D.</given-names></name></person-group> (<year>2020</year>). <article-title>Return of the coronavirus: 2019-nCoV</article-title>. <source>Viruses</source>
<volume>12</volume>:<fpage>135</fpage>. <pub-id pub-id-type="doi">10.3390/v12020135</pub-id><?supplied-pmid 31991541?><pub-id pub-id-type="pmid">31991541</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gralinski</surname><given-names>L. E.</given-names></name><name><surname>Sheahan</surname><given-names>T. P.</given-names></name><name><surname>Morrison</surname><given-names>T. E.</given-names></name><name><surname>Menachery</surname><given-names>V. D.</given-names></name><name><surname>Jensen</surname><given-names>K.</given-names></name><name><surname>Leist</surname><given-names>S. R.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis</article-title>. <source>MBio</source>
<volume>9</volume>:<fpage>e01753</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1128/mBio.01753-18</pub-id><?supplied-pmid 30301856?><pub-id pub-id-type="pmid">30301856</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grillet</surname><given-names>F.</given-names></name><name><surname>Behr</surname><given-names>J.</given-names></name><name><surname>Calame</surname><given-names>P.</given-names></name><name><surname>Aubry</surname><given-names>S.</given-names></name><name><surname>Delabrousse</surname><given-names>E.</given-names></name></person-group> (<year>2020</year>). <article-title>Acute pulmonary embolism associated with COVID-19 pneumonia detected by pulmonary CT angiography</article-title>. <source>Radiology</source>
<volume>23</volume>:<fpage>201544</fpage>. <pub-id pub-id-type="doi">10.1148/radiol.2020201544</pub-id><?supplied-pmid 32324103?><pub-id pub-id-type="pmid">32324103</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>W.</given-names></name><name><surname>Ni</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>W.</given-names></name><name><surname>Ou</surname><given-names>C.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title>. <source>N. Engl. J. Med.</source>
<volume>382</volume>, <fpage>1708</fpage>&#x02013;<lpage>1720</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id><pub-id pub-id-type="pmid">32109013</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haffizulla</surname><given-names>J.</given-names></name><name><surname>Hartman</surname><given-names>A.</given-names></name><name><surname>Hoppers</surname><given-names>M.</given-names></name><name><surname>Resnick</surname><given-names>H.</given-names></name><name><surname>Samudrala</surname><given-names>S.</given-names></name><name><surname>Ginocchio</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial</article-title>. <source>Lancet Infect. Dis.</source>
<volume>14</volume>, <fpage>609</fpage>&#x02013;<lpage>618</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(14)70717-0</pub-id><?supplied-pmid 24852376?><pub-id pub-id-type="pmid">24852376</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajat</surname><given-names>S.</given-names></name><name><surname>Kosatky</surname><given-names>T.</given-names></name></person-group> (<year>2010</year>). <article-title>Heat-related mortality: a review and exploration of heterogeneity</article-title>. <source>J. Epidemiol. Community Health</source>
<volume>64</volume>, <fpage>753</fpage>&#x02013;<lpage>760</lpage>. <pub-id pub-id-type="doi">10.1136/jech.2009.087999</pub-id><?supplied-pmid 19692725?><pub-id pub-id-type="pmid">19692725</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajeer</surname><given-names>A. H.</given-names></name><name><surname>Balkhy</surname><given-names>H.</given-names></name><name><surname>Johani</surname><given-names>S.</given-names></name><name><surname>Yousef</surname><given-names>M. Z.</given-names></name><name><surname>Arabi</surname><given-names>Y.</given-names></name></person-group> (<year>2016</year>). <article-title>Association of human leukocyte antigen class II alleles with severe middle east respiratory syndrome-coronavirus infection</article-title>. <source>Ann. Thorac. Med.</source>
<volume>11</volume>, <fpage>211</fpage>&#x02013;<lpage>213</lpage>. <pub-id pub-id-type="doi">10.4103/1817-1737.185756</pub-id><?supplied-pmid 27512511?><pub-id pub-id-type="pmid">27512511</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemil&#x000e4;</surname><given-names>H.</given-names></name><name><surname>Chalker</surname><given-names>E.</given-names></name></person-group> (<year>2013</year>). <article-title>Vitamin C for preventing and treating the common cold</article-title>. <source>Cochrane Database Syst. Rev.</source>
<volume>2013</volume>:<fpage>CD000980</fpage>
<pub-id pub-id-type="doi">10.1002/14651858.CD000980.pub4</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemil&#x000e4;</surname><given-names>H.</given-names></name><name><surname>Kaprio</surname><given-names>J.</given-names></name></person-group> (<year>2008</year>). <article-title>Vitamin E supplementation and pneumonia risk in males who initiated smoking at an early age: effect modification by body weight and dietary vitamin C</article-title>. <source>Nutr. J.</source>
<volume>7</volume>:<fpage>33</fpage>. <pub-id pub-id-type="doi">10.1186/1475-2891-7-33</pub-id><?supplied-pmid 19019244?><pub-id pub-id-type="pmid">19019244</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holshue</surname><given-names>M. L.</given-names></name><name><surname>DeBolt</surname><given-names>C.</given-names></name><name><surname>Lindquist</surname><given-names>S.</given-names></name><name><surname>Lofy</surname><given-names>K. H.</given-names></name><name><surname>Wiesman</surname><given-names>J.</given-names></name><name><surname>Bruce</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>First case of 2019 novel coronavirus in the united states</article-title>. <source>N. Engl. J. Med.</source>
<volume>382</volume>, <fpage>929</fpage>&#x02013;<lpage>936</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2001191</pub-id><pub-id pub-id-type="pmid">32004427</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title>. <source>Lancet</source>
<volume>395</volume>, <fpage>497</fpage>&#x02013;<lpage>506</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><?supplied-pmid 31986264?><pub-id pub-id-type="pmid">31986264</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Qi</surname><given-names>G.</given-names></name><name><surname>Brand</surname><given-names>D.</given-names></name><name><surname>Zheng</surname><given-names>S.</given-names></name></person-group> (<year>2018</year>). <article-title>Role of Vitamin A in the immune system</article-title>. <source>J. Clin. Med.</source>
<volume>7</volume>:<fpage>258</fpage>. <pub-id pub-id-type="doi">10.3390/jcm7090258</pub-id><?supplied-pmid 30200565?><pub-id pub-id-type="pmid">30200565</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>InvivoGen</collab></person-group> (<year>2020</year>). <source>Spotlight on COVID-19: Infection</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.invivogen.com/spotlight-covid-19-infection">https://www.invivogen.com/spotlight-covid-19-infection</ext-link> (accessed June 7, 2020).</mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iovino</surname><given-names>L.</given-names></name><name><surname>Mazziotta</surname><given-names>F.</given-names></name><name><surname>Carulli</surname><given-names>G.</given-names></name><name><surname>Guerrini</surname><given-names>F.</given-names></name><name><surname>Morganti</surname><given-names>R.</given-names></name><name><surname>Mazzotti</surname><given-names>V.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>High-dose zinc oral supplementation after stem cell transplantation causes an increase of TRECs and CD4+ na&#x000ef;ve lymphocytes and prevents TTV reactivation</article-title>. <source>Leuk. Res.</source>
<volume>70</volume>, <fpage>20</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/j.leukres.2018.04.016</pub-id><?supplied-pmid 29747074?><pub-id pub-id-type="pmid">29747074</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ip</surname><given-names>W. K. E.</given-names></name><name><surname>Chan</surname><given-names>K. H.</given-names></name><name><surname>Law</surname><given-names>H. K. W.</given-names></name><name><surname>Tso</surname><given-names>G. H. W.</given-names></name><name><surname>Kong</surname><given-names>E. K. P.</given-names></name><name><surname>Wong</surname><given-names>W. H. S.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection</article-title>. <source>J. Infect. Dis.</source>
<volume>191</volume>, <fpage>1697</fpage>&#x02013;<lpage>1704</lpage>. <pub-id pub-id-type="doi">10.1086/429631</pub-id><?supplied-pmid 15838797?><pub-id pub-id-type="pmid">15838797</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaakkola</surname><given-names>K.</given-names></name><name><surname>Saukkoriipi</surname><given-names>A.</given-names></name><name><surname>Jokelainen</surname><given-names>J.</given-names></name><name><surname>Juvonen</surname><given-names>R.</given-names></name><name><surname>Kauppila</surname><given-names>J.</given-names></name><name><surname>Vainio</surname><given-names>O.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Decline in temperature and humidity increases the occurrence of influenza in cold climate</article-title>. <source>Environ. Heal. A Glob. Access Sci. Source</source>
<volume>13</volume>:<fpage>22</fpage>. <pub-id pub-id-type="doi">10.1186/1476-069X-13-22</pub-id><?supplied-pmid 24678699?><pub-id pub-id-type="pmid">24678699</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jean</surname><given-names>S.-S.</given-names></name><name><surname>Chang</surname><given-names>Y.-C.</given-names></name><name><surname>Lin</surname><given-names>W.-C.</given-names></name><name><surname>Lee</surname><given-names>W.-S.</given-names></name><name><surname>Hsueh</surname><given-names>P.-R.</given-names></name><name><surname>Hsu</surname><given-names>C.-W.</given-names></name></person-group> (<year>2020a</year>). <article-title>Epidemiology, treatment, and prevention of nosocomial bacterial pneumonia</article-title>. <source>J. Clin. Med.</source>
<volume>9</volume>:<fpage>275</fpage>. <pub-id pub-id-type="doi">10.3390/jcm9010275</pub-id><?supplied-pmid 31963877?><pub-id pub-id-type="pmid">31963877</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jean</surname><given-names>S.-S.</given-names></name><name><surname>Lee</surname><given-names>P.-I.</given-names></name><name><surname>Hsueh</surname><given-names>P.-R.</given-names></name></person-group> (<year>2020b</year>). <article-title>Treatment options for COVID-19: the reality and challenges</article-title>. <source>J. Microbiol. Immunol. Infect.</source>
<volume>53</volume>, <fpage>436</fpage>&#x02013;<lpage>443</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmii.2020.03.034</pub-id><?supplied-pmid 32307245?><pub-id pub-id-type="pmid">32307245</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jolliffe</surname><given-names>D. A.</given-names></name><name><surname>Griffiths</surname><given-names>C. J.</given-names></name><name><surname>Martineau</surname><given-names>A. R.</given-names></name></person-group> (<year>2013</year>). <article-title>Vitamin D in the prevention of acute respiratory infection: systematic review of clinical studies</article-title>. <source>J. Steroid Biochem. Mol. Biol.</source>
<volume>136</volume>, <fpage>321</fpage>&#x02013;<lpage>329</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsbmb.2012.11.017</pub-id><?supplied-pmid 23220552?><pub-id pub-id-type="pmid">23220552</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Kaiser Health News</collab></person-group> (<year>2020</year>). <source>CDC Coronavirus Testing Decision Likely To Haunt Nation For Months To Come</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://khn.org/news/cdc-coronavirus-testing-decision-likely-to-haunt-nation-for-months-to-come/">https://khn.org/news/cdc-coronavirus-testing-decision-likely-to-haunt-nation-for-months-to-come/</ext-link> (accessed June 7, 2020).</mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kampf</surname><given-names>G.</given-names></name><name><surname>Todt</surname><given-names>D.</given-names></name><name><surname>Pfaender</surname><given-names>S.</given-names></name><name><surname>Steinmann</surname><given-names>E.</given-names></name></person-group> (<year>2020</year>). <article-title>Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents</article-title>. <source>J. Hosp. Infect.</source>
<volume>104</volume>, <fpage>246</fpage>&#x02013;<lpage>251</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhin.2020.01.022</pub-id><?supplied-pmid 32035997?><pub-id pub-id-type="pmid">32035997</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaneko</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>Tocilizumab in rheumatoid arthritis: efficacy, safety and its place in therapy</article-title>. <source>Ther. Adv. Chronic Dis.</source>
<volume>4</volume>, <fpage>15</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1177/2040622312466908</pub-id><?supplied-pmid 23342244?><pub-id pub-id-type="pmid">23342244</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawase</surname><given-names>M.</given-names></name><name><surname>Shirato</surname><given-names>K.</given-names></name><name><surname>van der Hoek</surname><given-names>L.</given-names></name><name><surname>Taguchi</surname><given-names>F.</given-names></name><name><surname>Matsuyama</surname><given-names>S.</given-names></name></person-group> (<year>2012</year>). <article-title>Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry</article-title>. <source>J. Virol.</source>
<volume>86</volume>, <fpage>6537</fpage>&#x02013;<lpage>6545</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.00094-12</pub-id><?supplied-pmid 22496216?><pub-id pub-id-type="pmid">22496216</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keicho</surname><given-names>N.</given-names></name><name><surname>Itoyama</surname><given-names>S.</given-names></name><name><surname>Kashiwase</surname><given-names>K.</given-names></name><name><surname>Phi</surname><given-names>N. C.</given-names></name><name><surname>Long</surname><given-names>H. T.</given-names></name><name><surname>Ha</surname><given-names>L. D.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Association of human leukocyte antigen class II alleles with severe acute respiratory syndrome in the vietnamese population</article-title>. <source>Hum. Immunol.</source>
<volume>70</volume>, <fpage>527</fpage>&#x02013;<lpage>531</lpage>. <pub-id pub-id-type="doi">10.1016/j.humimm.2009.05.006</pub-id><?supplied-pmid 19445991?><pub-id pub-id-type="pmid">19445991</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Bae</surname><given-names>S.</given-names></name><name><surname>Choi</surname><given-names>J.</given-names></name><name><surname>Lim</surname><given-names>S. Y.</given-names></name><name><surname>Lee</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Vitamin C is an essential factor on the anti-viral immune responses through the production of interferon-&#x003b1;/&#x003b2; at the initial stage of influenza a virus (H3N2) infection</article-title>. <source>Immune Netw.</source>
<volume>13</volume>:<fpage>70</fpage>. <pub-id pub-id-type="doi">10.4110/in.2013.13.2.70</pub-id><?supplied-pmid 23700397?><pub-id pub-id-type="pmid">23700397</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klok</surname><given-names>F. A.</given-names></name><name><surname>Kruip</surname><given-names>M. J. H. A.</given-names></name><name><surname>van der Meer</surname><given-names>N. J. M.</given-names></name><name><surname>Arbous</surname><given-names>M. S.</given-names></name><name><surname>Gommers</surname><given-names>D. A. M. P. J.</given-names></name><name><surname>Kant</surname><given-names>K. M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Incidence of thrombotic complications in critically ill ICU patients with COVID-19</article-title>. <source>Thromb. Res.</source>
<volume>191</volume>, <fpage>145</fpage>&#x02013;<lpage>147</lpage>. <pub-id pub-id-type="doi">10.1016/j.thromres.2020.04.013</pub-id><pub-id pub-id-type="pmid">32291094</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>W. C.</given-names></name><name><surname>Rolain</surname><given-names>J. M.</given-names></name><name><surname>Lee</surname><given-names>N. Y.</given-names></name><name><surname>Chen</surname><given-names>P. L.</given-names></name><name><surname>Huang</surname><given-names>C. T.</given-names></name><name><surname>Lee</surname><given-names>P. I.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Arguments in favour of remdesivir for treating SARS-CoV-2 infections</article-title>. <source>Int. J. Antimicrob. Agents</source>
<volume>55</volume>:<fpage>105933</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105933</pub-id><?supplied-pmid 32147516?><pub-id pub-id-type="pmid">32147516</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuba</surname><given-names>K.</given-names></name><name><surname>Imai</surname><given-names>Y.</given-names></name><name><surname>Ohto-Nakanishi</surname><given-names>T.</given-names></name><name><surname>Penninger</surname><given-names>J. M.</given-names></name></person-group> (<year>2010</year>). <article-title>Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters</article-title>. <source>Pharmacol. Ther.</source>
<volume>128</volume>, <fpage>119</fpage>&#x02013;<lpage>128</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2010.06.003</pub-id><?supplied-pmid 20599443?><pub-id pub-id-type="pmid">20599443</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kudo</surname><given-names>E.</given-names></name><name><surname>Song</surname><given-names>E.</given-names></name><name><surname>Yockey</surname><given-names>L. J.</given-names></name><name><surname>Rakib</surname><given-names>T.</given-names></name><name><surname>Wong</surname><given-names>P. W.</given-names></name><name><surname>Homer</surname><given-names>R. J.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Low ambient humidity impairs barrier function and innate resistance against influenza infection</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>166</volume>, <fpage>10905</fpage>&#x02013;<lpage>10910</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1902840116</pub-id><?supplied-pmid 31085641?><pub-id pub-id-type="pmid">31085641</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S.</given-names></name><name><surname>Nyodu</surname><given-names>R.</given-names></name><name><surname>Maurya</surname><given-names>V. K.</given-names></name><name><surname>Saxena</surname><given-names>S. K.</given-names></name></person-group> (<year>2020</year>). <article-title>Host immune response and immunobiology of human SARS-CoV-2 infection</article-title>, in <source>Coronavirus Disease 2019 (COVID-19)</source>, ed <person-group person-group-type="editor"><name><surname>Saxena</surname><given-names>S. K.</given-names></name></person-group> (<publisher-loc>Singapore</publisher-loc>: <publisher-name>Springer</publisher-name>), <fpage>43</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1007/978-981-15-4814-7_5</pub-id> Available online at: <ext-link ext-link-type="uri" xlink:href="https://link.springer.com/book/10.1007/978-981-15-4814-7#about">https://link.springer.com/book/10.1007/978-981-15-4814-7#about</ext-link></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauring</surname><given-names>A. S.</given-names></name><name><surname>Andino</surname><given-names>R.</given-names></name></person-group> (<year>2010</year>). <article-title>Quasispecies theory and the behavior of RNA viruses</article-title>. <source>PLoS Pathog.</source>
<volume>6</volume>:<fpage>e1001005</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1001005</pub-id><?supplied-pmid 20661479?><pub-id pub-id-type="pmid">20661479</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>N.</given-names></name><name><surname>Hui</surname><given-names>D.</given-names></name><name><surname>Wu</surname><given-names>A.</given-names></name><name><surname>Chan</surname><given-names>P.</given-names></name><name><surname>Cameron</surname><given-names>P.</given-names></name><name><surname>Joynt</surname><given-names>G. M.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>A major outbreak of severe acute respiratory syndrome in Hong Kong</article-title>. <source>N. Engl. J. Med.</source>
<volume>348</volume>, <fpage>1986</fpage>&#x02013;<lpage>1994</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa030685</pub-id><pub-id pub-id-type="pmid">12682352</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Qi</surname><given-names>X.</given-names></name></person-group> (<year>2020</year>). <article-title>CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia</article-title>. <source>Radiology</source>
<volume>295</volume>, <fpage>18</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1148/radiol.2020200236</pub-id><pub-id pub-id-type="pmid">32003646</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Ding</surname><given-names>C.</given-names></name></person-group> (<year>2019</year>). <article-title>The role of copper homeostasis at the host-pathogen axis: from bacteria to fungi</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>20</volume>:<fpage>175</fpage>. <pub-id pub-id-type="doi">10.3390/ijms20010175</pub-id><?supplied-pmid 30621285?><pub-id pub-id-type="pmid">30621285</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>A.</given-names></name></person-group> (<year>2003a</year>). <article-title>Profile of specific antibodies to the SARS-associated coronavirus [6]</article-title>. <source>N. Engl. J. Med.</source>
<volume>349</volume>, <fpage>508</fpage>&#x02013;<lpage>509</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM200307313490520</pub-id><?supplied-pmid 12890855?><pub-id pub-id-type="pmid">12890855</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>De Clercq</surname><given-names>E.</given-names></name></person-group> (<year>2020</year>). <article-title>Therapeutic options for the 2019 novel coronavirus (2019-nCoV)</article-title>. <source>Nat. Rev. Drug Discov.</source>
<volume>19</volume>, <fpage>149</fpage>&#x02013;<lpage>150</lpage>. <pub-id pub-id-type="doi">10.1038/d41573-020-00016-0</pub-id><?supplied-pmid 32127666?><pub-id pub-id-type="pmid">32127666</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Ge</surname><given-names>J.</given-names></name></person-group> (<year>2020a</year>). <article-title>Scientific research progress of COVID-19/ SARS-CoV-2 in the first five months</article-title>. <source>J. Cell. Mol. Med.</source>
<volume>24</volume>, <fpage>6558</fpage>&#x02013;<lpage>6570</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.15364</pub-id><?supplied-pmid 32320516?><pub-id pub-id-type="pmid">32320516</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Guan</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Tong</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2020b</year>). <article-title>Early transmission dynamics in Wuhan, China, of novel coronavirus&#x02013;infected pneumonia</article-title>. <source>N. Engl. J. Med.</source>
<volume>382</volume>, <fpage>1199</fpage>&#x02013;<lpage>1207</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2001316</pub-id><?supplied-pmid 31995857?><pub-id pub-id-type="pmid">31995857</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Moore</surname><given-names>M. J.</given-names></name><name><surname>Vasilieva</surname><given-names>N.</given-names></name><name><surname>Sui</surname><given-names>J.</given-names></name><name><surname>Wong</surname><given-names>S. K.</given-names></name><name><surname>Berne</surname><given-names>M. A.</given-names></name><etal/></person-group>. (<year>2003b</year>). <article-title>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</article-title>. <source>Nature</source>
<volume>426</volume>, <fpage>450</fpage>&#x02013;<lpage>454</lpage>. <pub-id pub-id-type="doi">10.1038/nature02145</pub-id><?supplied-pmid 14647384?><pub-id pub-id-type="pmid">14647384</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>R. Y.</given-names></name><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>S. P.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name></person-group> (<year>2012</year>). <article-title>Magnesium affects the cytokine secretion of CD4+ T lymphocytes in acute asthma</article-title>. <source>J. Asthma</source>
<volume>49</volume>, <fpage>1012</fpage>&#x02013;<lpage>1015</lpage>. <pub-id pub-id-type="doi">10.3109/02770903.2012.739240</pub-id><?supplied-pmid 23134345?><pub-id pub-id-type="pmid">23134345</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>K.</given-names></name><name><surname>Fong</surname><given-names>D. Y. T.</given-names></name><name><surname>Zhu</surname><given-names>B.</given-names></name><name><surname>Karlberg</surname><given-names>J.</given-names></name></person-group> (<year>2006</year>). <article-title>Environmental factors on the SARS epidemic: air temperature, passage of time and multiplicative effect of hospital infection</article-title>. <source>Epidemiol. Infect.</source>
<volume>134</volume>, <fpage>223</fpage>&#x02013;<lpage>230</lpage>. <pub-id pub-id-type="doi">10.1017/S0950268805005054</pub-id><?supplied-pmid 16490124?><pub-id pub-id-type="pmid">16490124</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>P.</given-names></name><name><surname>Gao</surname><given-names>F.</given-names></name><name><surname>Qi</surname><given-names>J.</given-names></name><name><surname>Kawana-Tachikawa</surname><given-names>A.</given-names></name><name><surname>Xie</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Novel immunodominant peptide presentation strategy: a featured HLA-A<sup>*</sup>2402-restricted cytotoxic T-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute respiratory syndrome coronavirus nucleocapsid protein</article-title>. <source>J. Virol.</source>
<volume>84</volume>, <fpage>11849</fpage>&#x02013;<lpage>11857</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.01464-10</pub-id><pub-id pub-id-type="pmid">20844028</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Kang</surname><given-names>M.</given-names></name><name><surname>Lin</surname><given-names>L.</given-names></name><name><surname>Zhong</surname><given-names>H.</given-names></name><name><surname>Xiao</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Time-varying transmission dynamics of novel coronavirus pneumonia in China</article-title>. <source>bioRxiv.</source>
<pub-id pub-id-type="doi">10.1101/2020.01.25.919787</pub-id>. [Epub ahead of print].</mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowen</surname><given-names>A. C.</given-names></name><name><surname>Steel</surname><given-names>J.</given-names></name></person-group> (<year>2014</year>). <article-title>Roles of humidity and temperature in shaping influenza seasonality</article-title>. <source>J. Virol.</source>
<volume>88</volume>, <fpage>7692</fpage>&#x02013;<lpage>7695</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.03544-13</pub-id><?supplied-pmid 24789791?><pub-id pub-id-type="pmid">24789791</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>H.</given-names></name><name><surname>Stratton</surname><given-names>C. W.</given-names></name><name><surname>Tang</surname><given-names>Y. W.</given-names></name></person-group> (<year>2020</year>). <article-title>Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle</article-title>. <source>J. Med. Virol.</source>
<volume>92</volume>, <fpage>401</fpage>&#x02013;<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.25678</pub-id><pub-id pub-id-type="pmid">31950516</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>H.</given-names></name><name><surname>Tang</surname><given-names>Q.</given-names></name><name><surname>ling</surname></name><name><surname>Shang</surname><given-names>Y.</given-names></name><name><surname>xi</surname></name><name><surname>Liang</surname><given-names>S.</given-names></name><name><surname>bing</surname></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Robinson</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? <italic>A</italic> review of historical classics, research evidence and current prevention programs</article-title>. <source>Chin. J. Integr. Med.</source>
<volume>26</volume>, <fpage>243</fpage>&#x02013;<lpage>250</lpage>. <pub-id pub-id-type="doi">10.1007/s11655-020-3192-6</pub-id><?supplied-pmid 32065348?><pub-id pub-id-type="pmid">32065348</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Fu</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Effects of temperature variation and humidity on the death of COVID-19 in Wuhan, China</article-title>. <source>Sci. Total Environ.</source>
<volume>724</volume>:<fpage>138226</fpage>
<pub-id pub-id-type="doi">10.1016/j.scitotenv.2020.138226</pub-id><pub-id pub-id-type="pmid">32408453</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madrid</surname><given-names>P. B.</given-names></name><name><surname>Panchal</surname><given-names>R. G.</given-names></name><name><surname>Warren</surname><given-names>T. K.</given-names></name><name><surname>Shurtleff</surname><given-names>A. C.</given-names></name><name><surname>Endsley</surname><given-names>A. N.</given-names></name><name><surname>Green</surname><given-names>C. E.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Evaluation of ebola virus inhibitors for drug repurposing</article-title>. <source>ACS Infect. Dis.</source>
<volume>1</volume>, <fpage>317</fpage>&#x02013;<lpage>326</lpage>. <pub-id pub-id-type="doi">10.1021/acsinfecdis.5b00030</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>M. A.</given-names></name></person-group> (<year>2020</year>). <article-title>Compounds with therapeutic potential against novel respiratory 2019 coronavirus</article-title>. <source>Antimicrob. Agents Chemother.</source>
<fpage>64</fpage>. <pub-id pub-id-type="doi">10.1128/aac.00399-20</pub-id><?supplied-pmid 32152082?><pub-id pub-id-type="pmid">32152082</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayence</surname><given-names>A.</given-names></name><name><surname>Vanden Eynde</surname><given-names>J.</given-names></name></person-group> (<year>2019</year>). <article-title>Baricitinib: a 2018 novel FDA-approved small molecule inhibiting janus kinases</article-title>. <source>Pharmaceuticals</source>
<volume>12</volume>:<fpage>37</fpage>. <pub-id pub-id-type="doi">10.3390/ph12010037</pub-id><?supplied-pmid 30871014?><pub-id pub-id-type="pmid">30871014</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCreary</surname><given-names>E. K.</given-names></name><name><surname>Pogue</surname><given-names>J. M.</given-names></name></person-group> (<year>2020</year>). <article-title>Coronavirus disease 2019 treatment: a review of early and emerging options</article-title>. <source>Open Forum Infect. Dis.</source>
<volume>7</volume>:<fpage>ofaa105</fpage>. <pub-id pub-id-type="doi">10.1093/ofid/ofaa105</pub-id><?supplied-pmid 32284951?><pub-id pub-id-type="pmid">32284951</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menachery</surname><given-names>V. D.</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>A.</given-names></name><name><surname>Burnum-Johnson</surname><given-names>K. E.</given-names></name><name><surname>Mitchell</surname><given-names>H. D.</given-names></name><name><surname>Eisfeld</surname><given-names>A. J.</given-names></name><name><surname>Walters</surname><given-names>K. B.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>115</volume>, <fpage>E1012</fpage>&#x02013;<lpage>E1021</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1706928115</pub-id><?supplied-pmid 29339515?><pub-id pub-id-type="pmid">29339515</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meydani</surname><given-names>S. N.</given-names></name><name><surname>Leka</surname><given-names>L. S.</given-names></name><name><surname>Fine</surname><given-names>B. C.</given-names></name><name><surname>Dallal</surname><given-names>G. E.</given-names></name><name><surname>Keusch</surname><given-names>G. T.</given-names></name><name><surname>Singh</surname><given-names>M. F.</given-names></name><etal/></person-group>. (<year>2004</year>). <article-title>Vitamin E and respiratory tract infections in elderly nursing home residents: a randomized controlled trial</article-title>. <source>J. Am. Med. Assoc.</source>
<volume>292</volume>, <fpage>828</fpage>&#x02013;<lpage>836</lpage>. <pub-id pub-id-type="doi">10.1001/jama.292.7.828</pub-id><?supplied-pmid 15315997?><pub-id pub-id-type="pmid">15315997</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mille</surname><given-names>J. K.</given-names></name><name><surname>Whittaker</surname><given-names>G. R.</given-names></name></person-group> (<year>2014</year>). <article-title>Host cell entry of middle east respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>111</volume>, <fpage>15214</fpage>&#x02013;<lpage>15219</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1407087111</pub-id><?supplied-pmid 25288733?><pub-id pub-id-type="pmid">25288733</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Min</surname><given-names>C. K.</given-names></name><name><surname>Cheon</surname><given-names>S.</given-names></name><name><surname>Ha</surname><given-names>N. Y.</given-names></name><name><surname>Sohn</surname><given-names>K. M.</given-names></name><name><surname>Kim</surname><given-names>Y.</given-names></name><name><surname>Aigerim</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity</article-title>. <source>Sci. Rep.</source>
<volume>6</volume>:<fpage>25359</fpage>. <pub-id pub-id-type="doi">10.1038/srep25359</pub-id><?supplied-pmid 27146253?><pub-id pub-id-type="pmid">27146253</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyamoto</surname><given-names>D.</given-names></name><name><surname>Kusagaya</surname><given-names>Y.</given-names></name><name><surname>Endo</surname><given-names>N.</given-names></name><name><surname>Sometani</surname><given-names>A.</given-names></name><name><surname>Takeo</surname><given-names>S.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>1998</year>). <article-title>Thujaplicin-copper chelates inhibit replication of human influenza viruses</article-title>. <source>Antiviral Res.</source>
<volume>39</volume>, <fpage>89</fpage>&#x02013;<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1016/S0166-3542(98)00034-5</pub-id><?supplied-pmid 9806486?><pub-id pub-id-type="pmid">9806486</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monlezun</surname><given-names>D. J.</given-names></name><name><surname>Bittner</surname><given-names>E. A.</given-names></name><name><surname>Christopher</surname><given-names>K. B.</given-names></name><name><surname>Camargo</surname><given-names>C. A.</given-names></name><name><surname>Quraishi</surname><given-names>S. A.</given-names></name></person-group> (<year>2015</year>). <article-title>Vitamin D status and acute respiratory infection: cross sectional results from the United States national health and nutrition examination survey, 2001-2006</article-title>. <source>Nutrients</source>
<volume>7</volume>, <fpage>1933</fpage>&#x02013;<lpage>1944</lpage>. <pub-id pub-id-type="doi">10.3390/nu7031933</pub-id><?supplied-pmid 25781219?><pub-id pub-id-type="pmid">25781219</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moriguchi</surname><given-names>S.</given-names></name><name><surname>Muraga</surname><given-names>M.</given-names></name></person-group> (<year>2000</year>). <article-title>Vitamin E and immunity</article-title>. <source>Vitam. Horm.</source>
<volume>59</volume>, <fpage>305</fpage>&#x02013;<lpage>336</lpage>. <pub-id pub-id-type="doi">10.1016/s0083-6729(00)59011-6</pub-id><?supplied-pmid 10714244?><pub-id pub-id-type="pmid">10714244</pub-id></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulangu</surname><given-names>S.</given-names></name><name><surname>Dodd</surname><given-names>L. E.</given-names></name><name><surname>Davey</surname><given-names>R. T.</given-names></name><name><surname>Tshiani Mbaya</surname><given-names>O.</given-names></name><name><surname>Proschan</surname><given-names>M.</given-names></name><name><surname>Mukadi</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>A randomized, controlled trial of ebola virus disease therapeutics</article-title>. <source>N. Engl. J. Med.</source>
<volume>381</volume>, <fpage>2293</fpage>&#x02013;<lpage>2303</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1910993</pub-id><?supplied-pmid 31774950?><pub-id pub-id-type="pmid">31774950</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mungroo</surname><given-names>M. R.</given-names></name><name><surname>Khan</surname><given-names>N. A.</given-names></name><name><surname>Siddiqui</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Novel coronavirus: current understanding of clinical features, diagnosis, pathogenesis, and treatment options</article-title>. <source>Pathogens</source>
<volume>9</volume>:<fpage>297</fpage>. <pub-id pub-id-type="doi">10.3390/pathogens9040297</pub-id><?supplied-pmid 32316618?><pub-id pub-id-type="pmid">32316618</pub-id></mixed-citation></ref><ref id="B136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niemeyer</surname><given-names>D.</given-names></name><name><surname>Zillinger</surname><given-names>T.</given-names></name><name><surname>Muth</surname><given-names>D.</given-names></name><name><surname>Zielecki</surname><given-names>F.</given-names></name><name><surname>Horvath</surname><given-names>G.</given-names></name><name><surname>Suliman</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Middle east respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist</article-title>. <source>J. Virol.</source>
<volume>87</volume>, <fpage>12489</fpage>&#x02013;<lpage>12495</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.01845-13</pub-id><?supplied-pmid 24027320?><pub-id pub-id-type="pmid">24027320</pub-id></mixed-citation></ref><ref id="B137"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nimer</surname><given-names>A.</given-names></name><name><surname>Mouch</surname><given-names>A.</given-names></name></person-group> (<year>2012</year>). <article-title>Vitamin D improves viral response in hepatitis C genotype 2-3 na&#x000ef;ve patients</article-title>. <source>World J. Gastroenterol.</source>
<volume>18</volume>, <fpage>800</fpage>&#x02013;<lpage>805</lpage>. <pub-id pub-id-type="doi">10.3748/wjg.v18.i8.800</pub-id><?supplied-pmid 22371640?><pub-id pub-id-type="pmid">22371640</pub-id></mixed-citation></ref><ref id="B138"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>NPR</collab></person-group> (<year>2020</year>). <source>Coronavirus Has Now Spread To All Regions Of Mainland China</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.npr.org/sections/goatsandsoda/2020/01/30/801142924/coronavirus-has-now-spread-to-all-regions-of-mainland-china">https://www.npr.org/sections/goatsandsoda/2020/01/30/801142924/coronavirus-has-now-spread-to-all-regions-of-mainland-china</ext-link> (accessed June 7, 2020).</mixed-citation></ref><ref id="B139"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogawa</surname><given-names>M.</given-names></name><name><surname>Morisada</surname><given-names>A.</given-names></name></person-group> (<year>2002</year>). <article-title>Novel mode of action of ribavirin (Rebetol&#x000ae;), a drug for the treatment of chronic hepatitis C: inducting the mutation of RNA viruses</article-title>. <source>Folia Pharmacol. Jpn.</source>
<volume>120</volume>, <fpage>398</fpage>&#x02013;<lpage>408</lpage>. <pub-id pub-id-type="doi">10.1254/fpj.120.398</pub-id><?supplied-pmid 12528471?><pub-id pub-id-type="pmid">12528471</pub-id></mixed-citation></ref><ref id="B140"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J. E.</given-names></name><name><surname>Son</surname><given-names>W. S.</given-names></name><name><surname>Ryu</surname><given-names>Y.</given-names></name><name><surname>Choi</surname><given-names>S. B.</given-names></name><name><surname>Kwon</surname><given-names>O.</given-names></name><name><surname>Ahn</surname><given-names>I.</given-names></name></person-group> (<year>2020</year>). <article-title>Effects of temperature, humidity, and diurnal temperature range on influenza incidence in a temperate region</article-title>. <source>Influenza Other Respi. Viruses</source>
<volume>14</volume>, <fpage>11</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1111/irv.12682</pub-id><?supplied-pmid 31631558?><pub-id pub-id-type="pmid">31631558</pub-id></mixed-citation></ref><ref id="B141"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>N.</given-names></name><name><surname>Penkert</surname><given-names>R. R.</given-names></name><name><surname>Jones</surname><given-names>B. G.</given-names></name><name><surname>Sealy</surname><given-names>R. E.</given-names></name><name><surname>Surman</surname><given-names>S. L.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Baseline serum vitamin A and D levels determine benefit of oral vitamin A&#x00026;D supplements to humoral immune responses following pediatric influenza vaccination</article-title>. <source>Viruses</source>
<volume>11</volume>:<fpage>907</fpage>. <pub-id pub-id-type="doi">10.3390/v11100907</pub-id><?supplied-pmid 31575021?><pub-id pub-id-type="pmid">31575021</pub-id></mixed-citation></ref><ref id="B142"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>J. S. M.</given-names></name><name><surname>Guan</surname><given-names>Y.</given-names></name><name><surname>Yuen</surname><given-names>K. Y.</given-names></name></person-group> (<year>2004</year>). <article-title>Severe acute respiratory syndrome</article-title>. <source>Nat. Med.</source>
<volume>10</volume>, <fpage>S88</fpage>&#x02013;<lpage>S97</lpage>. <pub-id pub-id-type="doi">10.1038/nm1143</pub-id><pub-id pub-id-type="pmid">15577937</pub-id></mixed-citation></ref><ref id="B143"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perlman</surname><given-names>S.</given-names></name><name><surname>Netland</surname><given-names>J.</given-names></name></person-group> (<year>2009</year>). <article-title>Coronaviruses post-SARS: update on replication and pathogenesis</article-title>. <source>Nat. Rev. Microbiol.</source>
<volume>7</volume>, <fpage>439</fpage>&#x02013;<lpage>450</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro2147</pub-id><?supplied-pmid 19430490?><pub-id pub-id-type="pmid">19430490</pub-id></mixed-citation></ref><ref id="B144"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phan</surname><given-names>L. T.</given-names></name><name><surname>Nguyen</surname><given-names>T. V.</given-names></name><name><surname>Luong</surname><given-names>Q. C.</given-names></name><name><surname>Nguyen</surname><given-names>T. V.</given-names></name><name><surname>Nguyen</surname><given-names>H. T.</given-names></name><name><surname>Le</surname><given-names>H. Q.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Importation and human-to-human transmission of a novel coronavirus in vietnam</article-title>. <source>N. Engl. J. Med.</source>
<volume>382</volume>, <fpage>872</fpage>&#x02013;<lpage>874</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMc2001272</pub-id><?supplied-pmid 31991079?><pub-id pub-id-type="pmid">31991079</pub-id></mixed-citation></ref><ref id="B145"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phan</surname><given-names>T.</given-names></name></person-group> (<year>2020a</year>). <article-title>Genetic diversity and evolution of SARS-CoV-2</article-title>. <source>Infect. Genet. Evol.</source>
<volume>81</volume>:<fpage>104260</fpage>. <pub-id pub-id-type="doi">10.1016/j.meegid.2020.104260</pub-id><?supplied-pmid 32092483?><pub-id pub-id-type="pmid">32092483</pub-id></mixed-citation></ref><ref id="B146"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phan</surname><given-names>T.</given-names></name></person-group> (<year>2020b</year>). <article-title>Novel coronavirus: from discovery to clinical diagnostics</article-title>. <source>Infect. Genet. Evol.</source>
<volume>79</volume>:<fpage>104211</fpage>. <pub-id pub-id-type="doi">10.1016/j.meegid.2020.104211</pub-id><?supplied-pmid 32007627?><pub-id pub-id-type="pmid">32007627</pub-id></mixed-citation></ref><ref id="B147"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>A. S.</given-names></name></person-group> (<year>2013</year>). <article-title>Discovery of human zinc deficiency: its impact on human health and disease</article-title>. <source>Adv. Nutr.</source>
<volume>4</volume>, <fpage>176</fpage>&#x02013;<lpage>190</lpage>. <pub-id pub-id-type="doi">10.3945/an.112.003210</pub-id><?supplied-pmid 23493534?><pub-id pub-id-type="pmid">23493534</pub-id></mixed-citation></ref><ref id="B148"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Provinciali</surname><given-names>M.</given-names></name><name><surname>Montenovo</surname><given-names>A.</given-names></name><name><surname>Di Stefano</surname><given-names>G.</given-names></name><name><surname>Colombo</surname><given-names>M.</given-names></name><name><surname>Daghetta</surname><given-names>L.</given-names></name><name><surname>Cairati</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>1998</year>). <article-title>Effect of zinc or zinc plus arginine supplementation on antibody titre and lymphocyte subsets after influenza vaccination in elderly subjects: a randomized controlled trial</article-title>. <source>Age Ageing</source>
<volume>27</volume>, <fpage>715</fpage>&#x02013;<lpage>722</lpage>. <pub-id pub-id-type="doi">10.1093/ageing/27.6.715</pub-id><?supplied-pmid 10408666?><pub-id pub-id-type="pmid">10408666</pub-id></mixed-citation></ref><ref id="B149"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>R.</given-names></name><name><surname>Wei</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>Zhong</surname><given-names>C.</given-names></name><name><surname>Zhao</surname><given-names>C.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Outcome reporting from protocols of clinical trials of coronavirus disease 2019 (COVID-19): a review</article-title>. <source>medRxiv</source>. <pub-id pub-id-type="doi">10.1101/2020.03.04.20031401</pub-id>. [Epub ahead of print].<?supplied-pmid 32574235?><pub-id pub-id-type="pmid">32574235</pub-id></mixed-citation></ref><ref id="B150"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raboud</surname><given-names>J.</given-names></name><name><surname>Shigayeva</surname><given-names>A.</given-names></name><name><surname>McGeer</surname><given-names>A.</given-names></name><name><surname>Bontovics</surname><given-names>E.</given-names></name><name><surname>Chapman</surname><given-names>M.</given-names></name><name><surname>Gravel</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Risk factors for SARS transmission from patients requiring intubation: a multicentre investigation in Toronto, Canada</article-title>. <source>PLoS ONE</source>
<volume>5</volume>:<fpage>e10717</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0010717</pub-id><?supplied-pmid 20502660?><pub-id pub-id-type="pmid">20502660</pub-id></mixed-citation></ref><ref id="B151"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radonovich</surname><given-names>L. J.</given-names></name><name><surname>Simberkoff</surname><given-names>M. S.</given-names></name><name><surname>Bessesen</surname><given-names>M. T.</given-names></name><name><surname>Brown</surname><given-names>A. C.</given-names></name><name><surname>Cummings</surname><given-names>D. A. T.</given-names></name><name><surname>Gaydos</surname><given-names>C. A.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>N95 respirators vs medical masks for preventing influenza among health care personnel: a randomized clinical trial</article-title>. <source>J. Am. Med. Assoc.</source>
<volume>322</volume>, <fpage>824</fpage>&#x02013;<lpage>833</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2019.11645</pub-id><?supplied-pmid 31479137?><pub-id pub-id-type="pmid">31479137</pub-id></mixed-citation></ref><ref id="B152"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>V. S.</given-names></name><name><surname>Mou</surname><given-names>H.</given-names></name><name><surname>Smits</surname><given-names>S. L.</given-names></name><name><surname>Dekkers</surname><given-names>D. H. W.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M. A.</given-names></name><name><surname>Dijkman</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC</article-title>. <source>Nature</source>
<volume>495</volume>, <fpage>251</fpage>&#x02013;<lpage>254</lpage>. <pub-id pub-id-type="doi">10.1038/nature12005</pub-id><?supplied-pmid 23486063?><pub-id pub-id-type="pmid">23486063</pub-id></mixed-citation></ref><ref id="B153"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raoult</surname><given-names>D.</given-names></name><name><surname>Zumla</surname><given-names>A.</given-names></name><name><surname>Locatelli</surname><given-names>F.</given-names></name><name><surname>Ippolito</surname><given-names>G.</given-names></name><name><surname>Kroemer</surname><given-names>G.</given-names></name></person-group> (<year>2020</year>). <article-title>Coronavirus infections: epidemiological, clinical and immunological features and hypotheses</article-title>. <source>Cell Stress</source>
<volume>4</volume>, <fpage>66</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.15698/cst2020.04.216</pub-id><?supplied-pmid 32292881?><pub-id pub-id-type="pmid">32292881</pub-id></mixed-citation></ref><ref id="B154"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rayman</surname><given-names>M. P.</given-names></name></person-group> (<year>2012</year>). <article-title>Selenium and human health</article-title>. <source>Lancet</source>
<volume>379</volume>, <fpage>1256</fpage>&#x02013;<lpage>1268</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(11)61452-9</pub-id><?supplied-pmid 22381456?><pub-id pub-id-type="pmid">22381456</pub-id></mixed-citation></ref><ref id="B155"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Read</surname><given-names>S. A.</given-names></name><name><surname>Obeid</surname><given-names>S.</given-names></name><name><surname>Ahlenstiel</surname><given-names>C.</given-names></name><name><surname>Ahlenstiel</surname><given-names>G.</given-names></name></person-group> (<year>2019</year>). <article-title>The role of zinc in antiviral immunity</article-title>. <source>Adv. Nutr.</source>
<volume>10</volume>, <fpage>696</fpage>&#x02013;<lpage>710</lpage>. <pub-id pub-id-type="doi">10.1093/advances/nmz013</pub-id><?supplied-pmid 31305906?><pub-id pub-id-type="pmid">31305906</pub-id></mixed-citation></ref><ref id="B156"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>L.-L.</given-names></name><name><surname>Wang</surname><given-names>Y.-M.</given-names></name><name><surname>Wu</surname><given-names>Z.-Q.</given-names></name><name><surname>Xiang</surname><given-names>Z.-C.</given-names></name><name><surname>Guo</surname><given-names>L.</given-names></name><name><surname>Xu</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Identification of a novel coronavirus causing severe pneumonia in human</article-title>. <source>Chin. Med. J.</source>
<volume>133</volume>, <fpage>1015</fpage>&#x02013;<lpage>1024</lpage>. <pub-id pub-id-type="doi">10.1097/cm9.0000000000000722</pub-id><?supplied-pmid 32004165?><pub-id pub-id-type="pmid">32004165</pub-id></mixed-citation></ref><ref id="B157"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>P.</given-names></name><name><surname>Griffin</surname><given-names>I.</given-names></name><name><surname>Tucker</surname><given-names>C.</given-names></name><name><surname>Smith</surname><given-names>D.</given-names></name><name><surname>Oechsle</surname><given-names>O.</given-names></name><name><surname>Phelan</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Baricitinib as potential treatment for 2019-nCoV acute respiratory disease</article-title>. <source>Lancet</source>
<volume>395</volume>, <fpage>e30</fpage>&#x02013;<lpage>e31</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30304-4</pub-id><?supplied-pmid 32032529?><pub-id pub-id-type="pmid">32032529</pub-id></mixed-citation></ref><ref id="B158"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossignol</surname><given-names>J. F.</given-names></name></person-group> (<year>2016</year>). <article-title>Nitazoxanide, a new drug candidate for the treatment of middle east respiratory syndrome coronavirus</article-title>. <source>J. Infect. Public Health</source>
<volume>9</volume>, <fpage>227</fpage>&#x02013;<lpage>230</lpage>. <pub-id pub-id-type="doi">10.1016/j.jiph.2016.04.001</pub-id><?supplied-pmid 27095301?><pub-id pub-id-type="pmid">27095301</pub-id></mixed-citation></ref><ref id="B159"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rupp</surname><given-names>J. C.</given-names></name><name><surname>Locatelli</surname><given-names>M.</given-names></name><name><surname>Grieser</surname><given-names>A.</given-names></name><name><surname>Ramos</surname><given-names>A.</given-names></name><name><surname>Campbell</surname><given-names>P. J.</given-names></name><name><surname>Yi</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Host cell copper transporters CTR1 and ATP7A are important for influenza A virus replication</article-title>. <source>Virol. J.</source>
<volume>14</volume>, <fpage>1</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1186/s12985-016-0671-7</pub-id><?supplied-pmid 28115001?><pub-id pub-id-type="pmid">28081705</pub-id></mixed-citation></ref><ref id="B160"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saitou</surname><given-names>N.</given-names></name><name><surname>Nei</surname><given-names>M.</given-names></name></person-group> (<year>1987</year>). <article-title>The neighbor-joining method: a new method for reconstructing phylogenetic trees</article-title>. <source>Mol. Biol. Evol.</source>
<volume>4</volume>, <fpage>406</fpage>&#x02013;<lpage>425</lpage>. <pub-id pub-id-type="doi">10.1093/oxfordjournals.molbev.a040454</pub-id><pub-id pub-id-type="pmid">3447015</pub-id></mixed-citation></ref><ref id="B161"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scavone</surname><given-names>C.</given-names></name><name><surname>Brusco</surname><given-names>S.</given-names></name><name><surname>Bertini</surname><given-names>M.</given-names></name><name><surname>Sportiello</surname><given-names>L.</given-names></name><name><surname>Rafaniello</surname><given-names>C.</given-names></name><name><surname>Zoccoli</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Current pharmacological treatments for COVID-19: what's next?</article-title>
<source>Br. J. Pharmacol</source>. <pub-id pub-id-type="doi">10.1111/bph.15072</pub-id>. [Epub ahead of print].<?supplied-pmid 32329520?><pub-id pub-id-type="pmid">32329520</pub-id></mixed-citation></ref><ref id="B162"><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Sciensano</collab></person-group> (<year>2020</year>). <article-title>Interim Clinical Guidance for Patients Suspected of Confirmed With COVID-19</article-title>. <publisher-loc>Belgium</publisher-loc>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://covid-19.sciensano.be/sites/default/files/Covid19/COVID-19_InterimGuidelines_Treatment_ENG.pdf">https://covid-19.sciensano.be/sites/default/files/Covid19/COVID-19_InterimGuidelines_Treatment_ENG.pdf</ext-link> (accessed June 7, 2020).<?supplied-pmid 32401360?></mixed-citation></ref><ref id="B163"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Du</surname><given-names>R.</given-names></name><name><surname>Cao</surname><given-names>B.</given-names></name></person-group> (<year>2020</year>). <article-title>On the use of corticosteroids for 2019-nCoV pneumonia</article-title>. <source>Lancet</source>
<volume>395</volume>, <fpage>683</fpage>&#x02013;<lpage>684</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30361-5</pub-id><pub-id pub-id-type="pmid">32122468</pub-id></mixed-citation></ref><ref id="B164"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>T. P.</given-names></name><name><surname>Sims</surname><given-names>A. C.</given-names></name><name><surname>Graham</surname><given-names>R. L.</given-names></name><name><surname>Menachery</surname><given-names>V. D.</given-names></name><name><surname>Gralinski</surname><given-names>L. E.</given-names></name><name><surname>Case</surname><given-names>J. B.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses</article-title>. <source>Sci. Transl. Med.</source>
<volume>9</volume>:<fpage>eaal3653</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.aal3653</pub-id><pub-id pub-id-type="pmid">28659436</pub-id></mixed-citation></ref><ref id="B165"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>F.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Treatment of 5 critically III patients with COVID-19 with convalescent plasma</article-title>. <source>J. Am. Med. Assoc.</source>
<volume>323</volume>, <fpage>1582</fpage>&#x02013;<lpage>1589</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.4783</pub-id><?supplied-pmid 32219428?><pub-id pub-id-type="pmid">32219428</pub-id></mixed-citation></ref><ref id="B166"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiraki</surname><given-names>K.</given-names></name><name><surname>Daikoku</surname><given-names>T.</given-names></name></person-group> (<year>2020</year>). <article-title>Favipiravir, an anti-influenza drug against life-threatening RNA virus infections</article-title>. <source>Pharmacol. Ther.</source>
<volume>209</volume>:<fpage>107512</fpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2020.107512</pub-id><?supplied-pmid 32097670?><pub-id pub-id-type="pmid">32097670</pub-id></mixed-citation></ref><ref id="B167"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddiqui</surname><given-names>F. Q.</given-names></name><name><surname>Ahmad</surname><given-names>M. M.</given-names></name><name><surname>Kakar</surname><given-names>F.</given-names></name><name><surname>Akhtar</surname><given-names>S.</given-names></name><name><surname>Dil</surname><given-names>A. S.</given-names></name></person-group> (<year>2001</year>). <article-title>The role of vitamin A in enhancing humoral immunity produced by antirabies vaccine</article-title>. <source>East. Mediterr. Health J.</source>
<volume>7</volume>, <fpage>799</fpage>&#x02013;<lpage>804</lpage>. Available online at: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/15332782">http://www.ncbi.nlm.nih.gov/pubmed/15332782</ext-link> (accessed June 4, 2020). <?supplied-pmid 15332782?><pub-id pub-id-type="pmid">15332782</pub-id></mixed-citation></ref><ref id="B168"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmons</surname><given-names>G.</given-names></name><name><surname>Reeves</surname><given-names>J. D.</given-names></name><name><surname>Rennekamp</surname><given-names>A. J.</given-names></name><name><surname>Amberg</surname><given-names>S. M.</given-names></name><name><surname>Piefer</surname><given-names>A. J.</given-names></name><name><surname>Bates</surname><given-names>P.</given-names></name></person-group> (<year>2004</year>). <article-title>Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>101</volume>, <fpage>4240</fpage>&#x02013;<lpage>4245</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0306446101</pub-id><?supplied-pmid 15010527?><pub-id pub-id-type="pmid">15010527</pub-id></mixed-citation></ref><ref id="B169"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinha</surname><given-names>N.</given-names></name><name><surname>Balayla</surname><given-names>G.</given-names></name></person-group> (<year>2020</year>). <article-title>Hydroxychloroquine and covid-19</article-title>. <source>Postgrad. Med. J.</source>
<pub-id pub-id-type="doi">10.1136/postgradmedj-2020-137785</pub-id>. [Epub ahead of print].</mixed-citation></ref><ref id="B170"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Slater</surname><given-names>H</given-names></name></person-group> (<year>2020</year>). <article-title>FDA Approves Phase III Clinical Trial of Tocilizumab for COVID-19 Pneumonia</article-title>. <source>Cancer Net</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.cancernetwork.com/view/fda-approves-phase-iii-clinical-trial-tocilizumab-covid-19-pneumonia">https://www.cancernetwork.com/view/fda-approves-phase-iii-clinical-trial-tocilizumab-covid-19-pneumonia</ext-link> (accessed June 7, 2020).</mixed-citation></ref><ref id="B171"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>J. D.</given-names></name><name><surname>MacDougall</surname><given-names>C. C.</given-names></name><name><surname>Johnstone</surname><given-names>J.</given-names></name><name><surname>Copes</surname><given-names>R. A.</given-names></name><name><surname>Schwartz</surname><given-names>B.</given-names></name><name><surname>Garber</surname><given-names>G. E.</given-names></name></person-group> (<year>2016</year>). <article-title>Effectiveness of N95 respirators versus surgical masks in protecting health care workers from acute respiratory infection: a systematic review and meta-analysis</article-title>. <source>CMAJ</source>
<volume>188</volume>, <fpage>567</fpage>&#x02013;<lpage>574</lpage>. <pub-id pub-id-type="doi">10.1503/cmaj.150835</pub-id><?supplied-pmid 26952529?><pub-id pub-id-type="pmid">26952529</pub-id></mixed-citation></ref><ref id="B172"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snijder</surname><given-names>E. J.</given-names></name><name><surname>van der Meer</surname><given-names>Y.</given-names></name><name><surname>Zevenhoven-Dobbe</surname><given-names>J.</given-names></name><name><surname>Onderwater</surname><given-names>J. J. M.</given-names></name><name><surname>van der Meulen</surname><given-names>J.</given-names></name><name><surname>Koerten</surname><given-names>H. K.</given-names></name><etal/></person-group>. (<year>2006</year>). <article-title>Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex</article-title>. <source>J. Virol.</source>
<volume>80</volume>, <fpage>5927</fpage>&#x02013;<lpage>5940</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.02501-05</pub-id><?supplied-pmid 16731931?><pub-id pub-id-type="pmid">16731931</pub-id></mixed-citation></ref><ref id="B173"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stebbing</surname><given-names>J.</given-names></name><name><surname>Phelan</surname><given-names>A.</given-names></name><name><surname>Griffin</surname><given-names>I.</given-names></name><name><surname>Tucker</surname><given-names>C.</given-names></name><name><surname>Oechsle</surname><given-names>O.</given-names></name><name><surname>Smith</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>COVID-19: combining antiviral and anti-inflammatory treatments</article-title>. <source>Lancet Infect. Dis.</source>
<volume>20</volume>, <fpage>400</fpage>&#x02013;<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30132-8</pub-id><?supplied-pmid 32113509?><pub-id pub-id-type="pmid">32113509</pub-id></mixed-citation></ref><ref id="B174"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stockman</surname><given-names>L. J.</given-names></name><name><surname>Bellamy</surname><given-names>R.</given-names></name><name><surname>Garner</surname><given-names>P.</given-names></name></person-group> (<year>2006</year>). <article-title>SARS: Systematic review of treatment effects</article-title>. <source>PLoS Med.</source>
<volume>3</volume>, <fpage>1525</fpage>&#x02013;<lpage>1531</lpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.0030343</pub-id><?supplied-pmid 16968120?><pub-id pub-id-type="pmid">16968120</pub-id></mixed-citation></ref><ref id="B175"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>F.</given-names></name><name><surname>Quan</surname><given-names>Y.</given-names></name><name><surname>Xin</surname><given-names>Z.-T.</given-names></name><name><surname>Wrammert</surname><given-names>J.</given-names></name><name><surname>Ma</surname><given-names>M.-J.</given-names></name><name><surname>Lv</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study</article-title>. <source>J. Immunol.</source>
<volume>186</volume>, <fpage>7264</fpage>&#x02013;<lpage>7268</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.0903490</pub-id><?supplied-pmid 21576510?><pub-id pub-id-type="pmid">21576510</pub-id></mixed-citation></ref><ref id="B176"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>N.</given-names></name><name><surname>Bai</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Gong</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name></person-group> (<year>2020</year>). <article-title>Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy</article-title>. <source>J. Thromb. Haemost.</source>
<volume>18</volume>, <fpage>1094</fpage>&#x02013;<lpage>1099</lpage>. <pub-id pub-id-type="doi">10.1111/jth.14817</pub-id><pub-id pub-id-type="pmid">32220112</pub-id></mixed-citation></ref><ref id="B177"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Therapeutics Initiative</collab></person-group> (<year>2020</year>). <source>Acetaminophen vs. NSAIDs During COVID-19 Pandemic</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.ti.ubc.ca/2020/03/18/acetaminophen-vs-nsaids-during-covid-19-pandemic/">https://www.ti.ubc.ca/2020/03/18/acetaminophen-vs-nsaids-during-covid-19-pandemic/</ext-link> (accessed June 7, 2020).<?supplied-pmid 32582330?></mixed-citation></ref><ref id="B178"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>To</surname><given-names>K. K.-W.</given-names></name><name><surname>Tsang</surname><given-names>O. T.-Y.</given-names></name><name><surname>Leung</surname><given-names>W.-S.</given-names></name><name><surname>Tam</surname><given-names>A. R.</given-names></name><name><surname>Wu</surname><given-names>T.-C.</given-names></name><name><surname>Lung</surname><given-names>D. C.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study</article-title>. <source>Lancet Infect. Dis.</source>
<volume>20</volume>, <fpage>P565</fpage>&#x02013;<lpage>P574</lpage>. <pub-id pub-id-type="doi">10.1016/s1473-3099(20)30196-1</pub-id><?supplied-pmid 32213337?><pub-id pub-id-type="pmid">32213337</pub-id></mixed-citation></ref><ref id="B179"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>K.</given-names></name><name><surname>Cimon</surname><given-names>K.</given-names></name><name><surname>Severn</surname><given-names>M.</given-names></name><name><surname>Pessoa-Silva</surname><given-names>C. L.</given-names></name><name><surname>Conly</surname><given-names>J.</given-names></name></person-group> (<year>2012</year>). <article-title>Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review</article-title>. <source>PLoS ONE</source>
<volume>7</volume>:<fpage>e35797</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0035797</pub-id><?supplied-pmid 22563403?><pub-id pub-id-type="pmid">22563403</pub-id></mixed-citation></ref><ref id="B180"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>X.</given-names></name><name><surname>Chong</surname><given-names>W. P.</given-names></name><name><surname>Zhai</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Functional polymorphisms of the CCL2 and MBL genes cumulatively increase susceptibility to severe acute respiratory syndrome coronavirus infection</article-title>. <source>J. Infect.</source>
<volume>71</volume>, <fpage>101</fpage>&#x02013;<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2015.03.006</pub-id><?supplied-pmid 25818534?><pub-id pub-id-type="pmid">25818534</pub-id></mixed-citation></ref><ref id="B181"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turnlund</surname><given-names>J. R.</given-names></name><name><surname>Jacob</surname><given-names>R. A.</given-names></name><name><surname>Keen</surname><given-names>C. L.</given-names></name><name><surname>Strain</surname><given-names>J. J.</given-names></name><name><surname>Kelley</surname><given-names>D. S.</given-names></name><name><surname>Domek</surname><given-names>J. M.</given-names></name><etal/></person-group>. (<year>2004</year>). <article-title>Long-term high copper intake: effects on indexes of copper status, antioxidant status, and immune function in young men</article-title>. <source>Am. J. Clin. Nutr.</source>
<volume>79</volume>, <fpage>1037</fpage>&#x02013;<lpage>1044</lpage>. <pub-id pub-id-type="doi">10.1093/ajcn/79.6.1037</pub-id><?supplied-pmid 15159234?><pub-id pub-id-type="pmid">15159234</pub-id></mixed-citation></ref><ref id="B182"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>M. J.</given-names></name><name><surname>Bergeron</surname><given-names>E.</given-names></name><name><surname>Benjannet</surname><given-names>S.</given-names></name><name><surname>Erickson</surname><given-names>B. R.</given-names></name><name><surname>Rollin</surname><given-names>P. E.</given-names></name><name><surname>Ksiazek</surname><given-names>T. G.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>Chloroquine is a potent inhibitor of SARS coronavirus infection and spread</article-title>. <source>Virol. J.</source>
<volume>2</volume>:<fpage>69</fpage>. <pub-id pub-id-type="doi">10.1186/1743-422X-2-69</pub-id><?supplied-pmid 16115318?><pub-id pub-id-type="pmid">16115318</pub-id></mixed-citation></ref><ref id="B183"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagstaff</surname><given-names>K. M.</given-names></name><name><surname>Sivakumaran</surname><given-names>H.</given-names></name><name><surname>Heaton</surname><given-names>S. M.</given-names></name><name><surname>Harrich</surname><given-names>D.</given-names></name><name><surname>Jans</surname><given-names>D. A.</given-names></name></person-group> (<year>2012</year>). <article-title>Ivermectin is a specific inhibitor of importin &#x003b1;/&#x003b2;-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus</article-title>. <source>Biochem. J.</source>
<volume>443</volume>, <fpage>851</fpage>&#x02013;<lpage>856</lpage>. <pub-id pub-id-type="doi">10.1042/BJ20120150</pub-id><?supplied-pmid 22417684?><pub-id pub-id-type="pmid">22417684</pub-id></mixed-citation></ref><ref id="B184"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Hu</surname><given-names>C.</given-names></name><name><surname>Zhu</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2020a</year>). <article-title>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China</article-title>. <source>J. Am. Med. Assoc.</source>
<volume>323</volume>, <fpage>1061</fpage>&#x02013;<lpage>1069</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.1585</pub-id><?supplied-pmid 32031570?><pub-id pub-id-type="pmid">32031570</pub-id></mixed-citation></ref><ref id="B185"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>K.</given-names></name><name><surname>Guo</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway</article-title>. <source>Cell Res.</source>
<volume>18</volume>, <fpage>290</fpage>&#x02013;<lpage>301</lpage>. <pub-id pub-id-type="doi">10.1038/cr.2008.15</pub-id><?supplied-pmid 18227861?><pub-id pub-id-type="pmid">18227861</pub-id></mixed-citation></ref><ref id="B186"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Cao</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2020b</year>). <article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) <italic>in vitro</italic></article-title>. <source>Cell Res.</source>
<volume>30</volume>, <fpage>269</fpage>&#x02013;<lpage>271</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-020-0282-0</pub-id><?supplied-pmid 32020029?><pub-id pub-id-type="pmid">32020029</pub-id></mixed-citation></ref><ref id="B187"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Jiang</surname><given-names>A.</given-names></name><name><surname>Gong</surname><given-names>L.</given-names></name><name><surname>Luo</surname><given-names>L.</given-names></name><name><surname>Guo</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2020c</year>). <article-title>Temperature significant change COVID-19 transmission in 429 cities</article-title>. <source>medRxiv</source>. <pub-id pub-id-type="doi">10.1101/2020.02.22.20025791</pub-id>. [Epub ahead of print].</mixed-citation></ref><ref id="B188"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S. F.</given-names></name><name><surname>Chen</surname><given-names>K. H.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>W. Y.</given-names></name><name><surname>Chen</surname><given-names>Y. J.</given-names></name><name><surname>Tsao</surname><given-names>C. H.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Human-leukocyte antigen class I Cw 1502 and class II DR 0301 genotypes are associated with resistance to severe acute respiratory syndrome (SARS) infection</article-title>. <source>Viral Immunol.</source>
<volume>24</volume>, <fpage>421</fpage>&#x02013;<lpage>426</lpage>. <pub-id pub-id-type="doi">10.1089/vim.2011.0024</pub-id><?supplied-pmid 21958371?><pub-id pub-id-type="pmid">21958371</pub-id></mixed-citation></ref><ref id="B189"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Tang</surname><given-names>J.</given-names></name><name><surname>Wei</surname><given-names>F.</given-names></name></person-group> (<year>2020d</year>). <article-title>Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China</article-title>. <source>J. Med. Virol.</source>
<volume>92</volume>, <fpage>441</fpage>&#x02013;<lpage>447</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.25689</pub-id><?supplied-pmid 31994742?><pub-id pub-id-type="pmid">31994742</pub-id></mixed-citation></ref><ref id="B190"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Cui</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Gao</surname><given-names>Q.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Altmeyer</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Teicoplanin inhibits Ebola pseudovirus infection in cell culture</article-title>. <source>Antiviral Res.</source>
<volume>125</volume>, <fpage>1</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2015.11.003</pub-id><?supplied-pmid 26585243?><pub-id pub-id-type="pmid">26585243</pub-id></mixed-citation></ref><ref id="B191"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>T. K.</given-names></name><name><surname>Jordan</surname><given-names>R.</given-names></name><name><surname>Lo</surname><given-names>M. K.</given-names></name><name><surname>Ray</surname><given-names>A. S.</given-names></name><name><surname>Mackman</surname><given-names>R. L.</given-names></name><name><surname>Soloveva</surname><given-names>V.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys</article-title>. <source>Nature</source>
<volume>531</volume>, <fpage>381</fpage>&#x02013;<lpage>385</lpage>. <pub-id pub-id-type="doi">10.1038/nature17180</pub-id><?supplied-pmid 26934220?><pub-id pub-id-type="pmid">26934220</pub-id></mixed-citation></ref><ref id="B192"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>S. R.</given-names></name><name><surname>Leibowitz</surname><given-names>J. L.</given-names></name></person-group> (<year>2011</year>). <article-title>Coronavirus pathogenesis</article-title>, in <source>Advances in Virus Research</source>, eds <person-group person-group-type="editor"><name><surname>Kielian</surname><given-names>M.</given-names></name><name><surname>Mettenleiter</surname><given-names>T. C.</given-names></name><name><surname>Roossinck</surname><given-names>M. J.</given-names></name></person-group> (<publisher-name>Academic Press</publisher-name>), <fpage>85</fpage>&#x02013;<lpage>164</lpage>. <pub-id pub-id-type="doi">10.1016/B978-0-12-385885-6.00009-2</pub-id> Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.sciencedirect.com/bookseries/advances-in-virus-research">https://www.sciencedirect.com/bookseries/advances-in-virus-research</ext-link></mixed-citation></ref><ref id="B193"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group> (<year>2020a</year>). <source>Coronavirus Disease (COVID-19) Technical Guidance: Laboratory Testing for 2019-nCoV in Humans</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance</ext-link> (accessed June 7, 2020).</mixed-citation></ref><ref id="B194"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group> (<year>2020b</year>). <source>Advice on the Use of Masks in the Context of COVID-19</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/rest/bitstreams/1274280/retrieve">https://apps.who.int/iris/rest/bitstreams/1274280/retrieve</ext-link> (accessed June 7, 2020).</mixed-citation></ref><ref id="B195"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group> (<year>2020c</year>). <source>Landscape Analysis of Therapeutics as 21st March 2020</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/blueprint/priority-diseases/key-action/Table_of_therapeutics_Appendix_17022020.pdf?ua=1">https://www.who.int/blueprint/priority-diseases/key-action/Table_of_therapeutics_Appendix_17022020.pdf?ua=1</ext-link> (accessed June 7, 2020).</mixed-citation></ref><ref id="B196"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group> (<year>2020d</year>). <source>Novel Coronavirus &#x02013; China</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/">https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/</ext-link> (accessed June 7, 2020).</mixed-citation></ref><ref id="B197"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group> (<year>2020e</year>). <source>Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf">http://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf</ext-link> (accessed June 7, 2020). <?supplied-pmid 32264957?></mixed-citation></ref><ref id="B198"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>A. E.</given-names></name><name><surname>Chambers</surname><given-names>R. C.</given-names></name></person-group> (<year>2014</year>). <article-title>The mercurial nature of neutrophils: still an enigma in ARDS?</article-title>
<source>Am. J. Physiol.</source>
<volume>306</volume>, <fpage>L217</fpage>&#x02013;<lpage>L30</lpage>. <pub-id pub-id-type="doi">10.1152/ajplung.00311.2013</pub-id><?supplied-pmid 24318116?><pub-id pub-id-type="pmid">24318116</pub-id></mixed-citation></ref><ref id="B199"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>W&#x000f6;sten-van Asperen</surname><given-names>R. M.</given-names></name><name><surname>Bos</surname><given-names>A. P.</given-names></name><name><surname>Bem</surname><given-names>R. A.</given-names></name><name><surname>Dierdorp</surname><given-names>B. S.</given-names></name><name><surname>Dekker</surname><given-names>T.</given-names></name><name><surname>van Goor</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Imbalance between pulmonary angiotensin-converting enzyme and angiotensin-converting enzyme 2 activity in acute respiratory distress syndrome</article-title>. <source>Pediatr. Crit. Care Med.</source>
<volume>14</volume>, <fpage>e438</fpage>&#x02013;<lpage>e441</lpage>. <pub-id pub-id-type="doi">10.1097/PCC.0b013e3182a55735</pub-id><?supplied-pmid 24226567?><pub-id pub-id-type="pmid">24226567</pub-id></mixed-citation></ref><ref id="B200"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Cai</surname><given-names>Y.</given-names></name><name><surname>Xia</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2020a</year>). <article-title>Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China</article-title>. <source>JAMA Intern. Med.</source>
<volume>13</volume>:<fpage>e200994</fpage>. <pub-id pub-id-type="doi">10.1001/jamainternmed.2020.0994</pub-id><?supplied-pmid 32167524?><pub-id pub-id-type="pmid">32167524</pub-id></mixed-citation></ref><ref id="B201"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>Y. M.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Song</surname><given-names>Z. G.</given-names></name><etal/></person-group>. (<year>2020b</year>). <article-title>A new coronavirus associated with human respiratory disease in China</article-title>. <source>Nature</source>
<volume>579</volume>, <fpage>265</fpage>&#x02013;<lpage>269</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2008-3</pub-id><?supplied-pmid 32015508?><pub-id pub-id-type="pmid">32015508</pub-id></mixed-citation></ref><ref id="B202"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Xinhua News Agency</collab></person-group> (<year>2020</year>). <source>Favipiravir Shows Good Clinical Efficacy in Treating COVID-19: Official</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="http://www.xinhuanet.com/english/2020-03/17/c_138887971.htm">http://www.xinhuanet.com/english/2020-03/17/c_138887971.htm</ext-link> (accessed June 7, 2020).</mixed-citation></ref><ref id="B203"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Shi</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Pathological findings of COVID-19 associated with acute respiratory distress syndrome</article-title>. <source>Lancet Respir. Med.</source>
<volume>8</volume>, <fpage>420</fpage>&#x02013;<lpage>422</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(20)30076-X</pub-id><?supplied-pmid 32085846?><pub-id pub-id-type="pmid">32085846</pub-id></mixed-citation></ref><ref id="B204"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Y.</given-names></name><name><surname>Zou</surname><given-names>Z.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>K. F.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model</article-title>. <source>Cell Res.</source>
<volume>23</volume>, <fpage>300</fpage>&#x02013;<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1038/cr.2012.165</pub-id><?supplied-pmid 23208422?><pub-id pub-id-type="pmid">23208422</pub-id></mixed-citation></ref><ref id="B205"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>S. N. Y.</given-names></name><name><surname>Atkinson</surname><given-names>S. C.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Lee</surname><given-names>A.</given-names></name><name><surname>Bogoyevitch</surname><given-names>M. A.</given-names></name><name><surname>Borg</surname><given-names>N. A.</given-names></name><etal/></person-group>. (<year>2020a</year>). <article-title>The broad spectrum antiviral ivermectin targets the host nuclear transport importin &#x003b1;/&#x003b2;1 heterodimer</article-title>. <source>Antiviral Res.</source>
<volume>177</volume>:<fpage>104760</fpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104760</pub-id><?supplied-pmid 32135219?><pub-id pub-id-type="pmid">32135219</pub-id></mixed-citation></ref><ref id="B206"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Shu</surname><given-names>H.</given-names></name><name><surname>Xia</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2020b</year>). <article-title>Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study</article-title>. <source>Lancet Respir. Med.</source>
<volume>8</volume>, <fpage>P475</fpage>&#x02013;<lpage>P481</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(20)30079-5</pub-id><?supplied-pmid 32105632?><pub-id pub-id-type="pmid">32105632</pub-id></mixed-citation></ref><ref id="B207"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Geng</surname><given-names>H.</given-names></name><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of middle east respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists</article-title>. <source>Protein Cell</source>
<volume>4</volume>, <fpage>951</fpage>&#x02013;<lpage>961</lpage>. <pub-id pub-id-type="doi">10.1007/s13238-013-3096-8</pub-id><?supplied-pmid 24318862?><pub-id pub-id-type="pmid">24318862</pub-id></mixed-citation></ref><ref id="B208"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>X.</given-names></name><name><surname>Ye</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Cui</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Niu</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title><italic>In vitro</italic> antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</article-title>. <source>Clin. Infect. Dis</source>. <volume>9</volume>:<fpage>eciaa237</fpage>. <pub-id pub-id-type="doi">10.1093/cid/ciaa237</pub-id><?supplied-pmid 32150618?><pub-id pub-id-type="pmid">32150618</pub-id></mixed-citation></ref><ref id="B209"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yee</surname><given-names>J.</given-names></name><name><surname>Unger</surname><given-names>L.</given-names></name><name><surname>Zadravecz</surname><given-names>F.</given-names></name><name><surname>Cariello</surname><given-names>P.</given-names></name><name><surname>Seibert</surname><given-names>A.</given-names></name><name><surname>Johnson</surname><given-names>M. A.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Novel coronavirus 2019 (COVID-19): emergence and implications for emergency care</article-title>. <source>J. Am. Coll. Emerg. Physicians Open</source>
<volume>1</volume>, <fpage>63</fpage>&#x02013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1002/emp2.12034</pub-id><?supplied-pmid 32427173?><pub-id pub-id-type="pmid">32427173</pub-id></mixed-citation></ref><ref id="B210"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeo</surname><given-names>C.</given-names></name><name><surname>Kaushal</surname><given-names>S.</given-names></name><name><surname>Yeo</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>). <article-title>Enteric involvement of coronaviruses: is faecal&#x02013;oral transmission of SARS-CoV-2 possible?</article-title>
<source>Lancet Gastroenterol. Hepatol.</source>
<volume>5</volume>, <fpage>335</fpage>&#x02013;<lpage>337</lpage>. <pub-id pub-id-type="doi">10.1016/S2468-1253(20)30048-0</pub-id><?supplied-pmid 32087098?><pub-id pub-id-type="pmid">32087098</pub-id></mixed-citation></ref><ref id="B211"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>F.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Ojcius</surname><given-names>D. M.</given-names></name><name><surname>Pan</surname><given-names>C.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China</article-title>. <source>Microbes Infect.</source>
<volume>22</volume>, <fpage>74</fpage>&#x02013;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1016/j.micinf.2020.01.003</pub-id><?supplied-pmid 32017984?><pub-id pub-id-type="pmid">32017984</pub-id></mixed-citation></ref><ref id="B212"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>F. F.</given-names></name><name><surname>Tanner</surname><given-names>J.</given-names></name><name><surname>Chan</surname><given-names>P. K. S.</given-names></name><name><surname>Biffin</surname><given-names>S.</given-names></name><name><surname>Dyer</surname><given-names>W. B.</given-names></name><name><surname>Geczy</surname><given-names>A. F.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>Influence of FcgammaRIIA and MBL polymorphisms on severe acute respiratory syndrome</article-title>. <source>Tissue Antigens</source>
<volume>66</volume>, <fpage>291</fpage>&#x02013;<lpage>296</lpage>. <pub-id pub-id-type="doi">10.1111/j.1399-0039.2005.00476.x</pub-id><?supplied-pmid 16185324?><pub-id pub-id-type="pmid">16185324</pub-id></mixed-citation></ref><ref id="B213"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zdrenghea</surname><given-names>M. T.</given-names></name><name><surname>Makrinioti</surname><given-names>H.</given-names></name><name><surname>Bagacean</surname><given-names>C.</given-names></name><name><surname>Bush</surname><given-names>A.</given-names></name><name><surname>Johnston</surname><given-names>S. L.</given-names></name><name><surname>Stanciu</surname><given-names>L. A.</given-names></name></person-group> (<year>2017</year>). <article-title>Vitamin D modulation of innate immune responses to respiratory viral infections</article-title>. <source>Rev. Med. Virol.</source>
<volume>27</volume>:<fpage>e1909</fpage>. <pub-id pub-id-type="doi">10.1002/rmv.1909</pub-id><?supplied-pmid 27714929?><pub-id pub-id-type="pmid">27714929</pub-id></mixed-citation></ref><ref id="B214"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>Zheng</surname><given-names>F.</given-names></name><name><surname>Dai</surname><given-names>Y.</given-names></name></person-group> (<year>2020a</year>). <article-title>Controversial treatments: an updated understanding of the coronavirus disease 2019</article-title>. <source>J. Med. Virol.</source>
<pub-id pub-id-type="doi">10.1002/jmv.25788</pub-id>. [Epub ahead of print].<?supplied-pmid 32219882?><pub-id pub-id-type="pmid">32219882</pub-id></mixed-citation></ref><ref id="B215"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Kang</surname><given-names>Z.</given-names></name><name><surname>Gong</surname><given-names>H.</given-names></name><name><surname>Xu</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes</article-title>. <source>bioRxiv</source>. <pub-id pub-id-type="doi">10.1101/2020.01.30.927806</pub-id>. [Epub ahead of print].</mixed-citation></ref><ref id="B216"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>K.</given-names></name><name><surname>Wohlford-Lenane</surname><given-names>C.</given-names></name><name><surname>Agnihothram</surname><given-names>S. S.</given-names></name><name><surname>Fett</surname><given-names>C.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Rapid generation of a mouse model for Middle East respiratory syndrome</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>111</volume>, <fpage>4970</fpage>&#x02013;<lpage>4975</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1323279111</pub-id><?supplied-pmid 24599590?><pub-id pub-id-type="pmid">24599590</pub-id></mixed-citation></ref><ref id="B217"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Lin</surname><given-names>Q.</given-names></name><name><surname>Ran</surname><given-names>J.</given-names></name><name><surname>Musa</surname><given-names>S. S.</given-names></name><name><surname>Yang</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak</article-title>. <source>Int. J. Infect. Dis.</source>
<volume>92</volume>, <fpage>214</fpage>&#x02013;<lpage>217</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2020.01.050</pub-id><?supplied-pmid 32007643?><pub-id pub-id-type="pmid">32007643</pub-id></mixed-citation></ref><ref id="B218"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Du</surname><given-names>R.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title>. <source>Lancet</source>
<volume>395</volume>, <fpage>1054</fpage>&#x02013;<lpage>1062</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30566-3</pub-id><?supplied-pmid 32171076?><pub-id pub-id-type="pmid">32171076</pub-id></mixed-citation></ref><ref id="B219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>N.</given-names></name><name><surname>Pan</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Bai</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Glycopeptide antibiotics potently inhibit cathepsin l in the late endosome/lysosome and block the entry of ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)</article-title>. <source>J. Biol. Chem.</source>
<volume>291</volume>, <fpage>9218</fpage>&#x02013;<lpage>9232</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M116.716100</pub-id><?supplied-pmid 26953343?><pub-id pub-id-type="pmid">26953343</pub-id></mixed-citation></ref><ref id="B220"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Vedantham</surname><given-names>P.</given-names></name><name><surname>Lu</surname><given-names>K.</given-names></name><name><surname>Agudelo</surname><given-names>J.</given-names></name><name><surname>Carrion</surname><given-names>R.</given-names></name><name><surname>Nunneley</surname><given-names>J. W.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Protease inhibitors targeting coronavirus and filovirus entry</article-title>. <source>Antiviral Res.</source>
<volume>116</volume>, <fpage>76</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2015.01.011</pub-id><?supplied-pmid 25666761?><pub-id pub-id-type="pmid">25666761</pub-id></mixed-citation></ref><ref id="B221"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A.</given-names></name><name><surname>Chan</surname><given-names>J. F. W.</given-names></name><name><surname>Azhar</surname><given-names>E. I.</given-names></name><name><surname>Hui</surname><given-names>D. S. C.</given-names></name><name><surname>Yuen</surname><given-names>K. Y.</given-names></name></person-group> (<year>2016</year>). <article-title>Coronaviruses-drug discovery and therapeutic options</article-title>. <source>Nat. Rev. Drug Discov.</source>
<volume>15</volume>, <fpage>327</fpage>&#x02013;<lpage>347</lpage>. <pub-id pub-id-type="doi">10.1038/nrd.2015.37</pub-id><?supplied-pmid 26868298?><pub-id pub-id-type="pmid">26868298</pub-id></mixed-citation></ref></ref-list><glossary><def-list><title>Abbreviations</title><def-item><term>ACE2</term><def><p>angiotensin converting enzyme 2</p></def></def-item><def-item><term>AP</term><def><p>antigen presentation</p></def></def-item><def-item><term>APCs</term><def><p>antigen presentation cells</p></def></def-item><def-item><term>APN, aminopeptidase N, ARBs</term><def><p>angiotensin II receptor blockers</p></def></def-item><def-item><term>ARDS</term><def><p>acute respiratory distress syndrome</p></def></def-item><def-item><term>CDC</term><def><p>Centers for Disease Control</p></def></def-item><def-item><term>nCOVID-19</term><def><p>novel coronavirus disease 2019</p></def></def-item><def-item><term>CoVs</term><def><p>coronaviruses</p></def></def-item><def-item><term>DPP4</term><def><p>dipeptidyl peptidase 4</p></def></def-item><def-item><term>dsRNA</term><def><p>double-strand RNA</p></def></def-item><def-item><term>EC<sub>50</sub></term><def><p>half maximal effective concentration</p></def></def-item><def-item><term>ED</term><def><p>emergency department</p></def></def-item><def-item><term>ELISA</term><def><p>enzyme-linked immunosorbent assay</p></def></def-item><def-item><term>EUA</term><def><p>emergency use authorization</p></def></def-item><def-item><term>FDA</term><def><p>Food and Drug Administration</p></def></def-item><def-item><term>GGO</term><def><p>ground-glass opacity</p></def></def-item><def-item><term>HCV</term><def><p>hepatitis C virus</p></def></def-item><def-item><term>HIV, human immunodeficiency virus;, MHC</term><def><p>major histocompatibility complex</p></def></def-item><def-item><term>or HLA</term><def><p>human leukocyte antigen</p></def></def-item><def-item><term>ICU</term><def><p>intensive care unit</p></def></def-item><def-item><term>IL-6</term><def><p>interleukin 6</p></def></def-item><def-item><term>LPV/r</term><def><p>lopinavir/ritonavir</p></def></def-item><def-item><term>mAbs</term><def><p>monoclonal antibodies</p></def></def-item><def-item><term>MERS</term><def><p>Middle East respiratory syndrome</p></def></def-item><def-item><term>N7-MTase</term><def><p>N7-methyltransferase</p></def></def-item><def-item><term>NSAIDs</term><def><p>nonsteroidal anti-inflammatory drugs</p></def></def-item><def-item><term>PRRs</term><def><p>pattern recognition receptors</p></def></def-item><def-item><term>PUI</term><def><p>patient under investigation</p></def></def-item><def-item><term>RdRp</term><def><p>RNA-dependent RNA polymerase</p></def></def-item><def-item><term>RSV</term><def><p>respiratory syncytial virus</p></def></def-item><def-item><term>S protein</term><def><p>spike protein</p></def></def-item><def-item><term>SAM</term><def><p>S-adenosyl-methionine</p></def></def-item><def-item><term>SARS</term><def><p>severe acute respiratory syndrome</p></def></def-item><def-item><term>SARS-CoV-2</term><def><p>Severe acute respiratory syndrome coronavirus 2</p></def></def-item><def-item><term>TMPRSS2</term><def><p>transmembrane serine protease 2</p></def></def-item><def-item><term>WHO</term><def><p>World Health Organization.</p></def></def-item></def-list></glossary></back></article>